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TBC1D1 and TBC1D4 are Rab-GTPase Activating Proteins (Rab-GAPs) 
expressed in insulin-responsive tissues. Both proteins are involved in 
mechanisms which regulate basal levels of glucose transport and have been 
identified as targets of insulin and AMP-dependant kinase (AMPK) signalling 
pathways, which regulate GLUT4 translocation to the plasma membrane in 
muscle.  
We have characterised the C2C12 muscle cell model retrovirally expressing 
HA-epitope tagged GLUT4 in order to investigate how distinct signalling 
pathways regulate GLUT4 trafficking. Insulin-stimulation and treatment with the 
AMPK-activator (AICAR) increased the levels of GLUT4 at the plasma 
membrane by two-fold in C2C12 myotubes. Insulin-stimulation and activation of 
AMPK mobilised GLUT4 in to the actively cycling pool. However, our data 
revealed that insulin-stimulation or AMPK activation resulted in distinct effects 
on GLUT4 trafficking parameters at steady-state. Insulin increased GLUT4 
exocytosis (kex) of this cycling pool. Activation of AMPK inhibited GLUT4 
internalisation (ken). The combined effect of insulin-stimulation and AMPK-
activation was synergistic and led to increased GLUT4 cell surface levels above 
those obtained with either treatment alone. Insulin-stimulation and AMPK 
activation in combination resulted in a partially additive effect on the size of the 
actively recycling GLUT4 pool and further enhanced kex of this cycling pool. 
Kinetic studies were performed to measure the effect of TBC1D1 and TBC1D4 
knockdown on GLUT4 trafficking in C2C12 myotubes. siRNA-mediated 
knockdown of TBC1D4 did not affect the basal levels of cell surface GLUT4. 
Knockdown of TBC1D1 increased cell surface levels of GLUT4 in basal and in 
insulin-stimulated C2C12 myotubes. The knockdown increased the release of 
GLUT4 in to the actively recycling pool. By contrast TBC1D1 knockdown did not 
change the levels of GLUT4 at the plasma membrane that occur in the 
presence of the AMPK-activator (AICAR). Our results support a model whereby 





GLUT4 translocation, but with insulin and AICAR having separate and 
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1 Introduction 
This thesis details the mechanisms that are involved in maintaining basal levels 
of glucose transport and which are involved in both insulin regulation and 
energy-status regulation of translocation of the glucose transporter GLUT4. It is 
widely considered that understanding these fundamental mechanisms can lead 
in turn to a greater understanding of factors that contribute to the insulin 
resistance that occurs in metabolic disease. Therefore, to put the thesis study 
into an appropriate context I introduce, in this chapter, a consideration of 
relevant aspects of obesity and type 2 diabetes. 
1.1 Obesity 
1.1.1 Classification 
Obesity is defined by the World Health Organisation (WHO) as an abnormal or 
excessive fat accumulation that may impair health. In 2008, the number of 
overweight and obese adults worldwide had reached 1.4 billion. Body Mass 
Index (BMI) (kg/m2) is the primary measurement used for the classification of 
obesity. An overweight individual is classified as having a BMI of over 25, and 
obesity is defined when the BMI is over 30. Obesity is described as a state of 
energy imbalance, where Individuals expend less energy than the food that they 
consume (Froguel & Boutin, 2001). A small percentage of severe obesity cases 
are the result of a number of monogenic mutations in the leptin–melanocortin 
system. These pathways are critical for the regulation of energy balance 
(Ranadive & Vaisse, 2008). However, in the majority of obesity cases, the 
disease is multifactorial associated with both genetic factors and environmental 
factors which include nutrition and lifestyle. The genetic component of common 
obesity is likely to be determined by a number of susceptibility genes 
(polygenic). These genetic and environmental factors interact with each other in 
complex ways to influence the development of the disease. Persistent obesity 
can lead to the dysregulation of glucose and fat metabolism, resulting in an 
array of clinical conditions collectively known as the metabolic syndrome (Misra 
& Khurana, 2008). These conditions include glucose intolerance, insulin 
resistance, dyslipidaemia and hypertension (Eckel, et al., 2005). All of these are 
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risk factors associated with the development of type 2 diabetes mellitus (T2DM) 
and cardiovascular disease (CVD). Furthermore, weight loss either through 
sustained lifestyle changes or surgical intervention can improve blood glucose 
levels which reduce the risk of developing the T2DM (Aucott, 2008).  
1.1.2 Whole-body insulin resistance  
Metabolic homeostasis is tightly regulated by two pancreatic hormones; these 
are glucagon and insulin. Glucagon is secreted from pancreatic alpha cells 
during the fasted state. Glucagon targets the liver and skeletal muscle cells and 
mediates the release of glucose from the glycogen stores a process known as 
glycogenolysis. In addition, glucagon targets adipose tissue and stimulates the 
up-regulation of lipolysis. In response to food intake, insulin is secreted from 
pancreatic beta cells to regulate the storage and utilisation of glucose in the 
liver and skeletal muscle. Skeletal muscle is the major site for post prandial 
glucose disposal. In addition, insulin stimulates the production of fatty acids and 
their storage in adipose tissue (Lazar, 2005).  
Obesity is associated with insulin resistance. Insulin resistance is a metabolic 
state which describes how peripheral tissues fail to respond to normal levels of 
insulin. As a consequence, the production of insulin and its secretion from the 
pancreas increases. However, if insulin resistance persists, this can eventually 
lead to an elevation in blood glucose levels (hyperglycaemia) and free fatty-
acids (FFA) (dyslipidaemia), which contribute to the development of T2DM. 
Equally, hyperglycaemia and dyslipidaemia can exacerbate an insulin-resistant 
state.  
1.1.3 Metabolic Flexibility 
The term ‘metabolic flexibility’ has been proposed to describe how muscle can 
dynamically switch between glucose and fat oxidation (Figure 1.1). This is 
related to fitness, body fat and insulin sensitivity. Lean individuals who regularly 
exercise are described as ‘metabolically flexible’. These individuals are able to 
switch between the utilisation of fatty acid in the fasted state and increased 
glucose oxidation during insulin stimulation. In contrast, individuals who are 
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obese and aerobically unfit are described as ‘metabolically inflexible’. These 
individuals have a blunted preference for fat oxidation during fasting and display 
an impaired insulin-stimulated glucose oxidation (Kelley, 2005). Furthermore, 
metabolic flexibility has been found to be an intrinsic property of muscle cells 
(Ukropcova, et al., 2005). Primary human muscle cells were isolated from a 
mixed population of donors. The metabolic phenotype in vitro was found to 
mirror the in vivo state of the donor. This study demonstrated that ‘metabolically 
inflexible’ muscle cells have a decreased ability to oxidise fatty acids in the 
presence of glucose. Furthermore, these muscle cells have a reduced capacity 
to increase fatty acid oxidation when treated with high concentration of the 
saturated fatty acid palmitate.  
 
Figure 1.1: Metabolic Flexibility. The flexibility of skeletal muscle to switch between fat and 
glucose oxidation is related to fitness, insulin sensitivity and body fat. (A) An aerobically fit 
individual with preference for fat oxidation in the fasted state. Insulin stimulation inhibits fat 
oxidation and switches muscle to utilise glucose. (B) An aerobically unfit individual with a 
blunted fat oxidation in the fasted state reliance on glucose metabolism. The muscle is less 
sensitive to insulin and so there is a reduced stimulation for glucose oxidation and 
suppression of fat oxidation. This diagram has been adapted from (Kelley, 2005). 
1.1.4 Glucose-fatty acid cycle  
In 1964, Randle and co-workers proposed a mechanism which described the 
relationship between glucose and fatty acid utilisation in skeletal muscle 
(Randle, 1964). This model is known as the ‘Randle hypothesis’ and describes 
how nutrient levels independently determine the metabolic effects within the 
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cell. Circulatory FFAs are transported in to muscle cells to be oxidised which 
elevates cellular levels of Acetyl CoA and citrate. This results in the inhibition of 
Phosphofructokinase (PFK) and Pyruvate Dehydrogenase (PDH), enzymes 
which are involved in glycolysis and glucose utilisation. The relationship 
between elevated serum triglycerides, insulin sensitivity and T2DM has been 
widely investigated (Bergman & Ader, 2000). A European study conducted on a 
large cohort of healthy individuals, concluded that there was a negative 
correlation between levels of non-esterified fatty-acids (NEFA) and insulin 
sensitivity (Baldeweg, et al., 2000). In contrast, excess circulating glucose 
typically associated with insulin resistance could inhibit fatty acid oxidation. This 
is known as the reverse Randle cycle. This process is associated with 
individuals who are ‘metabolically inflexible’ (described in section 1.1.3).  
1.1.5 Skeletal muscle classification 
As skeletal muscle contributes extensively to metabolic interactions between 
glucose and fat metabolism, with differences in the interactions occurring in 
different muscle types, it is necessary to consider muscle type classification. 
Skeletal muscles are classed depending on their fibre type composition. There 
are four main muscle fibre types (Type I, IIA, IIB and IIX). Muscle fibres are 
defined by their strength of contraction (slow or fast) and resistance to fatigue 
(oxidative or glycolytic) which are correlated with sarcoplasmic reticulum 
development (poor or richly developed) and mitochondria content (abundant or 
few) respectively (Tasic, et al., 2003) (Schiaffino & Reggiani, 2011). Type I 
muscle fibres are slow twitch and have a high oxidative capacity. Type IIA, IIB 
and IIX are fast twitch glycolytic muscle fibres however type IIA fibres have an 
increased oxidative capacity and resistance to fatigue (Schiaffino & Reggiani, 
2011). The Soleus muscle is a slow-twitch oxidative muscle composed of 
entirely type I and type IIA muscle fibres (Song, et al., 1999). The tibialis 
anterior (TA), extensor digitorum longus (EDL), epitrochlearis muscles (EPI) 
and flexor digitorum brevis (FDB) are fast-twitch and contain predominately type 
II fibres (Henriksen, et al., 1990). It has been suggested that fibre-type 
composition may affect how muscle responds to contraction-stimuli. In TA 
muscle the mitochondrial content is inversely correlated with the basal kinase 
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activity. For instance in glycolytic (white) TA muscle fibres the basal 
phosphorylation levels of the protein kinases AMPK, p38, p42 and p44 MAPK 
are significantly greater than in oxidative (red) TA fibres. Comparatively, the 
level of Akt phosphorylation was similar between the two fibres types (Ljubicic & 
Hood, 2008)  
1.2 Fatty acid Transport  
Fatty acids are elevated in the circulation either after the consumption of dietary 
long chain fatty acids (LCFA) esterified in triacylglycerol (TAG) or as a result of 
the lipolysis of fat stored in adipose tissue. Fatty-acids are a major fuel source 
for skeletal muscle during fasting and exercise. The uptake of fatty acids in to 
target tissues either occurs by means of passive diffusion across the plasma 
membrane or this process is facilitated through fatty-acid transporter proteins 
(FATPs). Insulin and muscle contraction mediate the translocation of FAT/CD36 
present in intracellular vesicles to the plasma membrane in skeletal muscle to 
increase fatty-acid uptake (Bonen, et al., 2000). The oxidative soleus muscle 
expresses increased levels of fatty acid transport proteins FAT/CD36 and FABP 
proteins compared with the glycolytic flexor digitorum brevis (FDB) muscle. The 
increased expression of FATPs in the soleus muscle accounts for the increased 
rate of palmitate transport and oxidation in soleus muscle (Bonen, et al., 1998).  
1.3 Glucose Transporters 
1.3.1 The GLUT Family 
Circulating glucose is removed from the blood stream by a family of glucose 
transporters (GLUTs). Glucose transporters are expressed on the surface of 
target tissues and function to facilitate the transfer of glucose across the plasma 
membrane. Glucose transporters are a group of homologous plasma membrane 
proteins comprised of 12 trans-membrane alpha helices (Figure 1.2). There are 
14 GLUT family members to date (Thorens & Mueckler, 2009). These have 
been divided into three distinct sub classes (Joost, et al., 2002) (Table 1.1).  
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Figure 1.2: A schematic diagram of the GLUT4. There are 14 GLUT family members to date 
which are predicted to comprise of 12 trans-membrane alpha helices. The N and C Termini 
are located in the cytosol. The family has been divided into three distinct classes, which are 
outlined in Table 1.1. This diagram is modified from (Bryant, et al., 2002). 
GLUT1 was isolated from human erythrocyte membranes and was the first 
transporter to be identified. In 1985, GLUT1 was characterised and successfully 
cloned (Mueckler, et al., 1985). GLUT1 is ubiquitously expressed in most 
tissues including in insulin-responsive tissues. Skeletal muscle, adipose and 
liver are the major tissues which contribute in whole-body post-prandial glucose 
disposal. The liver is responsible for the removal of approximately 7% of dietary 
glucose (Fernandes, et al., 2011). This is facilitated by the transporter GLUT2, 
which is localised at the cell surface. Skeletal muscle is responsible for the 
clearance of around 69% of dietary glucose and a further 7% is transported into 
adipose tissue (Fernandes, et al., 2011). In contrast to in the liver, it is well 
established that glucose transport into skeletal muscle and adipose tissue is 
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Table 1.1: Summary of the glucose transporter family (GLUT) members. 
Class Protein Expression Proposed Function 
I GLUT 1 Ubiquitous, erythrocytes, brain 
Basal glucose uptake; transport across 
blood brain barriers 
 GLUT 3 Brain; neuronal Neuronal transport 
 GLUT 4 
Adipose, skeletal muscle and 
heart 
Insulin-regulated transport in fat and 
muscle 
 GLUT 2 
Liver, islets, kidney, small 
intestine 
High capacity low affinity transport 
 GLUT 14 Testes High sequence similarity to GLUT3 
II GLUT 5 Intestine, kidney, testis Transport of fructose 
 GLUT 7 Small intestine, colon, testis Transport of fructose 
 GLUT 9 Liver, kidney  
 GLUT 11 Heart, muscle Muscle specific fructose transporter 
III GLUT 6 Spleen, leukocytes, brain  
 GLUT 8 
Testes, blastocyst, brain, 
muscle, adipocytes 
Insulin-responsive transport blastocyst. 
Fuel supply mature spermatozoa 
 GLUT 10 Liver, pancreas  
 GLUT 12 








1.3.2 Glucose Transporter 4 (GLUT4) 
1.3.2.1 Identification and cloning 
It was in the 1950s that a direct role for insulin in the regulation of glucose-
uptake into peripheral tissues was established (Levine & Goldstein, 1955). 
However, it wasn’t until methods were developed to isolate adipose cells that it 
became possible to study the molecular mechanism of insulin action. In 1980, 
two independent research groups reported that insulin stimulation increased the 
glucose transport activity at the plasma membrane in adipose cells (Suzuki & 
Kono, 1980) (Cushman & Wardzala, 1980). Cushman and colleagues used a 
radiolabelled [3H] cytochalasin b which binds to and inhibits glucose 
transporters. The use of [3H] cytochalasin b demonstrated that upon insulin 
stimulation ‘glucose transport systems’ move (translocate) from an intracellular 
vesicular compartment to the plasma membrane in isolated rat adipocytes cells. 
In 1989, nearly a decade after the ‘translocation hypothesis’ was proposed, the 
elusive ‘insulin-responsive glucose transporter’ was cloned by several 
independent research groups (James, et al., 1989) (Birnbaum, 1989) (Charron, 
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et al., 1989) (Fukumoto, et al., 1989). This transporter was later referred to as 
GLUT4, the fourth member of the facilitative glucose transporter family (Figure 
1.2). Subsequently, antibodies were developed against the specific glucose 
transporters and used to confirm that insulin stimulates the translocation of 
GLUT4 to the cell surface in adipose cells.  
Since the cloning and identification of GLUT4, an extensive amount of research 
has been dedicated to understanding how insulin regulates the translocation of 
GLUT4 from specialised intracellular storage compartments to the plasma 
membrane in both adipose and muscle tissue. Several biochemical and 
immuno-cytochemical methods have been developed over the years for the 
studies of GLUT4 trafficking. These include subcellular-fractionation techniques, 
biotinylated bis-mannose photolabelling (Holman, et al., 1990) (Yang & Holman, 
1993) (Koumanov, et al., 1998), electron and fluorescence-based microscopy 
(Ploug, et al., 1998) (Slot, et al., 1991) (Malide, et al., 2000) (Malide, et al., 
1997) (Dawson, et al., 2001) (Ralston & Ploug, 1996). In more recent years, 
GLUT4 reporter constructs have been designed to contain a hemagglutinin (HA) 
or Myc tag in the first exofacial loop and can also have a C-Terminal GFP tag 
(HA/Myc GLUT4 GFP). These have been utilised to study GLUT4 trafficking in 
both adipose (Karylowski, et al., 2004) (Zeigerer, et al., 2002) (Govers, et al., 
2004) (Shewan, et al., 2003) and in muscle cells (Hoehn, et al., 2008) 
(Fazakerely, et al., 2009) and in primary muscle (Lauritzen, et al., 2008) 
(Lauritzen, et al., 2006) (Lauritzen, et al., 2010).  
1.3.2.2 The GLUT4 translocation hypothesis 
The use of a cell impermeant bismannose photolabel 2-N-4(1-azi-2,2,2-
trifluoroethyl) benzoyl-1,3-bis(D-manos-4-yloxy)-2-propylamine (ATB-BMPA) in 
combination with anti-GLUT4 and anti-GLUT1 specific antibodies have been 
used to quantify the abundance of glucose transporters at the cell surface in rat 
adipose and muscle cells. In non-stimulated rat adipose cells, GLUT1 and 
GLUT4 transporters are present at low levels at the plasma membrane. 
Following insulin stimulation the level of GLUT4 and GLUT1 at the cell surface 
are increased 15-20-fold and five-fold respectively. However, the increased 
level of GLUT4 transporters accounted for the majority of the insulin-stimulated 
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glucose transport activity (Holman, et al., 1990). Furthermore, in isolated rat 
soleus muscle cells insulin stimulates an 8-fold increase in GLUT4 at the cell 
surface compared to the non-stimulated state. The level of cell surface 
accessible GLUT4 was directly correlated with the increased glucose transport 
activity (Wilson & Cushman, 1994). Subsequently, it has been demonstrated 
that in adipose cells the cell surface level of GLUT1 is primarily responsible for 
basal cell glucose uptake (James & Piper, 1994).  
1.3.2.3 GLUT4 intracellular localisation  
The intracellular distribution of GLUT4 within the endosomal system was 
demonstrated in early studies using immuno-gold electron microscopy. A similar 
distribution pattern of GLUT4 has been observed in both adipose and muscle 
tissue (Malide, et al., 2000) (Slot, et al., 1991) (Slot, et al., 1991) (Ploug, et al., 
1998). In non-stimulated white and brown adipose cells the majority of immuno-
gold labelled GLUT4 is found located in tubular-vesicular (TV) structures within 
the cytoplasm, enriched near the Trans Golgi Network (TGN) and in endosomes 
(Malide, et al., 2000) (Slot, et al., 1991). Similarly, in muscle and heart, GLUT4 
is located in small TV structures near to the sarcolemma and transverse tubular 
system and associated with larger endosomal depots in close proximity to the 
TGN (Slot, et al., 1991) (Ploug, et al., 1998).  
Co-localisation studies using immuno-fluorescence microscopy revealed that a 
proportion of GLUT4 resides in large peri-nuclear structures which display 
partial overlap with mannose 6-phosphate receptor (M6PR), TGN 38-
mannosidase II and giantin. These are cell compartment markers of late 
endosomes, TGN and Golgi respectively (Malide, et al., 1997) (Ploug, et al., 
1998) (Ralston & Ploug, 1996). Furthermore, sub-cellular fractionation 
techniques together with immuno-adsorption of intracellular GLUT4 containing 
membranes has been used by several studies to identify proteins components 
which associate with GLUT4 storage compartment in rat adipocytes and 3T3-L1 
cells. Major protein cargo constituents include the insulin-regulated amino 
peptidase (IRAP), sortilin, mannose-6-phosphate receptor (M6PR) and the 
transferrin receptor (TfR) (Kandror, et al., 1995) (Kandror & Pilch, 1996) (Morris, 
et al., 1998) (Hashiramoto & James, 2000) (Larance, et al., 2005). However, the 
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majority of GLUT4 is found present in a distinct vesicular population that 
resemble the TGN but which are segregated away from the Transferrin receptor 
(TfR) which a marker for constitutively recycling endosomes (Malide, et al., 
1997) (Ploug, et al., 1998) (Ralston & Ploug, 1996) (Hashiramoto & James, 
2000).  
1.3.2.4 Insulin-stimulated GLUT4 trafficking 
Immuno-cytochemical studies in adipose and cardiac muscle cells under basal 
conditions and following insulin stimulation provide further support for insulin-
stimulated GLUT4 translocation. These results support the findings from earlier 
photo-labelling studies performed by (Holman, et al., 1990). These studies 
revealed that a relatively small amount of GLUT4 (approximately 1-5% of total 
labelled GLUT4) is immuno-located at the cell surface under basal conditions. 
In the insulin-stimulated state the proportion of GLUT4 at the plasma membrane 
increased to approximately 40% (Malide, et al., 2000) (Slot, et al., 1991). In 
addition, the amount of GLUT4 within the endocytic pathway and within clathrin 
coated vesicles/pits is increased in the continued presence of insulin (Slot, et 
al., 1991) (Slot, et al., 1991). These findings provided the first evidence that 
GLUT4 is continuously recycled with the plasma membrane and the main effect 
of insulin was to increase GLUT4 exocytosis.  
The development and use of cell impermeable photo affinity glucose transporter 
labelling reagents has enabled the kinetics of endogenous GLUT4 recycling to 
be investigated under basal and insulin-stimulated steady-state conditions. 
Using these methods the rate for GLUT4 internalisation and exocytosis can be 
directly determined. Firstly, it was demonstrated that GLUT4 continuously 
recycles between the plasma membrane and a storage compartment in both 
non-stimulated and insulin-stimulated adipocytes (Yang, et al., 1992) (Jhun, et 
al., 1992). In the absence of insulin, GLUT4 is rapidly internalised from the cell 
surface and slowly recycled. The net effect is that the majority of GLUT4 
transporters are sequestered within an intracellular compartment and absent 
from the plasma membrane pool. 
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The use of a bis-mannose photolabel, ATB-BMPA in 3T3-L1 adipocytes 
revealed that main effect of insulin was to increase GLUT4 transporter 
exocytosis (~9 fold) (Yang & Holman, 1993). In addition, the rate for GLUT4 
endocytosis was reduced by ~30%. These findings contrast those of Juhn et al, 
who used the photo-reactive probe B3-GL in rat adipose cells. Here, they 
demonstrated that insulin exerts an equal effect to increase GLUT4 exocytosis 
and reduce GLUT4 endocytosis by approximately 3-fold (Jhun, et al., 1992). 
The action of insulin to stimulate GLUT4 exocytic pathways is also conserved in 
primary muscle cells. Using a biotinylated photolabel GP15, insulin stimulation 
has been shown to markedly increase GLUT4 exocytosis rate in both skeletal 
muscle and in rat cardiomyocytes (Karlsson, et al., 2009) (Yang & Holman, 
2005). Furthermore, insulin stimulation did not alter the rate for GLUT4 
endocytosis in cardiomyocytes (Yang & Holman, 2005). This is in contrast to the 
effect observed in adipose cells.  
In 1994, Holman et al. identified several important features of GLUT4 trafficking 
behaviour based on modelling data from photo-labelling and sub-fractionation 
studies (Holman, et al., 1994). This study indicated that the behaviour of GLUT4 
is inconsistent with a straightforward two-pool model (one intra-cellular 
compartment and the plasma membrane) but that a 3-pool model can more 
appropriately account for the experimental results. The presence of an 
additional pool can explain the initial rapid stimulation of GLUT4 translocation to 
the plasma membrane following insulin stimulation. Furthermore, recycling 
through two intracellular pools can account for the reduced steady-state t1/2 
values for GLUT4 exocytosis in the continued presence of insulin. 
1.3.2.5 GLUT4 storage vesicular (GSV) compartment 
In non-stimulated adipocyte cells, using immuno-fluorescence microscopy, a 
large proportion of GLUT4 is localised in punctate 50-80nm diameter vesicular 
structures (Malide, et al., 2000). These punctate GLUT4-containing structures 
co-localise with vesicles containing the vesicular SNAP (Soluble NSF 
Attachment Protein) REceptor (SNARE) protein, vesicle-associated membrane 
protein 2 (VAMP2). VAMP2 is a member of the VAMP/synaptobrevin family. 
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The primary function of SNARE proteins is to mediate vesicle fusion (Malide, et 
al., 1997) (Ralston & Ploug, 1996).  
Further evidence for a distinct GLUT4 storage vesicular (GSV) compartment 
comes from biochemical studies performed in 3T3-L1 adipocytes using the 
transferrin (Tf) endosome ablation technique using Tf coupled-horse radish 
peroxidase (HRP)-3, 3’-diaminobenzidine (DAB). Briefly, 3T3-L1 adipocytes are 
first treated with a transferrin/HRP (Tf/HRP) conjugate. Following which cells 
are then incubated with DAB/peroxidise which results in the selective ablation of 
cellular compartments containing the TfR (Martin, et al., 1996) (Karylowski, et 
al., 2004). Using this method, it has been demonstrated that ~60% of GLUT4 is 
present within a distinct population of post-endocytic vesicles, enriched with 
VAMP2 (Martin, et al., 1996).  
Sub cellular fractionation techniques have enabled the isolation and 
characterisation of GLUT4 storage vesicles (GSVs). Using this technique it has 
been discovered that GLUT4 resides in a population of homogenous GLUT4 
vesicles that are distinct from other light microsomes in both adipose and 
muscle cells (Kandror, et al., 1995). GSVs have been further characterised into 
insulin-responsive and non-insulin-responsive, the former being defined by the 
presence of the protein cellugyrin. Cellugyrin is a homolog of the synaptic 
vesicle protein synaptogyrin. Approximately 50-60% of immuno-isolated GSVs 
are enriched with cellugyrin (Kupriyanova & Kandror, 2000). In addition, the 
protein IRAP is enriched within insulin-responsive GSVs isolated from non-
stimulated adipocyte cells (Kupriyanova, et al., 2002). The expression of IRAP 
is up-regulated during adipocyte differentiation (Keller, 2003). Moreover, sortilin 
and low-density lipoprotein receptor-1 (LRP1) have been identified as major 
constituents of insulin-responsive GSVs. The expression of sortilin and LRP1 
are also increased during adipocyte differentiation. Moreover, shRNA-mediated 
knockdown of sortilin (Shi & Kandror, 2005) or LRP1 (Jedrychowski, et al., 
2010) in 3T3-L1 adipocytes significantly reduces total GLUT4 expression levels 
and subsequently decreases insulin-stimulated glucose uptake. Furthermore, 
the silencing of sortilin in 3T3-L1 cells impairs the formation of GLUT4 storage 
vesicles. More recently, siRNA-mediated knockdown of sortilin reduces GLUT4 
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translocation to the cell surface in C2C12 skeletal muscle cells (Tsuchiya, et al., 
2010). Together, these findings indicate that IRAP, sortilin and LRP1 are major 
components of GSVs and are likely to be required for the stability of GSVs and 
involved in the regulation of insulin-dependent GLUT4 translocation.  
In addition to the major cargo proteins outlined above, other ubiquitously 
expressed proteins are enriched within GSVs membranes and are involved in 
general membrane trafficking and fusion events. These include vesicle-
associated membrane protein 2 (VAMP2), secretory carrier-associated 
membrane proteins (SCAMPs) and small GTP-binding proteins (Kandror & 
Pilch, 1996) (Laurie, et al., 1993). Furthermore, other studies have reported on 
several GSV associated proteins which are involved in regulating insulin-
responsive GLUT4 translocation. These include the Rab-GTPase-activating 
protein AS160/TBC1D4 (Larance, et al., 2005), Tether-containing UBX domain 
for GLUT4 (TUG) (Bogan, et al., 2012) and the small ubiquitin regulated 
modifier (SUMO) conjugating enzyme Ubc9 (Liu, et al., 2007). In addition, rab 
proteins 2A, 4A, 8A, 8B, 10, 11 and 14 have been found to associate with 
GLUT4 storage vesicles (Larance, et al., 2005) (Miinea, et al., 2005) (Kaddai, et 
al., 2009). Rabs are part of a family of small GTPase proteins which regulate 
cellular processes involved in vesicle trafficking, membrane budding and fusion 
(Stenmark & Olkkonen, 2001). SiRNA-mediated depletion of rab 10 has been 
found to impair insulin-stimulated GLUT4 translocation to the cell surface in 
3T3-L1 adipocytes (Sano, et al., 2007). In a recent study, employing total 
internal reflection fluorescence (TIRF) microscopy, it has been demonstrated 
that rab10 directly facilitates the translocation and docking of insulin-responsive 
GSVs to the plasma membrane (Chen, et al., 2012). Whereas, rabs 4, 8A and 
14 mediate GLUT4 movement through specific routes of the general endocytic 
recycling pathway.  
1.3.2.6 GLUT4 trafficking models 
The intracellular trafficking route for GLUT4 can be partitioned into six discrete 
trafficking steps illustrated in Figure 1.3 (Larance, et al., 2008). These are the 
biogenesis of GSVs (trafficking of GLUT4 from the TGN to the GSV 
compartment and release of GSV from sequestration mechanisms), the 
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translocation/movement of GSVs to the cell surface (exocytosis), tethering (the 
low affinity interaction of GSVs and plasma membrane), docking (assembly of 
SNARE complex before fusion of the GSVs with the plasma membrane), fusion 
(the lipid bilayers of the GSVs and the plasma membrane combine) and 
endocytosis (the removal of GLUT4 from the cell surface and trafficking to the 
endosomal compartment). Additionally, as GLUT4 undergoes endocytosis it is 
sorted from the endosomes into vesicles associated with the general 
endosomal pathway. These vesicles undergo regulated constitutive trafficking 
and fusion with the plasma membrane. Therefore, it is likely that insulin can 
regulate any number of these discrete trafficking steps. However, the question 
is which of these steps of GLUT4 trafficking are the major sites of insulin action.  
In 1994, Holman et al concluded that the original two-pool model (one intra-
cellular compartment and the plasma membrane) could not accurately predict 
GLUT4 trafficking behaviour (Figure 1.4A). Instead a three-pool model could 
account for the fast transition from basal to insulin-stimulated steady state and 
the slower rate of GLUT4 recycling in the insulin-stimulated state (Figure 1.4B) 
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Figure 1.3: The trafficking routes of GLUT4. GLUT4 trafficking can be segregated into at least 
six processes: Exocytic processes: Budding of GSVs (release from sequestration 
mechanism or biogenesis of vesicles from endosomes/TGN), movement (transport of 
vesicles to the plasma membrane along microtubules and actin), tethering (interaction 
between GSVs and plasma membrane is mediated by a multisubunit tethering complex such 
as the exocyst complex), docking (assembly of the trans-SNARE complex), fusion (the 
merging of the GSV and plasma membrane lipid bilayers) and endocytosis (the retrieval of 
GLUT4 from the plasma membrane to the cell interior). Additionally, as GLUT4 undergoes 
endocytosis it is sorted from the endosomes into vesicles associated with the general 
endosomal pathway. These constitutive vesicles will also undergo regulated trafficking and 
fusion steps with the plasma membrane. This schematic has been adapted from (Larance, et 
al., 2008). Key: Red circle – Rab 10, light yellow shape – myosin motor proteins, Myo1C, 
dark blue oval, orange, pink and purple oblongs – subunits of the exocyst, light blue oblong – 
VAMP2, pale pink and green shapes – t-SNAREs, yellow circles – glucose.  
 
More recently, the ectopic expression of exofacial epitope-tagged GLUT4 fusion 
proteins have been extensively used to study GLUT4 trafficking in both adipose 
and muscle cells. These GLUT4 reporter constructs contain a hemagglutinin 
(HA) or Myc tag in the first exofacial loop and can also have a C-Terminal GFP 
tag (HA/Myc-GLUT4-GFP). The exofacial (HA/Myc) tag allows for the rapid 
detection of GLUT4 which has been inserted into the plasma membrane. Firstly, 
using these reporter proteins the rate at which GLUT4 arrives at the cell surface 
can be measured as a function of time (transition kinetics). Secondly, several 
studies have used these reporter proteins to study the effect of insulin on 
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GLUT4 exocytic pathways at steady-state (Martin, et al., 2006) (Karylowski, et 
al., 2004) (Govers, et al., 2004) (Fazakerely, et al., 2009). For these studies 
intact live cells are labelled with a saturating concentration of purified anti-HA 
antibody. The concentration of antibody used is sufficient to label all HA-GLUT4 
that appears at the cell surface. Thus, anti-HA accumulation (uptake) over time 
is a function of the rate of the exchange of GLUT4 between intracellular 
compartments and the plasma membrane (kex). In addition, the size of the 
GLUT4 recycling pool can be determined. Therefore, the effect of insulin on the 
release of GLUT4 from an intracellular storage in to the continuously recycling 
pool can be resolved. 
Thus far, two distinctly different models of GLUT4 retention have been 
proposed. These are supported primarily from experimental data from studies 
performed in 3T3-L1 adipocytes. The GLUT4 retention models outlined below 
are depicted in Figure 1.4. The first model proposed by McGraw and colleagues 
details that intracellular GLUT4 traffic is governed by a dynamic system (Figure 
1.4C). In this ‘dynamic retention’ model the actively cycling GLUT4 pool is 
governed by a very slow exocytosis rate to the cell surface and a rapid 
internalisation rate under basal conditions. Importantly, the entire insulin-
responsive GLUT4 pool can eventually recycle with the plasma membrane in 
basal cells (Martin, et al., 2006) (Karylowski, et al., 2004). Insulin stimulation 
markedly increases kex for GLUT4 ~7-13 fold from 0.006-0.007 min
-1 to 0.05-
0.08 min-1 and concurrently, inhibits ken (Karylowski, et al., 2004) (Martin, et al., 
2006). A key feature of this model is that insulin solely regulates the rate of 
GLUT4 movement between the intracellular compartments and the plasma 
membrane.  
Conversely, the second model pioneered by James and colleagues is one of 
‘GLUT4 static retention’ (Govers, et al., 2004) (Coster, et al., 2004) (Figure 
1.4D). The model for GLUT4 static retention is further supported by data from 
studies performed by Mastick and colleagues (Muretta, et al., 2008) (Brewer, et 
al., 2011). Govers et al. observed that only ~10% of the total GLUT4 pool is 
actively engaged in recycling with the plasma membrane in 3T3-L1 adipocytes 
under basal conditions. Intracellular GLUT4 is sequestered within specialised 
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static GLUT4 storage vesicles (GSV) away from the general endosomal 
recycling compartment (ERC). Insulin stimulation releases GLUT4 from a ‘static 
retention mechanism’ increasing cell surface GLUT4 levels thus, substantially 
increasing the amount of GLUT4 within the general recycling pathway. 
Furthermore, insulin stimulates a modest increase in kex for GLUT4 from 0.014 
min-1 to 0.03 min-1 (Govers, et al., 2004) (Coster, et al., 2004). No effect on ken 
was observed. More recently, direct analysis of GLUT4 dynamics using 
quantum dot technology has revealed the existence of a large stationary GLUT4 
compartment in differentiated 3T3-L1 basal cells which further supports the 
model for ‘static retention’ (Fujita, et al., 2010).  
The reason for the conflicting trafficking data and proposed GLUT4 trafficking 
models is yet to be determined. However, Muretta et al., discovered that the re-
plating of confluent differentiated 3T3-L1 adipocytes (as performed in Martin et 
al, for microscopy based studies) increases the size of the basal GLUT4 
recycling pool (Muretta, et al., 2008). It is therefore possible that re-plating of 
3T3-L1 cells somehow affects adipogenic differentiation. In support of this, 
Govers et al observed that the ‘static retention’ capacity is not present in 
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Figure 1.4: Models for GLUT4 trafficking. (A) The original two-pool model for GLUT4 
recycling. In the two-pool model the plasma membrane GLUT4 pool is in equilibrium with one 
intracellular recycling pool. (B) In the three-pool model GLUT4 recycles through two 
intracellular compartments and the plasma membrane. The additional pool can account for 
the initial rapid stimulation of GLUT4 translocation to the plasma membrane following insulin 
stimulation and the slower steady-state t1/2 value for GLUT4 exocytosis in the continued 
presence of insulin. (C) The dynamic-retention (three-pool) model proposed by Mcgraw and 
collegues. In the basal state, cell surface levels of GLUT4 are kept low from the slow 
movement of GLUT4 to the plasma membrane (t1/2 115 min) and the rapid retrieval back to 
endosomal recycling compartment (ERC). GLUT4 storage vesicles (GSVs) are in continual 
exchange with the endosomal recycling compartment. (D) The model of GLUT4 static 
retention (three-pool). In basal cells the majority of GLUT4 transporters are sequestered 
away from the ERC (via TGN) to a stationary non-cycling GSV compartment. This maintains 
the low cell surface levels of GLUT4 in the basal state. Insulin simulates the release of this 
GSV pool to the plasma membrane. This diagram has been adapted from (Larance, et al., 
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1.3.2.7 GLUT4 and T2DM 
The dysregulation of insulin-stimulated glucose uptake into peripheral tissues is 
a major feature of T2DM. Insulin-stimulated glucose transport is decreased in 
human muscle from obese diabetic subjects compared with control individuals. 
This correlated with a reduced increase of GLUT4 transporters at the plasma 
membrane (Zierath et al., 1996). Furthermore, it has been reported that GLUT4 
protein expression levels are decreased in both adipose and muscle tissues 
from diabetic rats compared with control rats (Kahn, 1992).  
GLUT4 transgenic mouse models provide valuable information about the 
importance of GLUT4 expression in insulin-responsive tissues and the 
development of T2DM. Approximately half of heterozygous GLUT4 knock out 
(GLUT4 +/-) male mice developed moderate T2DM symptoms. This is correlated 
with the decreased abundance of GLUT4 in adipose and muscle tissues 
(Stenbit, et al., 1997). Furthermore, muscle-specific GLUT4 knockout mice 
(muscle-G4KO) develop severe insulin resistance and glucose intolerance. 
These mice exhibit significantly impaired basal and insulin-stimulated glucose 
transport  (Zisman, et al., 2000). Furthermore, adipose-selective (adipose-
G4KO) GLUT4 knockout mice display markedly impaired insulin-stimulated 
glucose transport (Abel, et al., 2001). Interestingly, even though GLUT4 levels 
were normal in muscle, adipose-G4KO mice displayed impaired in vivo glucose 
transport in muscle. Conversely, transgenic mice overexpressing GLUT4 
selectively in skeletal muscle or adipose tissue display an increased enhanced 
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1.4 Signalling pathways to GLUT4 translocation  
Since the identification of GLUT4, a vast amount of research has been 
dedicated to further advance our understanding of how GLUT4 traffics from 
specialised intracellular storage compartments to the plasma membrane. As 
skeletal muscle is the major site of glucose disposal, it is therefore important to 
understand the mechanisms which regulate GLUT4 translocation in muscle. 
Here, we review the signalling pathways that regulate GLUT4 trafficking. A 
schematic is depicted in Figure 1.5. 
 
Figure 1.5: Insulin and contraction-mediated signalling pathways which lead to GLUT4 
translocation. Insulin stimulation mediates a signalling cascade through insulin receptor 
substrates (IRS) and phosphatidyl inositol 3-kinase (PI3K) which leads to the activation of Akt 
via its phosphorylation by phosphoinositide dependant kinase 1(PDK-1) and mammalian 
target of rapamycin complex-2 (mTORC2). Activated Akt phosphorylates Rab-GTPase-
activating proteins (Rab-GAP) which inactivates GAP activity towards associated rab 
proteins. This promotes the association of rab proteins with GTP and therefore in its active 
conformation. GTP-loaded rab proteins facilitate the translocation of GLUT4 storage vesicles 
(GSVs) and fusion with the plasma membrane. Muscle contraction results in the elevation of 
AMP and Ca
2+
 which through LKB1 and Ca
2
+/calmodulin-dependant protein kinase-2 
(CaMKII) phosphorylate and activate AMP-activated protein kinase (AMPK). These signalling 
cascades lead to the phosphorylation of Rab-GAP proteins and the translocation of GLUT4. 
This diagram has been adapted from (Sakamoto & Holman, 2008). 
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1.4.1 The Insulin signalling pathway  
The binding of insulin to its receptors on the surface of insulin-responsive cells 
leads to the activation of complex downstream signalling cascades involved in 
cell metabolism (Watson & Pessin, 2006) (Bryant, et al., 2002) 
1.4.1.1 The insulin Receptor 
The insulin receptor (IR) is part of a large family of trans-membrane receptor 
tyrosine kinases. The IR is a heterotetrameric glycoprotein which is comprised 
of two extracellular α-subunits and two trans-membrane β-subunits. The β-
subunits possess intrinsic tyrosine kinase activity. The binding of insulin to α-
subunits initiates a conformational change in the insulin receptor. This induces 
intracellular β-subunit auto-phosphorylation of tyrosine residues and results in 
the activation of the tyrosine kinase domains. Activated tyrosine kinase domains 
transduce the insulin response through the recruitment and phosphorylation of 
an array of adaptor proteins. The best characterised are the insulin receptor 
substrates (IRS-1-4) proteins. However, others IR substrates include Shc, Clb, 
signal regulatory proteins (SIRPs) and adaptor protein with pleckstrin homology 
(PH) and Src homology 2 domains (APS) (White, 2002). 
1.4.1.2 The insulin receptor substrates (IRS) 
IRS proteins contain pleckstin homology (PH) and phosphotyrosine binding 
domains (PTB) domains situated at the N-terminus. PTB domains mediate 
interactions with the IR (White, 2002). IRS-1 and IRS-2 are proteins involved in 
maintaining normal glucose homeostasis. Transgenic mice deficient in IRS-1 
(IRS-1 KO) are glucose intolerant and have an impaired insulin-stimulated 
glucose uptake (Araki, et al., 1994). In comparison, transgenic mice deficient in 
IRS-2 (IRS-2 KO) display a severe insulin resistance phenotype, associated 
with an impaired function of pancreatic β-cells (Withers, et al., 1998). IRS 
proteins contain multiple phosphotyrosine motifs which function as protein 
scaffolds for binding of Src homology 2 (SH2) domain-containing proteins (Sun, 
et al., 1991). IRS interacts with many SH2 domain containing proteins such the 
phosphatidyl inositol 3-kinase (PI3K) regulatory subunit p85, Grb-2 and SHP-2 
(Boura-Halfon & Zick, 2009).  
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1.4.1.3 Phosphatidyl inositol 3-kinase (PI3K) 
PI3K is a key intermediate in insulin-stimulated signalling responses leading to 
glucose transport. Early evidence for this arose from studies in adipocytes using 
the PI3K inhibitor, wortmannin (Clarke, et al., 1994) (Okada, et al., 1994). 
Furthermore, treatment with wortmannin inhibits insulin-stimulated cell surface 
levels of GLUT4 in L6 myotubes and muscle (Stockli, et al., 2008).  
PI3Ks are signalling transducing enzymes involved in many cellular responses. 
PI3Ks phosphorylate inositol phospholipids at the 3’OH position to generate 3’ 
phosphoinositides (3’PI). PI3Ks can be divided into three classes, I, II, III. Class 
I PI3Ks are further divided into two groups, class IA PI3Ks and class IB PI3Ks. 
Class IA PI3Ks facilitate signalling responses downstream of the insulin and 
insulin-like growth factor (IGF) receptors (Cantley, 2002). Class IA PI3Ks are 
heterodimers composed of a regulatory subunit (p85) and a catalytic subunit 
(p110). The regulatory subunit p85 of PI3Ks facilitate its interaction with adaptor 
proteins, directly associated with the insulin receptor. The class IA PI3Ks 
preferentially catalyse the phosphorylation of membrane phosphatidylinositol (4, 
5) bisphosphate (PI(4,5)P-2) (PIP2) to generate phosphatidylinositol (3, 4, 5) 
trisphosphate (PI(3,4,5)P-3) (PIP3) (Vanhaesebroeck & Alessi, 2000). PI3K 
signalling is modulated by the activity of two independent phosphatases. Src-
Homology 2 (SH2) containing phosphatases (SHIPs) dephosphorylates 
PI(3,4,5)P-3 at the 5’ position to generate PI(3,4)P-2. The lipid phosphatase 
PTEN, dephosphorylates at the 3’ position to generate PI(4,5)P-2 (Cantley, 
2002).  
The accumulation of PIP3 at the cell membrane results in the recruitment of 
downstream signalling proteins which contain pleckstrin-homology (PH) 
domains. These include phosphoinositide-dependant protein kinase 1 (PDK-1) 
and isoforms of Akt, also known as protein kinase B (PKB). Activated PDK-1 
phosphorylates and activates downstream serine/threonine kinases. Those of 
importance to insulin signalling are Akt and isoforms of atypical protein kinase C 
(aPKC) (Sajan, et al., 2006).  
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1.4.1.4 Akt/protein kinase b (PKB) 
The serine/threonine kinase Akt is a major downstream effector of PI3K. The full 
activation of the serine/threonine kinase Akt requires phosphorylation at two 
distinct residues, threonine 308 and serine 473 (Alessi, et al., 1996). PIP3 in the 
plasma membrane recruits Akt and PDK-1 into close proximity. This facilitates 
PDK-1 phosphorylation of Akt on threonine 308 (Alessi, 2001). Mammalian 
target of Rapamycin (mTOR) in complex with rapamycin-insensitive companion 
of mTOR (raptor-mTOR protein complex (TORC2)) mediates serine 473 
phosphorylation of Akt (Jacinto, et al., 2006).  
The serine/threonine kinase Akt is a major downstream effector of PI3K. Insulin 
stimulation leads to the phosphorylation and activation of Akt which mediates 
GLUT4 translocation to the plasma membrane and increases glucose uptake 
(Franke, et al., 1995) (Alessi, et al., 1996). Akt has three isoforms Akt1/PKBα 
Akt2/PKBβ Akt3/PKBγ. Akt1 and Akt2 are expressed in adipose and muscle 
tissue (Kim, et al., 2000). Akt2 has been shown to be crucial for the regulation 
of normal glucose homeostasis. Transgenic mice deficient for Akt2 develop 
insulin resistance, hyperglycaemia and hyperinsulinemia (Cho, et al., 2001). 
Furthermore, Akt2 is essential for insulin-stimulated glucose uptake in muscle. 
Ex vivo insulin-stimulated glucose uptake was impaired in muscle from Akt2 
knockout mice compared with control mice (Sakamoto, et al., 2006). In contrast, 
the over-expression of a constitutively active form of Akt increases GLUT4 
translocation to the plasma membrane in 3T3-L1 adipocytes in the absence of 
insulin (Kohn, et al., 1996).  
1.4.1.5 Protein kinase C (PKC) 
There are three aPKC isoforms (PKC-ζ- λ- ι). PDK1 phosphorylates PKC-ζ, λ 
and ι on threonine residues 410, 411 and 403 respectively. RNAi mediated 
knock down of endogenous PKC-ζ or the viral expression of kinase inactive (KI) 
PKC-ζ has been found to significantly impair insulin-stimulated glucose uptake 
in L6 myotubes (Sajan, et al., 2006) (Sajan, et al., 2010). 
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1.4.1.6 Insulin resistance 
Insulin resistance is a metabolic state which is caused by a range of factors 
which include hyperglycaemia, hyperinsulinemia, dyslipidaemia, inflammation 
and anti-inflammatory steroids. It is a complex condition and it still remains 
unclear whether there are discrete cellular mechanisms which regulate insulin 
resistance (Hoehn, et al., 2008).  
High-fat diet (HFD) fed rodents provide robust models to study the effects of 
fatty acids on whole body metabolism and directly on insulin action in muscle. 
Mice fed on a HFD for 3-4 weeks impaired insulin-stimulated recruitment of 
GLUT4 to the cell surface and reduced glucose uptake in isolated soleus 
muscle compared to mice fed on a standard low-fat chow diet (Zeirath, et al., 
1997). In addition, another study reported that high–fat feeding in mice for just 
17 days was enough to impair insulin-stimulated glucose uptake in muscle 
(Hoehn, et al., 2008). Studies carried out in skeletal muscle cell models provide 
further information about the direct effect of the increased availability of fatty 
acids on insulin signalling. Treatment of L6 myotubes with palmitate significantly 
reduced insulin-stimulated cell surface levels of GLUT4 (Hoehn, et al., 2008) 
(Hoehn, et al., 2009). Additionally, Lee et al confirmed that treatment with 
palmitate reduced insulin-stimulated glucose uptake in L6 myotubes (Lee, et al., 
2006). In addition treatment with palmitate reduced insulin-stimulated glycogen 
synthesis and glucose oxidation in C2C12 myotubes (Hirabara, et al., 2009).  
Several studies support that a reduction in insulin-stimulated responses occurs 
through mechanisms that affect the levels of phosphorylated Akt. C2C12 
myotubes treated with saturated fatty acids palmitate or stearate at a range of 
concentrations between 0.1-1 mM for between 16-24 hours inhibited insulin-
stimulated Akt activation (Chavez, et al., 2003) (Hirabara, et al., 2009) 
(Tsuchiya, et al., 2010), but did not inhibit PI3K activity (Chavez, et al., 2003). 
However, in a study performed by Hoehn et al, low doses of palmitate (0.05- 0.3 
mM) that were sufficient to significantly reduce insulin-stimulated cell surface 
levels of GLUT4 in L6 myotubes, did not affect the levels of phosphorylated IRS 
proteins or Akt (Hoehn, et al., 2008). Therefore, insulin resistance is associated 
with defects which occur through IRS-independent mechanisms.  
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The reduced fatty acid oxidative capacity of muscle from obese and insulin-
resistant subjects is in part associated with the increased accumulation 
intracellular lipid-mediates (Holland, et al., 2007). In C2C12 or L6 myotubes, 
treatment with palmitate stimulated the accumulation of ceramide and 
diacylglycerol (DAG) (Chavez, et al., 2003) (Lee, et al., 2006). Furthermore, 
Chavez et al. demonstrated that increased levels of intramuscular ceramide 
impaired insulin action through inhibiting Akt activity (Chavez, et al., 2003). The 
inhibitory effect of palmitate on Akt phosphorylation was reversed in myotubes 
pre-treated with myriocin a serine palmitoyl transferase (SPT) inhibitor or 
cycloserine a citrate synthase inhibitor which are important enzymes regulating 
ceramide biosynthesis.  
1.4.2 Contraction-mediated signalling.  
It is well established that physical exercise is important and beneficial for overall 
fitness, body weight and for the management of T2DM. Acute exercise has 
been shown to enhance glucose uptake in muscle (Defronzo, et al., 1981) by 
mediating the translocation of GLUT4 from intracellular compartment to the 
plasma membrane (Douen, et al., 1990). Even though insulin-stimulated GLUT4 
translocation is impaired in people with T2DM, exercise mediated GLUT4 
translocation appears normal (Zeirath, et al., 1997). Our current understanding 
is that insulin and contraction mediate independent signalling mechanisms to 
regulate glucose disposal.  
Contraction-mediated signalling activates multiple downstream signalling 
cascades which are independent of insulin/PI3K signalling (Funai & Cartee, 
2009). Keys mediators include AMP-activated protein kinase (AMPK) (Hayashi, 
et al., 1998) (Musi, et al., 2001) and Ca2+ /calmodulin-dependant protein kinases 
(CaMK) (Funai & Cartee, 2008) (Funai & Cartee, 2009) (Witczak, et al., 2010) 
and atypical PKC. 
1.4.2.1 AMP-activated protein kinase (AMPK) 
The AMP-activated protein kinase (AMPK) is a mediator of hormonal signalling 
and is activated in response to exercise or cellular stress. The energy-status of 
a cell is determined by the abundance of adenosine mono-phosphate (AMP) 
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and adenosine tri-phosphate (ATP) nucleotides. Various stimuli activate AMPK 
by increasing the cellular ratio of AMP/ATP. AMPK detects discrete changes in 
the AMP/ATP ratio. Activated AMPK regulates mechanisms to restore the 
cellular energy balance (Hardie, 2004).  
AMPK is a heterotrimeric protein which is comprised of a catalytic α-subunit 
along with regulatory scaffolding β-and nucleotide binding γ-subunits. The α-
subunit possesses intrinsic serine/threonine kinase activity. There are multiple 
isoforms of each subunit. There are two α-subunits, α1 and α2. In addition there 
are two β-subunits β1, β2 and three γ-subunits γ1, γ2 and γ3. The catalytic 
subunit α2 isoform is found highly expressed in skeletal muscle and heart, 
whereas the AMPK-α1 isoform is ubiquitously expressed in most tissues (Musi, 
et al., 2001). In addition, both α-subunits are expressed in C2C12 skeletal 
muscle cells (Niu, et al., 2010). The isoforms associate together to form 12 
heterotrimeric protein complexes. These complexes exhibit differential tissue 
distribution patterns (Woods, et al., 2003). Only three of the 12 complexes are 
present in human skeletal muscle (α2β2γ1> α2β2γ3=α1β2γ1) (Wojtaszewski, et 
al., 2005). In addition, mouse skeletal muscle expresses predominately α2β2γ3 
hetero-trimeric complexes (O’Neil et al., 2011).  
The binding of AMP to the γ-subunit results in a conformational rearrangement 
in the AMPK complex. This facilitates the phosphorylation of γ-subunit at 
threonine 172 mediated by the serine/ threonine kinase, LKB1. The 
phosphorylation of AMPK is necessary for regulating AMPK activity (Shaw, et 
al., 2004) (Lizcano, et al., 2004). Muscle-specific knock-out of LKB1 (LKB1 KO) 
prevents contraction-mediated activation of AMPK-α2. (Sakamoto, et al., 2004). 
Ex vivo muscle contraction does not directly stimulate LKB1 activity (Sakamoto 
et al., 2004). AMPK is allosterically activated by the binding of AMP to the γ-
subunit which results in a conformation change to induce the phosphorylation of 
threonine 172 by LKB1.  
Further evidence that AMPK activity directly stimulates glucose uptake in 
muscle comes from studies which utilise the adenosine analogue AICAR. 
AICAR, 5-Aminoimidazole-4-carboxamide 1-β-D-ribofuranoside is a cell-
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permeable compound that can be phosphorylated in the target cell to ZMP, 
which mimics the activity of AMP. Treatment with AICAR increased the 
phosphorylation of AMPK at threonine 172 and stimulated glucose uptake in L6 
myotubes (Sajan, et al., 2010). This is mediated by the increased levels of 
GLUT4 (Fazakerely, et al., 2009) (Sajan, et al., 2010) and GLUT1 transporters 
at the cell surface in L6 myotubes. In addition, treatment with AICAR increased 
the level of GLUT4 transporters at the cell surface and enhanced glucose 
transport in isolated muscle explants (Koistinen, et al., 2003) (Hayashi, et al., 
1998) (Sajan, et al., 2010). Furthermore, the drug metformin has been shown to 
mimic AICAR’s effect on muscle by significantly increasing both AMPK-α1 and -
α2 catalytic activity in isolated rat skeletal muscle (Zhou, et al., 2001) (Sajan, et 
al., 2010) (Jorgensen, et al., 2004). Metformin is a biguanide hyperglycaemic 
drug which is widely administered to treat T2DM. The drug functions to reduce 
hepatic glucose production and to increase muscle glucose uptake.  
AICAR-stimulated phosphorylation of AMPK and ACCβ and glucose uptake in 
muscle is dependent on the presence of the AMPK-α2 isoform. AICAR-
stimulated glucose uptake was significantly ablated in muscle from AMPK-α2 
knockout (AMPK-α2 KO) mice but not affected in muscle from AMPK-α1 
knockout (AMPK-α1 KO) mice. In contrast, contraction-mediated glucose uptake 
was not affected in either AMPK-α2 or AMPK-α1 KO mice (Jorgensen, et al., 
2004). Even though contraction mediated phosphorylation of γ-subunit of AMPK 
at threonine 172 was impaired. Interestingly the protein expression level of the 
α1-subunit was up-regulated in the skeletal muscle from AMPK-α2 KO mice 
(Jorgensen, et al., 2004). There appears to be some functional redundancy 
between the two catalytic isoforms (α2/α1) of AMPK. Furthermore, contraction-
mediated glucose uptake is only partially inhibited in mouse skeletal muscle 
expressing the kinase dead AMPK-α2 kinase dead (AMPK-α2 KD) or in L6 
myotubes expressing the kinase-inactive (KI) dominant-negative AMPK-α2 
(AMPK-α2 KI) (Sajan, et al., 2010).  
AICAR allows us to study the downstream signalling effects of AMPK, a key 
regulator of energy balance. However, it is important to note that AICAR doesn’t 
recapitulate the full extent of exercise signalling. Muscle contraction activates 
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complex cell signalling mechanisms and activation of AMPK only accounts for 
part of this. In vitro and in situ studies provide evidence that muscle contraction 
increases Akt activity and that this is dependent on signalling through PI3K 
(Kramer, et al., 2006). However, this pathway does not seem to contribute to 
contraction-stimulated glucose uptake (Funai & Cartee, 2009). In vitro 
contraction has also been shown to increase the phosphorylation of CaMKII at 
threonine 286 via an AMPK-independent signalling pathway. Contraction-
stimulated phosphorylation of CaMKII was not affected in muscle pre-treated 
with compound C. Compound C (also known as dorsomorphin) is a small-
molecule inhibitor of AMPK (Funai & Cartee, 2009). Compound C directly and 
reversibly inhibits AMPK and is competitive with ATP. Treatment with 
compound C led to only a partial inhibition of contraction-stimulated glucose 
transport. This indicated that AMPK-independent mechanisms can account for 
part of the stimulation of glucose transport. However, a significant portion is 
dependent on signalling via AMPK. Compound C has been reported to 
selectively inhibit the bone morphogenic protein (BMP) type I receptors ALK2, 
ALK3 and ALK6 (Yu, et al., 2008). The lack of specificity of compound C has 
limited its use.  
1.4.2.2 Ca2+/calmodulin-dependant protein kinases 
An essential step in muscle contraction is the release of Ca2+ from ryanodine 
receptors at the sarcoplasmic reticulum. Exercise elevates the cytosolic 
concentrations of Ca2+. Ca2+/calmodulin-dependant protein kinase CaMKII, is 
regulated by Ca2+/calmodulin, and is auto-phosphorylated upon binding. CaMKII 
has been implicated in the regulation of glucose uptake in muscle. In vivo 
muscle contraction induces CaMKII phosphorylation at threonine 286/287. 
Electrically-stimulated contraction but not insulin-stimulated glucose uptake was 
impaired in mouse muscle expressing a CaMKII specific inhibitory peptide 
compared with a control peptide (Witczak, et al., 2010).   
1.4.2.3 PKC  
PDK1 phosphorylates PKC-ζ, λ and ι on threonine residues 410, 411 and 403 
respectively. Metformin and AICAR are reported to mediate the phosphorylation 
of atypical protein kinase C (aPKC) by PDK. AICAR and metformin stimulate 
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glucose uptake by increasing AMPK phosphorylation which activates 
downstream signalling pathways through ERK and aPKC. In support of this, 
when a kinase-inactive AMPK α2 is expressed in L6 myotubes, AICAR and 
metformin induced phosphorylation of AMPK, ERK and PKC-ζ were significantly 
impaired (Sajan, et al., 2010). In addition, muscle-specific KO of PKC-λ 
significantly inhibited AICAR and metformin but not exercise-stimulated 2DG 
uptake in vastus lateralis muscle (Sajan, et al., 2010).  
1.4.2.4 Exercise and insulin sensitivity 
In obese subjects moderate-intensity aerobic exercise improved insulin 
sensitivity and oxidative capacity which correlated with reduced intramuscular 
levels of ceramide and DAG. (Bruce, et al., 2006) (Dube, et al., 2008). In 
addition, a 16 week exercise intervention moderately increased the percentage 
of type I oxidative muscle fibres in vastus lateralis muscle (Dube, et al., 2008). 
As well as this, exercise and the drug metformin have been reported to 
significantly increase AMPK-α2 activity in muscle from T2DM subjects who have 
an impaired insulin-stimulated glucose uptake (Musi, et al., 2001).  
Furthermore, numerous studies have reported additive effects of both AMPK-
activators and insulin on glucose uptake and/or GLUT4 translocation in to 
muscle (Hayashi, et al., 1998) (Yang & Holman, 2005) (Yang & Holman, 2006) 
(Bergeron, et al., 1999) (Fazakerely, et al., 2009). Additionally, metformin has 
been shown to enhance basal and insulin-stimulated glucose uptake in skeletal 
muscle (Zhou, et al., 2001) and in L6 myotubes (Hundal, et al., 1992). 
A vast amount of research is focused on finding potential therapeutic targets 
which increase insulin sensitivity and oxidative capacity of muscle. In which 
overcome insulin resistance associated with T2DM (Hawley & Lessard, 2008) 
(Maarbjerg, et al., 2011). It is important therefore to understand in detail how 
insulin- and contraction-mediated signalling regulates subsequent downstream 
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1.5 Rab-GTPase Activating Proteins 
1.5.1 Identification of AS160 (Akt Substrate of 160 kDa)/TBC1D4  
AS160 is a protein of 160 kDa that was discovered in adipocytes as a novel 
phosphorylation substrate of Akt/PKB (Kane, et al., 2002). Phosphorylated 
AS160 was immuno-precipitated using a phosphorylated (serine/threonine) Akt 
antibody (PAS) from 3T3-L1 cells following insulin stimulation. The PAS 
antibody has been raised towards the phosphorylated Akt phospho-motif 
RXRXXpS/T and is used to detect Akt substrates. AS160 was predicted to 
contain a GTPase activating protein (GAP) domain (Kane, et al., 2002). In 
addition, AS160 contains two phosphotyrosine binding domains (PTB) which 
are situated at the N terminus. PTB domains are required for protein-protein 
interactions and are found to typically bind to phosphorylated tyrosine residues 
(Yan, et al., 2002). AS160 also possesses a calmodulin binding domain (CBD), 
situated just upstream from the GAP domain. AS160 was found to interact with 
Ca2+/calmodulin based on co-immunoprecipitation analysis carried out in 3T3 
L1 adipocytes (Kane & Lienhard, 2005).  
 
Figure 1.6: A schematic diagram of TBC1D1 and TBC1D4. TBC1D1 and TBC1D4 contain 
two phospho-tyrosine binding domains (PTB), a GTPase activating domain (GAP) and a 
calmodulin binding domain (CBD). There are appears two major splicing variants (SV). The 
long variant codes for an additional segment within the center of the protein. Insulin-
stimulated phosphorylation sites are depicted in black. AMPK phosphorylation sites are 
displayed in green. Sites in blue are predicted Akt and AMPK phosphorylation sites. The R/K 
point mutation in the GAP domain inhibits its activity. The R125W mutation in TBC1D1 has 
been identified as a candidate causing severe familial obesity predisposition in humans, 
Diagram is modified from (Sakamoto & Holman, 2008).  
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AS160 is highly expressed in white adipose tissue, brown adipose tissue, brain, 
heart and in oxidative soleus muscle (Nagase, et al., 1998) (Taylor, et al., 
2008). The expression of AS160 in the soleus muscle is greater compared to 
that in the glycolytic TA, EDL and gastrocnemius skeletal muscles. Therefore it 
appears to correlate with the increased oxidative capacity and insulin 
responsiveness of the soleus muscle. 
AS160 is frequently referred to as TBC1D4 (tre-2/USP6, BUB2, cdc16 domain 
family member 4). Preceding its discovery as an Akt substrate, it was cloned 
from the brain (clone: KIAA 0603) as part of a series of studies which were 
carried out to sequence unidentified human genes. TBC1D4 belongs to a family 
of proteins which contain a highly conserved TBC domain which is located to a 
region of 180-200 amino acids at the C terminus (Nagase, et al., 1998). This 
domain shares significant homology to regions within ubiquitin specific protease 
6, oncogene (tre-2/USP6) and the yeast cell cycle regulated phospho-protein 
(BUB2) and the yeast cell division cycle 16 protein (cdc16) (Richardson & Li, 
1995). A schematic representation of TBC1D4 is depicted in Figure 1.6. 
1.5.2 Identification of TBC1D1 
Phylogeny analysis revealed that the closest relative of TBC1D4 is TBC1D1. 
TBC1D1 (tre-2/USP6, BUB2, cdc16 domain family member 1), was first 
identified by Richardson & Li. as a gene which was differentially regulated 
during mast cell development, highlighting its potential role in the cell cycle and 
cell differentiation (Richardson & Li, 1995). Phylogenetic data has indicated that 
TBC1D4 emerged after TBC1D1 in evolution during vertebrate development 
(Chen, et al., 2008). The two proteins are 47% identical and share similar 
protein domains including a TBC domain at the C-Terminus along with two N-
Terminal PTB domains and a CBD domain (Roach, et al., 2007) (Figure 1.6).  
TBC1D1 is expressed in skeletal muscle, heart and uterus (Stone, et al., 2002) 
(Chadt, et al., 2008). The highest levels of TBC1D1 protein are expressed in 
glycolytic TA and EDL muscles which contain predominately type II fibres. 
Lower expression levels are detected in oxidative soleus and in the 
gastrocnemius muscle. Furthermore, the expression of TBC1D1 is up-regulated 
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in C2C12 muscle cells during differentiation in to myotubes (Peck, et al., 2009). 
In comparison to TBC1D4, very little TBC1D1 is found to be expressed in 
adipose tissue (Taylor, et al., 2008) (Szekeres, et al., 2012). 
1.5.3 Proposed function of Rab-GAPs 
It is now well established that proteins which contain a TBC domain primarily 
function as a GAP for small GTPase rab proteins (Pan, et al., 2006). Rabs are 
part of a family of small GTPase proteins which regulate cellular processes 
involved in vesicle trafficking, membrane budding and fusion (Stenmark & 
Olkkonen, 2001). The rab family consists of more than 60 members and have 
been found to localise to discrete subcellular membrane compartments 
(Stenmark & Olkkonen, 2001). Rab proteins are found in two conformations, 
either in an ‘inactive state’ bound to guanoside diphosphate (GDP) or in an 
‘active state’ bound to guanosine triphosphate (GTP) (Figure 1.7). The release 
of GDP and the subsequent binding to GTP is mediated by proteins known as 
guanosine nucleotide exchange factors (GEFs). Furthermore, activated GTP 
bound rab proteins associate with ‘effector’ proteins which regulate the diverse 
steps in vesicular trafficking. Conversely, Rab-GAP proteins function to 
accelerate the slow intrinsic hydrolysis (GTPase activity) of GTP to GDP on 
associated rab proteins. Therefore they are negative regulators of rab activity. 
The TBC1D4 and TBC1D1 GAP domains have been shown to exhibit catalytic 
activity towards rab proteins 2A, 8, 10 and 14. Furthermore, rab 10 has been 
shown to function downstream of TBC1D4 and is required for insulin-stimulated 
GLUT4 translocation in 3T3-L1 adipocytes (Sano, et al., 2007). In addition, rab 
8A and rab 14 may be targets of AS160 in muscle cells and are found to co-
localise with GLUT4 (Ishikura, et al., 2007). Additionally, these rab proteins 
have been found to be immuno-located on GLUT4 containing vesicles isolated 
from 3T3-L1 adipocytes (Miinea, et al., 2005) (Larance, et al., 2005).  
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Figure 1.7: A schematic diagram of rab activity. Rab proteins exist in two conformations, 
either in an ‘inactive state’ (red) bound to GDP or in an ‘active state’ (green) bound to GTP. 
The release of GDP and the binding to GTP is mediated by proteins known as GEFs (blue). 
Rab-GAPs (TBC1D1 and TBC1D4) proteins (green) function to accelerate the slow intrinsic 
hydrolysis (GTPase activity) of GTP to GDP on associated rab proteins. It has proposed that 
the phosphorylation of the Rab-GAP suppresses its GAP activity (red) and as a result 
promotes the association of rab proteins with GTP and therefore in an active state.  
Analysis of TBC1D4 revealed that it contains six potential Akt phosphorylation 
sites (Figure 1.6). Furthermore TBC1D4 was found to be phosphorylated at five 
of these sites in 3T3-L1 adipocytes following insulin stimulation. Of these sites 
four represent consensus motifs (RXRXXpS/T). These are located at serine 324 
(318), serine 596 (588), threonine 649 (642) and threonine 758 (751) on mouse 
TBC1D4 (equivalent sites on human TBC1D4 are shown in brackets). A partial 
Akt phosphorylation motif is located at serine 577 (570) (Sano, et al., 2003) 
(Roach, et al., 2007). Similarly, TBC1D1 has been found to be phosphorylated 
at distinct sites in response to insulin stimulation. Two Akt phosphorylation sites 
originally detected in TBC1D4 are conserved in TBC1D1. These are threonine 
590 (596) and serine 501 (507) which corresponded to threonine 649 (642) and 
serine 577 (570) on TBC1D4 respectively. Subsequently, other potential insulin-
regulated phosphorylation sites on mouse TBC1D1 have been identified at 
serine 489 and threonine 499 in C2C12 muscle cells (Peck, et al., 2009) and at 
threonine 253 and serine 621 in TA muscle (Taylor, et al., 2008).  
Several AMPK phosphorylation sites have been identified in TBC1D1. The most 
well studied site is the consensus motif at serine 231 (Stone, et al., 2002) 
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(Figure 1.6). A number of other AMPK sites have been identified in TBC1D1 at 
serine 660, serine 700 and threonine 499 and serine 621. These are 
phosphorylated in response to AICAR treatment in TA muscle. Furthermore, 
one predicted AMPK site has been identified in TBC1D4 at serine 711. 
The identification of kinase modifiable sites led to the hypothesis that the 
phosphorylation of TBC1D4/TBC1D1 is important to inactivate the protein and 
inhibit its GAP activity. In basal cells, TBC1D4/TBC1D1 accelerates the slow 
intrinsic hydrolysis (GTPase activity) of GTP to GDP on associated rab proteins 
to switch off rab activity. Support for this hypothesis comes from studies carried 
out in 3T3-L1 adipocytes. Wild-type TBC1D4 or TBC1D4 4P (TBC1D4 mutated 
to alanine at four phosphorylation sites serine 318, serine 588, threonine 642 
and serine 751, therefore removing its capacity to undergo phosphorylation) 
were expressed in 3T3-L1 adipocytes and the effects on GLUT4 translocation 
were assessed (Kane, et al., 2002) (Sano, et al., 2003). Insulin-stimulated cell 
surface GLUT4 levels were inhibited by approximately 80% in adipocytes over-
expressing TBC1D4 4P. The TBC1D4 4P mutant completes with endogenous 
protein and functions as a ‘dominant-negative’ inhibitor of GLUT4 translocation. 
Insulin-stimulated cell surface levels of GLUT4 were rescued when cells were 
expressed with TBC1D4 4P simultaneously expressing an R/K point mutation 
which inactivated GAP activity (AS160 4P/RK). Therefore the inhibition on 
GLUT4 translocation was dependant on an active GAP domain.  
It is important to note that the expression of TBC1D4 2P (TBC1D4 mutated at 
threonine 642 and serine 588) in 3T3-L1 adipocytes was able to reduce insulin-
stimulated GLUT4 at the plasma membrane to the same extent as TBC1D4 4P. 
This indicated that threonine 642 and serine 588 are key sites within TBC1D4 
which are phosphorylated by Akt and for the regulation of insulin-stimulated 
GLUT4 trafficking (Kane, et al., 2002) (Sano, et al., 2003). 
Similarly, the ectopic expression of TBC1D1 3P (TBC1D1 mutated to alanine at 
four phosphorylation sites serine 489, serine 499, serine 501 and threonine 
590) in 3T3 adipocytes inhibited insulin-stimulated GLUT4 at the cell surface 
(Roach, et al., 2007) (Peck, et al., 2009). Once again, this inhibition was 
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rescued when mutant proteins simultaneously expressed the catalytic dead 
mutation R/K. However, the expression of wild-type TBC1D1 also had an 
inhibitory effect on insulin-stimulated GLUT4 at the plasma membrane (Roach, 
et al., 2007). In contrast to TBC1D4, the expression of TBC1D1 in differentiated 
3T3-L1 adipocytes is relatively low. Therefore, the expression of TBC1D1 may 
result in an increased level of active GAP which cannot be correctly regulated in 
these cells. In support of this, the inhibition on insulin-stimulated cell surface 
GLUT4 in 3T3-L1 cells was partially relieved by reducing the level of 
overexpression (Peck, et al., 2009). Furthermore, it has also been reported that 
over expression of wild-type TBC1D1 inhibited insulin-stimulated plasma 
membrane GLUT4 in L6 myoblasts (Park, et al., 2011). The expression of 
endogenous TBC1D1 is relatively low in L6 myoblasts. This supports the 
hypothesis that in cells where endogenous TBC1D1 is low, over expression 
may interfere with normal trafficking events leading to the inhibition of glucose 
transport. In addition, shRNA-mediated knockdown of TBC1D1 in 3T3 
adipocytes did not affect insulin-stimulated cell surface GLUT4 levels (Chavez, 
et al., 2008).  
1.5.4 Rab-GAPs and Obesity 
A mutation in TBC1D1 to Tryptophan at Arginine 125 (TBC1D1 R125W) has 
been identified as a candidate causing severe familial obesity predisposition in 
females (Stone, et al., 2006) (Stone, et al., 2002). Further evidence for the 
association of TBC1D1 R125W and severe familial obesity was demonstrated 
within an independent French cohort (Meyre, et al., 2008). The mutation is 
found within the first phosphotyrosine-binding domain (PTB) domain (Figure 
1.6). PTB domains are required for protein-protein interactions (Yan, et al., 
2002). Therefore a mutation within this domain may alter TBC1D1 affinity for 
subsequent binding partners. In addition, a truncation mutant of Tbc1d4 has 
also been identified and which causes severe postprandial hyperinsulinemia in 
humans (Dash, et al., 2009).  
A further mutation of TBC1D1 has been discovered in certain chicken breeds 
with phenotypes for increased body weight and growth rate. Furthermore, a 
different genetic variant of Tbc1d1 has been discovered in the lean 
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Swiss/Jackson Laboratory (SJL) mice strain. Tbc1d1 was mapped to an obesity 
quantitative trait locus (QTL) Nob1 (Chadt, et al., 2008). New Zealand obese 
(NZO) mice are a polygenic obesity model. They are susceptible to high fat diet 
induced obesity and develop symptoms of the metabolic syndrome (West & 
York, 1998). A backcross model of NZO mice with the lean SJL strain was 
established. Carriers of the NZO allele of Nob1 (Nob1NZO) were susceptible to 
high fat diet induced diabetes (Kluge et al., 2000). The Nob1SJL allele protected 
mice from diet induced obesity and confers leanness. TBC1D1 was found to be 
down regulated in skeletal muscle of the SJL mouse strain. This was the result 
of a 7 base-pair deletion in exon 18 which resulted in a frame-shift mutation and 
premature termination of the protein (Chadt, et al., 2008). Insulin-stimulated 
glucose uptake was impaired in EDL muscle from TBC1D1 deficient 
recombinant congenic B6.SJL-Nob1SJL/SJL mice. Furthermore, it was discovered 
that palmitate oxidation and the expression of genes including Fatty acid 
translocase (Cd36), Peroxisome proliferator activated receptor gamma co-
activator 1 (Ppargc1) and Fatty acid binding protein (Fabp3) were increased in 
the soleus and EDL muscle from TBC1D1 deficient mice. These studies provide 
evidence that both TBC1D1 and TBC1D4 are involved in the regulation glucose 
metabolism. TBC1D1 may also play an important role in regulating fatty acid 
metabolism. 
1.5.5 TBC1D1 and TBC1D4 role in skeletal muscle 
As detailed in section 1.5.3, the early characterisation studies of TBC1D1 and 
TBC1D4 were performed in 3T3-L1 adipocyte cells. The results suggest that 
endogenous TBC1D1 may not play a significant role in insulin-stimulated 
GLUT4 trafficking in adipocytes. However, both TBC1D4 and TBC1D1 proteins 
are expressed in skeletal muscle and so it is of importance to further investigate 
their roles.  
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Figure 1.8: The regulation of TBC1D1 and TBC1D4 in skeletal muscle. Currently proposed 
insulin and contraction mediated signalling mechanisms leading to GLUT4 translocation in 
muscle. Insulin activates Akt via the canonical insulin receptor (IR) -insulin receptor substrate 
(IRS) -phosphatidyl inositol 3-kinase (PI3K) -phosphoinositide dependant kinase-1 (PDK-1) 
pathway. Activated Akt phosphorylates TBC1D4 and TBC1D1 primarily at threonine 649/642 
and threonine 590/596 respectively. Muscle contraction elevates AMP and Ca
2+
 which 
through LKB1 and Ca
2
+/calmodulin-dependant protein kinase-2 (CaMKII) activate AMP-
activated protein kinase (AMPK). These signalling cascades result in the phosphorylation of 
TBC1D1 at threonine 590/596 and serine 231/237, serine 660, serine 700 and threonine 499 
and serine 621 and TBC1D4 at serine 711. Muscle contraction also leads to the 
phosphorylation of TBC1D4 at threonine 649/642 via a PI 3-kinase dependent signalling 
mechanism.  
 
1.5.5.1 Insulin-stimulated Glucose Transport 
Insulin stimulation directly induces the phosphorylation of TBC1D4 and TBC1D1 
detected using either the PAS antibody (Funai & Cartee, 2009) (Bruss, et al., 
2005)(Kramer, et al., 2006) (Pehmoller, et al., 2009) (Vichaiwong, et al., 2010) 
or of TBC1D1 at threonine 596 using site-specific phospho-antibodies in 
skeletal muscles (EPI and EDL) (Pehmoller, et al., 2009) (Vichaiwong, et al., 
2010). Furthermore, insulin-induced phosphorylation of TBC1D1 and TBC1D4 
is dependent on signalling via PI3K pathways (Figure 1.8). Insulin-mediated 
phosphorylation and glucose uptake were impaired in muscle pre-treated with 
the PI 3-kinase inhibitor wortmannin (Kramer, et al., 2006) (Funai & Cartee, 
2009)(Pehmoller, et al., 2009). Moreover, insulin-stimulated phosphorylation of 
TBC1D4 (detected using PAS) (Kramer, et al., 2006) and TBC1D1 at threonine 
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590 (Vichaiwong, et al., 2010) were significantly impaired in muscle from Akt2 
KO mice compared to wild-type litter mates. These findings support the concept 
that both TBC1D4 and TBC1D1 are key intermediates downstream of insulin 
signalling. Furthermore, the over expression of TBC1D4 4P (S318A, S588A, 
T642A, S751A) in TA muscle using in vivo electroporation techniques impaired 
insulin-stimulated glucose uptake. This was dependant on TBC1D4 GAP 
activity, as the addition of the R/K mutation (which disrupts GAP activity) 
reversed the inhibitory effect (Kramer, et al., 2006). Thong et al., 2007 reported 
a similar inhibition of insulin-stimulated GLUT4 at the cell surface in L6 cells 
expressing the mutant protein TBC1D4 4P. Furthermore, mice with 
AS160/TBC1D4-Thr649Ala knockin mutation displayed impaired glucose 
disposal and insulin sensitivity. This coincided with a decreased insulin-
stimulated glucose uptake and reduced cell surface GLUT4 levels in isolated 
muscles (Chen, et al., 2011). Conversely, the over expression TBC1D1 4P 
(TBC1D1 in which four phosphorylation sites had been mutated to alanine 
S231A, S499A, T590A, S621A) in TA did not affect insulin-stimulated glucose 
transport (An, et al., 2010). However, the over expression TBC1D1 R125W 
(TBC1D1 carrying the genetic mutation to associated with severe obesity) 
impaired insulin-stimulated glucose transport. The inhibition on glucose 
transport was rescued when TBC1D1 simultaneously expressed the R/K 
mutation which inactivated its GAP activity. These findings support the concept 
that both TBC1D4 and TBC1D1 are key signalling intermediates for insulin-
mediated glucose transport. Intriguingly, the phosphorylation of TBC1D1 
R125W detected with the PAS antibody was not impaired. Therefore, this raises 
important questions regarding the regulation of TBC1D1 through insulin-
stimulated phosphorylation. Further investigations are required to determine 
how the R125W mutation affects the function of TBC1D1 and how this impairs 
insulin-regulated glucose transport in muscle leading to obesity. 
1.5.5.2 Contraction-mediated Glucose Transport 
It has been reported that other distinct signals that regulate GLUT4 
translocation and glucose disposal including contraction and AICAR are 
mediated through the phosphorylation of TBC1D4 and TBC1D1 (Figure 1.8). 
Muscle contraction activates multiple downstream signalling pathways through 
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key mediators including AMPK and CAMKII. It is important to note that the PAS 
(phosphorylated Akt substrates) antibody which is used to detect downstream 
substrates of Akt signalling may also recognise AMPK phosphorylation motifs of 
(L/M)XRXXpS/T) and CaMKII motifs of HydXRXXpS/T. As detailed earlier 
TBC1D1 contains a number of AMPK phosphorylation sites (Figure 1.6). The 
most well studied site is the consensus motif at serine 231. TBC1D1 is 
phosphorylated at serine 237 (equivalent site in rat) in response to AICAR 
stimulation in L6 myotubes (Chen, et al., 2008). Furthermore, data from several 
studies have shown that phosphorylation of TBC1D1 at serine 231 is increased 
in response to in situ contraction or AICAR-treatment in skeletal muscle (Taylor, 
et al., 2008) (Vichaiwong, et al., 2010) (Pehmoller, et al., 2009). A number of 
other AMPK sites have been identified in TBC1D1 at serine 660, serine 700 and 
threonine 499 and serine 621. These are phosphorylated in response to AICAR-
treatment in TA muscle (Vichaiwong, et al., 2010). The identification of TBC1D1 
as an AMPK substrate supports a role for TBC1D1 as a downstream signalling 
intermediate of contraction signalling. In contrast only one AMPK site has been 
identified in TBC1D4 at serine 711. This site is phosphorylated in response to 
AICAR-treatment and contraction in mouse muscle (Treebak, et al., 2010).  
In vivo exercise and contraction have been found to induce the phosphorylation 
of TBC1D4 and TBC1D1 (detected with PAS antibodies) (Bruss, et al., 2005) 
(Kramer, et al., 2006) (Funai & Cartee, 2009) and TBC1D4 at threonine 642 
using a site-specific phospho-antibody (Kramer, et al., 2006) in GN, TA and EPI 
muscles. Furthermore, TBC1D1 is phosphorylated at serine 231 and at 
threonine 590 in response to in situ contraction or AICAR-stimulation in 
glycolytic muscles TA and EDL (Vichaiwong, et al., 2010) (Pehmoller, et al., 
2009). Therefore, these results implicate both TBC1D1 and TBC1D4 Rab-GAPs 
as downstream signalling intermediates of contraction. In addition, the over 
expression of TBC1D4 4P (S318A, S588A, T642A, S751A) or TBC1D1 4P 
(S231A, S499A, T590A, S621A) in TA muscle inhibited contraction-mediated 
glucose uptake (An, et al., 2010) (Kramer, et al., 2006). This was reversed 
when GAP activity was disrupted with the R/K mutation. Thus, TBC1D1 and 
TBC1D4 could represent a convergent point for insulin- and contraction-
regulated GLUT4 trafficking. 
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Interestingly, PI 3-kinase dependent signalling mechanisms were found to be 
essential for contraction-mediated phosphorylation of TBC1D4. Contraction-
stimulated phosphorylation of TBC1D4 (detected using PAS antibody) was 
inhibited when muscle (EPI and TA) was treated with the PI3K inhibitor 
wortmannin (Bruss, et al., 2005) (Funai & Cartee, 2009). By contrast, 
contraction-mediated glucose transport and TBC1D1 phosphorylation (detected 
with PAS antibody) are facilitated via PI3K-independent mechanisms. These 
findings support the concept that TBC1D1 could predominately function to 
regulate contraction-mediated glucose disposal, at least in certain types of 
skeletal muscle. Taylor et al., 2008 demonstrated that in vivo injection of insulin 
or in situ contraction increased the phosphorylation of PAS-160 in TA, EDL and 
soleus muscles isolated from rat. Immuno-depletion of TBC1D4 from TA muscle 
lysates did not reduce PAS-160 and revealed that the major PAS band in TA 
muscle corresponded to TBC1D1. Furthermore, TBC1D1 is the major PAS 
band in EDL muscle (Pehmoller, et al., 2009). In contrast the major immuno-
reactive band at 160 kDa in rat soleus muscle, gastrocnemius muscle and in 
adipocytes was confirmed to be TBC1D4 (Taylor, et al., 2008) (Lansey, et al., 
2012). 
The use of the muscle-specific transgenic mouse expressing inactive α2-AMPK 
isoform (AMPK-α2i Tg), muscle-specific AMPK-α2 kinase dead (AMPK-α2 KD) 
and the whole body AMPK knockout (AMPK-α2 KO) mice models along with the 
development AMPK phosphorylation site-specific antibodies provide evidence 
that AMPK directly phosphorylates TBC1D1 and that this regulates glucose 
uptake in muscle. The AMPK-α2 catalytic isoform plays a functional role in 
regulating basal and contraction-stimulated levels of phosphorylated TBC1D1. 
In the AMPK-α2i Tg (Vichaiwong, et al., 2010) and the AMPK-α2 KD mice 
(Pehmoller, et al., 2009) and whole body AMPK-α2 knockout mice (Frosig, et 
al., 2010) basal and contraction-stimulated phosphorylation of TBC1D1 was 
significantly reduced.   
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1.6 GLUT4 trafficking studies 
Glucose transport into adipose and muscle cells is controlled through processes 
which regulate the rate at which GLUT4 is trafficked and inserted in to the 
plasma membrane and the rate GLUT4 is retrieved from the cell surface. The 
dysregulation of insulin-stimulated glucose uptake into peripheral tissues is a 
major feature of T2DM. Therefore, current research in part aims to find means 
by which glucose disposal in to muscle can be enhanced. This could be either 
through improving insulin sensitivity or discovering mechanisms which bypass 
insulin signalling altogether in cases of insulin resistance. Interestingly, 
exercise-mediated GLUT4 translocation and glucose disposal appears to be 
normal in insulin-resistant individuals. Furthermore, contraction or AMPK-
activation in combination with insulin are additive to increase GLUT4 to the cell 
surface and enhance glucose uptake.  
Both Rab-GAPs TBC1D1 and TBC1D4 are expressed in skeletal muscle and 
are phosphorylated in response to insulin and contraction stimulation. Therefore 
they have been identified as key intermediates linking upstream signalling 
pathways to downstream GLUT4 trafficking events. Furthermore, Tbc1d1 has 
been identified as a candidate gene for obesity predisposition in some rare 
cases of severe obesity. In addition a truncation mutation of Tbc1d4 has been 
identified to cause severe postprandial hyperinsulinemia in humans. Moreover, 
a different genetic mutation in Tbc1d1 has been found to confer leanness in 
mice and protection from diet induced obesity. It is as yet unknown exactly how 
some of these mutations affect TBC1D1 function and how this impacts on 
normal metabolic pathways. Thus, it is of interest to further investigate the role 
of TBC1D1 and TBC1D4 with respect to GLUT4 trafficking in response to 
insulin- and/or contraction-mediated stimulation.  
There have been many technical challenges associated with the investigation of 
GLUT4 trafficking in skeletal muscle. The abundance of cytoskeletal and 
structural proteins in muscle has made sub-cellular membrane fractionation 
procedures problematic for the analysis of GLUT4 intracellular distribution. 
Furthermore, there are difficulties associated with the isolation of single skeletal 
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muscle fibres which has impeded detailed kinetic analysis of endogenous 
GLUT4 trafficking using biotinylated photolabelling techniques. Therefore, 
alternative methods have been developed utilising the ectopic expression of 
epitope-tagged GLUT4. GLUT4 reporter constructs have been designed to 
contain a hemagglutinin (HA) or Myc tag in the first exofacial loop and can also 
have a C-Terminal GFP tag (HA/Myc GLUT4 GFP). The exofacial (HA/Myc) tag 
allows for the rapid detection of GLUT4 which has been inserted into the 
plasma membrane. In primary skeletal muscle tissue the expression of GLUT4-
GFP has enabled more detailed investigations of GLUT4 translocation in 
response to insulin- and contraction-mediated signalling in vivo (Lauritzen, et 
al., 2008) (Lauritzen, et al., 2006). More recently, the transgenic expression of 
an exofacial-tagged GLUT4 (HA-GLUT4-GFP) in mice has enabled direct 
measurements of GLUT4 inserted into the cell membrane of intact single 
muscle fibres (Lizunov, et al., 2012) (Fazakerely, et al., 2009).  
Immortal skeletal muscle cell lines (L6 cells and C2C12 myotubes) expressing 
exofacial tagged GLUT4 proteins have provided alternative model systems to 
study GLUT4 trafficking kinetics. In contrast to primary muscle cells, cell culture 
models can be efficiently manipulated through transduction and transfection 
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1.7 Experimental Design and Aims 
The studies described in this thesis were completed in order to further enhance 
our understanding of how GLUT4 trafficking is regulated in response to insulin 
and AMPK-activation. Exercise-mediated GLUT4 translocation and glucose 
disposal appears to be normal in insulin-resistant individuals. Furthermore, 
contraction or AMPK-activation in combination with insulin are additive to 
increase glucose transport. A vast amount of research is focused on finding 
potential therapeutic targets which increase insulin sensitivity and oxidative 
capacity of muscle in order to overcome an insulin resistant state associated 
with T2DM and obesity. Therefore, an important overall aim of the work 
described in this thesis is to provide mechanistic evidence to support AMP-
activated protein kinase and subsequent downstream signalling and membrane 
trafficking pathways leading to an alteration in GLUT4 translocation kinetics as 
important therapeutic targets.  
The focus of these investigations is to address the importance of the Rab-GAPs 
TBC1D1 and TBC1D4 in muscle cells with regard to GLUT4 translocation. The 
Rab-GAP proteins TBC1D1 and TBC1D4 have been identified as potential 
downstream signalling intermediates which regulate GLUT4 translocation 
(Roach, et al., 2007). Several studies have demonstrated that TBC1D4 and 
TBC1D1 are phosphorylated in response to insulin and contraction stimulation 
in skeletal muscle (Kramer, et al., 2006) (Bruss, et al., 2005) (Funai & Cartee, 
2008) (Funai & Cartee, 2009). It is generally accepted that the phosphorylation 
of these Rab-GAP proteins inhibits their function as negative regulators of 
GLUT4 trafficking and as a result any associated rab proteins would be in their 
active GTP-bound state. It has been recently proposed that TBC1D1 could be 
primarily responsible for regulating contraction-mediated glucose uptake in 
muscle (Funai & Cartee, 2009) (An, et al., 2010) (Pehmoller, et al., 2009) 
(Vichaiwong, et al., 2010). Several AMPK phosphorylation sites have been 
identified in TBC1D1. The most well studied site is the consensus motif at 
serine 231 (Stone, et al., 2002). However, whether TBC1D1 and TBC1D4 are 
both essential in muscle is not fully understood. In order to address this we 
have firstly comprehensively investigated the tissue-specific expression pattern 
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of TBC1D1 and TBC1D4 within different tissues using quantitative real-time 
PCR. Furthermore, we have quantified TBC1D1 and TBC1D4 protein levels in 
different muscles and other insulin-responsive tissues using western blotting 
techniques. At the time this project commenced there were no commercial 
antibodies available against TBC1D1 protein or TBC1D1 phosphorylated at 
serine 231 and so specific anti-serum was generated. It was therefore 
necessary to initially evaluate their use as potential tools for studying the role of 
TBC1D1 in AMPK-mediated GLUT4 translocation.  
There is limited and in-conclusive evidence available to support the use of 
immortal skeletal muscle cell lines (L6 cells and C2C12 myotubes) to study 
GLUT4 trafficking kinetics. These muscle cell models are advantageous and 
can be easily manipulated to express exofacial tagged GLUT4 proteins to 
provide alternative in vitro model systems. Furthermore, they can be readily 
sourced and cultured with ease and so have great potential for industry 
applications. Therefore, the final aim of these investigations is to address 
whether immortal cell lines can provide a promising model for accurately 
measuring GLUT4 trafficking in muscle and if so, whether quantitative HA-
GLUT4 trafficking assays can be optimised which may be useful as a reliable 
end-point tool for application in industry.  
We have used the C2C12 muscle cell model to investigate how insulin 
stimulation and/or AMPK-activation affects the kinetics of GLUT4 trafficking. 
Our data support the current concepts that insulin stimulates the rapid release 
of GLUT4 to the plasma membrane and increases the rate of GLUT4 exocytosis 
(kex) at steady state. In addition, treatment with the AMPK-activator, AICAR, 
stimulates the slow accumulation of GLUT4 at the cell surface through the 
inhibition of GLUT4 endocytosis. Furthermore, our findings revealed that the 
combination of insulin plus AICAR treatments was synergistic to increase 
GLUT4 cell surface levels through increasing both the kex for GLUT4 and the 




~ 63 ~ 
 
Finally, we have used siRNA-mediated knockdown to investigate the role of 
TBC1D1 and TBC1D4 in basal GLUT4 retention mechanisms. Furthermore, we 
have explored the potential involvement for TBC1D1 and TBC1D4 in insulin- 
and AMPK-mediated GLUT4 translocation. We have shown that TBC1D1 may 
play an important role in retention mechanisms which regulate basal cell 
surface levels of GLUT4.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Buffers and Solutions 
Table 2.1: Laboratory material sources and list of abbreviations. 
 
Company Address Abbreviation 
Abcam Cambridge, UK ABM 
BD  Oxford, UK BD 
Beckman Coulter High Wycombe, Buck, UK BEC 
BMG Lab Tech Aylesbury, Buck, UK BMG 
Bio-Rad Hemel Hempstead, Herts, UK BIO 
CBS-Scientific Del Mar, CA, USA CBS 
Celluliance Corporation  Norcross, GA, USA CEL 
Cell Signalling Technology  Hitchin, Herts, UK CST 
Clontech Mountain View, CA, USA CLO 
Covance Maidenhead, Berk, UK COV 
Electron Microscopy Sciences Hatfield, PA, USA EMS 
Eppendorf Stevenage, Herts, UK EPP 
Eurogentech Southampton, UK EUR 
Fisher Thermo Scientific Loughborough, Leis, UK FIS 
GE Healthcare Little Chalfont, Buck, UK GE 
Greiner Bio-One Stone house, Glos, UK GRE 
Life Technologies Ltd Paisley, UK LTC 
Lonza  Tewkesbury, Glos, UK LON 
Merck Millipore Watford, Herts, UK MIL 
Novo Nordisk Crawley, W. Sus, UK NOV 
Promega Southampton, UK PRO 
Peqlab  Southampton, UK PEQ 
Qiagen Manchester, UK QIA 
Roche  Burgess Hill, W. Sus, UK ROC 
Sigma Gillingham, Kent, UK SIG 
Symansis Timaru, NZ SYM 
UVP Cambridge, UK UVP 
VWR Lutterworth, Leis, UK VWR 
 
2 Materials and Methods 
 
~ 65 ~ 
 
Table 2.2: Buffers and solutions. 
 
Name Composition 
BCA Reagent B 4% (w/v) CuSO4.5H2O 
 
C2C12 normal growth media Dulbecco’s Modified Essential Medium 
(DMEM) (D6546, SIG),10% (v/v) Foetal 
Bovine Serum (FBS) (SIG), 50 units /ml 
penicillin, 50 μg/ml streptomycin (P4458,SIG), 
2 mM L-glutamine (G7313, SIG) 
 
C2C12 (HA-GLUT4) growth media DMEM (SIG), 10% (v/v) FBS (SIG), 50 
units/ml penicillin, 50 μg/ml streptomycin 
(SIG), 2 mM L-glutamine (SIG), 2 μg/ml (w/v) 
puromycin (540411, Calbiochem, MIL) 
 
C2C12 differentiation media DMEM (SIG), 5% (v/v) Horse Serum (HS) 
(SIG), 50 units/ml penicillin, 50 μg/ml 
streptomycin (SIG), 2 mM L-glutamine (SIG) 
 
C2C12 serum-free media DMEM (SIG), 0.2% (w/v) bovine serum 
albumin (BSA) (CEL), 2 mM L-glutamine (SIG) 
 
C2C12 serum-free media (without 
bicarbonate) 
11 mg/ml (w/v) GIBCO® DMEM (119 00-073, 
FIS), 20 mM (w/v) HEPES, 0.2% (w/v) BSA 
(CEL) (filter sterilised) 
 
DEPC-treated ddH2O (RNase-free) 1% (v/v) diethyl pyro carbonate (DEPC) 
(D5758, SIG) in ddH2O (autoclaved) 
 
Enhanced Chemi-luminescence buffer A 100 mM (w/v) Glycine (pH 10), 0.4 mM (w/v) 
luminol, 8 mM (w/v) 4-iodophenol 
 
Enhanced Chemi-luminescence buffer B 0.12% (v/v) hydrogen peroxide 
 
0.5% Glutaldehyde 25% (w/v) Glutaldehyde (16220, EMS) in 1x 
PBS 
 
Quench solution (sterile) 50 mM Glycine (w/v) in 1x DPBS 
 
Quench solution 50 mM Glycine (w/v) in 1x PBS 
 
HA-GLUT4 Assay blocking buffer 1% (w/v) BSA (CEL), 3% (v/v) Goat serum 
(G9023, SIG, (±) 0.2% (w/v) saponin in PBS 
 
HA-GLUT4 Assay antibody buffer  1% (w/v) BSA (CEL), (±) 0.025% (w/v) saponin 
in PBS 
 
2x HBS 280 mM (W/V) NaCl, 50 mM (w/v) HEPES, 
1.42 mM (w/v) Na2HPO4•7H2O (pH 7.05)  
Adjust pH to 7.05 with 10 M NaOH 
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HEK 293 cell growth media DMEM (SIG),10% (v/v) FBS, 50 units/ml 
penicillin, 50 μg/ml streptomycin (SIG), 2 mM 
L-glutamine (SIG) 
 
HEK 293 cell lysis buffer 50 mM (w/v) Tris-HCL (PH 7.4), 150 mM (w/v) 
NaCl, 1 mM (w/v) EDTA, 0.5% (v/v) Triton X-
100 
Luria broth 1% (w/v) Bacto tryptone, 0.5%(w/v) Bacto 
yeast extract, 0.5% (w/v) NaCl (pH 7.5, 
autoclaved) 
 
3% Paraformaldehyde 16% paraformaldehyde (15710, EMS) in 1x 
PBS (foil wrapped) 
1x Phosphate buffered saline (PBS) 12.5 mM (w/v) Na2HPO4, 154 mM (w/v) NaCl 
(pH 7.2) 
 
1x PBS (RNase-free and sterile) 10x PBS (10468543, FIS) in DEPC-treated 
ddH2O 
 
1x DPBS (sterile) 10x Gibco® DPBS (14200-067, LTC) in 
autoclaved ddH2O 
 
Plat-E cell growth media DMEM (SIG),10% (v/v) FBS (SIG) 50 units/ml 
penicillin, 50 μg/ml streptomycin (SIG), 2 mM 
L-glutamine (SIG) 10 μg/ml (w/v) blastocidin, 1 
μg/ml puromycin (540411, Calbiochem, MIL) 
 
Ponceau S stain 0.1% (w/v) Ponceau S, 3% (w/v) 
trichloroacetic acid (TCA) 
 
Cell lysis buffer 20 mM (w/v) Tris-HCL (PH 7.4), 150 mM (w/v) 
NaCl ,1 mM (w/v) EDTA, 1 mM (w/v) EGTA, 1 
% (v/v) Triton X-100 
 
Resolving gel buffer 1.5 M (w/v) Tris HCl (pH 8.8), 0.4 % (w/v) SDS 
 
3x Sample buffer 62.5 mM (w/v) Tris-HCl (pH 6.8), 2% (w/v) 
SDS, 10% (w/v) glycerol, 0.01% (w/v) 
bromophenol blue, 100 mM Dithiothreitol 
(DTT) 
 
Stacking gel buffer 0.5 M (w/v) Tris HCl (pH 6.8), 0.4 % (w/v) SDS 
 
SDS Electrophoresis buffer 25 mM (w/v) Tris HCL (pH 6.3), 0.2 M (w/v) 
glycine, 0.1% (w/v) SDS 
 
SDS Transfer buffer 49 mM (w/v) Tris-HCl, 39 mM (w/v) glycine, 
0.0375% (w/v) SDS, 20% (v/v) methanol 
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1x Tris buffered saline (1x TBS) 10 mM (w/v) Tris-HCl (pH 7.4), 154 mM (w/v) 
NaCl, 
 
Tris buffered saline with Tween 20 (TBST) 10 mM (w/v) Tris-HCl (pH 7.4), 154 mM (w/v) 
NaCl, 0.1% (v/v) Tween 20 
10x TAE Tris-Acetate EDTA 
1x TAE Tris-Acetate EDTA 
 
2.1.2 Antibodies 
Cell and tissue lysates were resolved by SDS-PAGE and analysed using 
western blotting. A list of primary antibodies is detailed in Table 2.3.  
Table 2.3: Primary Antibodies.  
 
Antibody Name Dilution Species Source 
AMPK 1:1000 1% BSA Rabbit #2532, CEL 
AKT2 1:1000 Rabbit #3063, CEL 
AS160 1:1000 Rabbit #07-741, UPS, FIS 
Monoclonal β Tubulin, clone 1:5000 Mouse T0198, SIG 
FLAG, clone M2 1:1000 Mouse F3165, SIG 
GAPDH 1:5000 Mouse 9484, ABM 
GLUT 4 1:4000 Rabbit In House 
HA.11, clone 16B12 1:1000 Mouse MMS 101P, COV 
Phospho-ACC (serine 79) 1:1000 Rabbit #07-303, MIL 
Phospho-AMPK (threonine 172) 1:1000 Rabbit #2535, CEL 
Phospho-AKT (serine 473) 1:1000 Rabbit #4058, CEL 
Phospho-AS160 (threonine 642) 1:1000 Sheep 3028 P1, SYM 
TBC1D1 AGG 4397 1:120 Rabbit Astra Zeneca 
TBC1D1 AGG 4398 1:170 Rabbit Astra Zeneca 
TBC1D1 AGG 4399 1:450 Rabbit Astra Zeneca 
TBC1D1 AGG 4400 1:280 Rabbit Astra Zeneca 
TBC1D1 AGG 4401 1:230 Rabbit Astra Zeneca 
TBC1D1 AGG 4402A 1:370 Rabbit Astra Zeneca 
TBC1D1 AGG 4402B 1:250 Rabbit Astra Zeneca 
TBC1D1 AGG 4403 1:280 Rabbit Astra Zeneca 
TBC1D1 AGG 4404 1:280 Rabbit Astra Zeneca 
TBC1D1 AGG 4405 1:220 Rabbit Astra Zeneca 
TBC1D1 H-AH 1:1000 Rabbit Germany  
TBC1D1 #4629 1:1000 Rabbit #4629, CEL 
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Phospho-TBC1D1 AGG 4989 1:160 Rabbit Astra Zeneca 
Phospho-TBC1D1 AGG 4990 1:230 Rabbit Astra Zeneca 
Phospho-TBC1D1 AGG 4991 1:230 Rabbit Astra Zeneca 
 
Table 2.4: Secondary Antibodies. 
 
Antibody Name Dilution Species Source 
anti-mouse, HRP conjugate 1: 4000 Goat 31430, FIS 
anti-rabbit, HRP conjugate 1: 4000 Goat AP187P, MIL 
anti-sheep IgG, HRP conjugate 1: 4000  AP147P, MIL 
Alexa Fluor 488 anti-mouse IgG 1: 100 Goat A1101, FIS 
 
2.1.2.1 Anti-TBC1D1 Antibody Generation 
Specific anti-serum was raised against three different peptides sequences 
corresponding to rat TBC1D1 (AZ 3001724, AZ 3001725, and AZ 3001726) 
(Table 2.5, 2.1.2.2). The antibodies were generated by the Antibody Generation 
Group (AGG), Astra Zeneca, Macclesfield, UK as part of CASE PhD 
studentship between the University of Bath and Astra Zeneca. Three or four 
rabbits were injected with each peptide and affinity purified anti-serum from 
terminal bleeds were obtained.  
2.1.2.2 Anti-TBC1D1 Phospho-specific Antibody  
A phospho peptide matching the sequence around serine 237 of rat TBC1D1 
was used to generate antibodies which would specifically recognise 
phosphorylated TBC1D1 (AZ 3003376) (Table 2.5). Three rabbits were injected 
with the peptide and anti-serum from terminal bleeds was obtained.  Terminal 
bleeds were passed over a non-phosphorylated peptide column to isolate 
antibodies that do not recognise the phosphorylated peptide. The resulting flow 
through was then applied to a phospho-specific column in order to purify the 
phospho-specific antibodies. Antibodies were examined for specificity in 
western blots. These antibodies have been shown to display specificity by 
western blotting towards an in-vitro phosphorylated recombinant TBC1D1 N-
terminal construct containing the two PTB domains of the protein (Fazakerely, 
2010).  
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Table 2.5: Synthetic peptide sequences used to generate TBC1D1 antibodies. A sequence 
alignment comparing mouse and human TBC1D1 with the four epitopes of rat TBC1D1 used 
to generate 13 polyclonal antisera.   
 
Antibody ID Peptide  Mouse Sequence Human Sequence 
AGG 97-99 
AZ 3001724 
CEPDLRKSQPWDP CEPDLEKSQPWDP CEPEPGRSQQWDP 
AGG 00-02B 
AZ 3001725 
CDSPSRTEDYSE Same CDSSSRTEDYSE 
AGG 03-05 
AZ 3001726 
QKLRPRNEQREN Same Same 
AGG 89-91p 
AZ 3003376 
CPMRKSFpSQPGLR   
 
2.1.3 Oligonucleotides and Taqman® Probes 
2.1.3.1 PCR Primers  
Two sets of exon-splicing PCR primers were designed against the regions 
flanking exons 11-12 of full-length Tbc1d1 and synthesised (EUR). Primers 
were used to determine the qualitative expression pattern of splice variants of 
Tbc1d1 in a panel of rodent tissues.  
Table 2.6: PCR primers for qualitative reverse transcription (RT)-PCR experiments.  
Name Sequence 5’ - 3’ 
Tbc1d1 exon flanking primers 1 Fwd. taagtaacaccagcaaagagct 
Rev. tgaataatcttcatatctgct 
Tbc1d1 exon flanking primers 2 Fwd. tctgtcccggggcaataaagcc 
Rev. tcggaggaatatctgctcca 
 
2.1.3.2 SiRNA Oligonucleotides 
SiRNA Oligonucleotides were purchased from Dharmacon (FIS).  
Table 2.7: siRNA Oligo-nucleotides. 
 
Name Product Ordering number/sequence 
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2.1.3.3 Taqman Probes 
Predesigned Applied Biosystems® Taqman® gene expression assays were 
purchased (Invitrogen, LTC). TaqMan® gene expression assays consist of a 
pair of unlabelled PCR primers and TaqMan® probe with a FAM™ label on the 
5' end and minor groove binder (MGB) non-fluorescent quencher (NFQ) on the 
3' end. Rat Tbc1d4 assay was designed using in-house primer design software 
(Astra Zeneca) and synthesised (EUR).  
Table 2.8: Taqman® probes for real-time quantitative PCR experiments.  
Gene  Gene Name Assay ID 
Tbc1d1 TBC1 (tre-2/USP6, BUB2, cdc16 domain family, member 1 Rn 01413271.m1 
Tbc1d1 TBC1 (tre-2/USP6, BUB2, cdc16 domain family, member 1 Mm 00497989.m1 
TBC1D1 TBC1 (tre-2/USP6, BUB2, cdc16 domain family, member 1 Hs 00207999.m1 
Tbc1d4 TBC1 domain family, member 4  Rn 
Tbc1d4 TBC1 domain family, member 4 Mm 00557659.m1 
TBC1D4 TBC1 domain family, member 4 Hs 00411484.m1 
Hprt Hypoxanthine phosphoribosyltransferase 1 Rn 01527840.m1 
Hprt Hypoxanthine phosphoribosyltransferase 1 Mm 01324427.m1 
B2m Beta-2-microglobulin Rn 00560865.m1 
B2M Beta-2-microglobulin Hs 
Gus B Glucuronidase, beta Rn 00566655.m1 
Gus B Glucuronidase, beta Mm 00446953.m1 
GUS B Glucuronidase, beta Hs 
Tbp TATA box binding protein Mm 00446971.m1 
CYP A Cyclophilin A Hs 
Myo g Myogenin Mm 00446194.m1 
Myo d Myogenic differentiation 1 Mm 00440387.m1 
 
2.1.4 Animals 
Adult male Wistar rats weighing ~200-240 g and adult male mice were used for 
the isolation of tissue samples. Tissues harvested from rats were used for the 
preparation of protein lysates and extraction of total RNA. Mouse tissues were 
used for the preparation of protein lysates. All animals were fed ad libitum a 
standard laboratory chow and housed in a 12h: 12h light dark cycle. Procedures 
involving use of animal material conformed to UK Home Office Guidelines on 
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the Operation of the Animals (Scientific Procedures) Act and were approved by 
the University of Bath Animal Care and Use Committee. 
2.2 Experimental Methods 
2.2.1 Molecular Biology Methods 
2.2.1.1 Determining DNA/RNA Concentration 
The concentration of DNA/RNA within samples was determined by absorbance 
at the wavelengths 260/280 nm. Absorbance measurements were made with a 
Bio Photometer UV spectrophotometer (EPP), using quartz cuvettes or using 
the Nano Drop ND-1000 Spectrophotometer (FIS). A selection of RNA samples 
were visualised using agarose gel electrophoresis as described in 2.2.1.3. 
2.2.1.2 Plasmids  
HA-tagged GLUT4 cloned into the retroviral vector pBabe was provided by 
Professor David James. Full-length Tbc1d1 and As160/Tbc1d4 cloned into the 
pcDNA3, which contains a FLAG coding sequence, were provided by Professor 
Francis Barr. The constructs were transformed into competent XL-1 blue E.Coli 
cells (HA-GLUT4 was cloned by Daniel Fazakerely and full-length FLAG-
Tbc1d1 and FLAG-As160/Tbc1d4 were cloned by Judith Richardson).  
Bacterial cell glycerol stocks were inoculated into luria broth (LB) supplemented 
with 50 μg/ml ampicillin (SIG) and cultured overnight at 30oC with shaking. 
Plasmid DNA was purified using Wizard® Plus SV Minipreps purification kit 
(A1460, PRO), following manufacturer instructions. 
2.2.1.3 Agarose Gel Electrophoresis 
Agarose gels were used to visualise nucleic acid fragments. 1% agarose 
(SeaKem Agarose, LON) was prepared in TAE buffer. After boiling, 0.01% Sybr 
Safe (S33102, LTC) was added. Samples were prepared in a 6X type II gel 
loading buffer (AB-0594, FIS). DNA fragment size was determined using 100 bp 
(G2101, PRO) and 1 kb-ladders (G7511, PRO). Electrophoresis was run at 120-
150 Volts, for approximately 20 min. After migration the DNA bands were 
visualised using UV light at wavelength on a trans-illuminator (UVP).  
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2.2.1.4 Preparation of total RNA from cultured cells 
RNA was isolated from differentiating C2C12 myotubes. 600 μl of RLT buffer 
was added to each 6-Well, pipetted up and down several times and transferred 
to eppendorf tubes. Total RNA was isolated from samples using the using the 
RNA Easy Mini Kit (74106, QIA) and processed using an automated QiaCube 
(9001213, QIA). RNA concentration was determined as detailed in 2.2.1.1. RNA 
samples were snap frozen on dry ice and stored at -80oC until required. 
2.2.1.5 Preparation of RNA from pancreatic Islets 
Approximately 100 rat pancreatic islets were lysed in 350 μl RLT buffer then 
snap frozen and stored at -80oC. Samples were thawed and total RNA was 
isolated using the RNA Easy Micro Kit (74004, QIA) and processed using an 
automated QiaCube (9001213, QIA). An on-column digestion of DNA during 
RNA purification was performed using the RNase-free DNase set (79254, QIA). 
RNA concentration was determined as detailed in 2.2.1.1. RNA samples were 
snap frozen on dry ice and stored at -80oC until required. 
2.2.1.6 Preparation of total RNA from rat tissue (excluding muscle, 
adipose) 
The homogenisation of rat tissues for the isolation of total RNA was performed 
using the Precellys Homogeniser Keramik-Kit (91-PCS-CKM, PEQ) following 
manufacturer’s instructions. 60-80 mg of tissue was homogenised in 1.4/2.8 mm 
tubes, prefilled with ceramic beads, containing 1.4 ml of RLT buffer (79216, 
QIA). Tissues were homogenised in a Precellys 24 (91-PCS24, PEQ) for three 
cycles (run time: 30 seconds, pause time: 1.5 min) at 4oC. The homogeniser 
was pre cooled to 4oC using the Cryolys cooling module (91-PCS-CRYO, PEQ). 
Total RNA was isolated from homogenised tissue samples using the RNA Easy 
Mini Kit (74106, QIA) and processed using an automated QiaCube (9001213, 
QIA) following manufacturer’s instructions. An on-column digestion of DNA was 
performed using the RNase-free DNase set (79254.QIA). RNA concentration 
was determined as detailed in 2.2.1.1. RNA samples were snap frozen on dry 
ice and stored at -80oC until required. 
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2.2.1.7 Preparation of RNA from adipose and muscle tissue 
RNA was isolated from adipose and muscle tissue using Trizol® method. 
100mg of adipose tissue or 30-60 mg of muscle tissue was homogenised in 
1.4/2.8 mm tubes, prefilled with ceramic beads, containing 1.4 ml of Trizol® 
(15596-026, Invitrogen, LTC). Tissues were homogenised in a Precellys 24 (91-
PCS24, PEQ) as previously described. The samples were incubated at room 
temperature for 5 min and then centrifuged at 10,000 rpm for 10 min at 4oC. 
The aqueous phase was transferred to new eppendorf tubes. Chloroform was 
added at one fifth of the sample volume and the suspension was vigorously 
shaken for 15 sec and incubated at room temperature for a further three min. 
The samples were phase-separated using centrifugation at 10,000 rpm for 15 
min at 4oC. Following centrifugation, 500 μl of the colourless aqueous phase 
was transferred to new eppendorf tubes. Total RNA was isolated from samples 
using the RNA easy Mini Kit (74106, QIA) and processed using an automated 
QiaCube (9001213, QIA). 
2.2.1.8 DNase-Treatment 
Total RNA samples extracted using the Trizol® method were subjected to 
DNase-treatment to remove genomic contamination. The digestion of DNA was 
performed using the Turbo DNA-freeTM kit (AM1907, LTC), following 
manufacturer’s instructions. 10 μg of total RNA, 1 μl of TURBO DNase and 0.1x 
volume of TURBO DNase buffer (10X) were added together and made up to 50 
μl with DEPC-treated ddH2O. The reactions were incubated at 37oC for 30 min. 
10 μl of DNase Inactivation Reagent was added and incubated for 2 min with 
agitation. The samples were centrifuged for 2 min at 10,000 rpm and the 
supernatant was transferred to new eppendorf tubes. RNA samples were snap 
frozen on dry ice and stored at -80oC until required.  
2.2.1.9 Reverse-Transcription; CDNA Synthesis 
cDNA was synthesised from RNA using the Applied Biosystems® TaqMan® 
Reverse Transcription Kit (N808 0234, LTC), following manufacturer’s 
instructions.  
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2.2.1.10 Reverse-Transcription Polymerase Chain Reaction  
Qualitative reverse-transcription Polymerase Chain Reaction (RT-PCR) was 
used to determine the expression pattern of Tbc1d1 splice variants within 
primary rat tissues and cultured cells. Reverse transcription of RNA to cDNA 
was performed as described in 2.2.1.9. Two sets of exon-splicing primers which 
flank the predicted insertion exons 11 and 12 of the long variant of Tbc1d1 were 
designed (EUR) (Table 2.6, 2.1.3.1). Exon-flanking primers bind to the template 
cDNA and PCR was used to amplify the DNA sequences. PCR was performed 
using the ThermoPrime Plus Taq DNA Polymerase within a ReddyMixTM PCR 
Master Mix (AB-0575/LD/B, FIS), following manufacturer’s instructions (Table 
2.9). Final 1x reaction contains 1 U Taq DNA Polymerase and 200 μM of each 
dNTP. DNA amplification was conducted using the following reaction conditions. 
Table 2.9: PCR reaction conditions. 
Step Temperature Time Number of cycles 
Initial Denaturation  95oC 2 min 1 cycle 
Denaturation 95oC 25 35 cycles 
Annealing  55oC 35 35 cycles 
Extension  72oC 65 35 cycles 
Final Extension  72oC 5 min 1 cycle 
 
The resulting PCR products were visualised using agarose gel electrophoresis 
as described in 2.2.1.3. 
2.2.1.11 Taqman two-step real-time qPCR  
A broad-coverage panel of 26 human tissue cDNAs was purchased from 
Clontech. 31 separate mouse tissue cDNAs were kindly pre-made by Alison 
Davies (CVGI group, Astra Zeneca, Macclesfield, UK). cDNA was prepared 
from C2C12 cells as detailed in (2.2.1.4 and 2.2.1.9). 20 ng of each cDNA 
sample was plated in triplicate in to wells of a 384-well plate. Pre-designed 
Taqman® gene expression assay kits were purchased from Applied Biosystems 
(Table 2.8, 2.1.3.3) Samples were processed using the Absolute qPCR Mix 
(AB1138/B, FIS) following manufacturer’s instructions. Briefly, qPCR was 
performed using the Thermo-Start DNA Polymerase within a master mix 
reaction buffer (Table 2.10). Gene expression analysis was performed using an 
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Applied Biosystems 7900HT real-time PCR system (QIA). The relative gene 
expression levels for each tissue were calculated using the ∆CT method by 
normalising data to a geometric mean from three independent reference genes. 
Table 2.10: Preparation of two-step qPCR reaction per well of 384-well plate. 
Component Volume (μl) 
cDNA 2  
Primer/probe (20X) 0.5 
Master mix 5  
RNase free ddH2O 2.5 
Total Volume (μl) 10 
 
2.2.1.12 Taqman one-step real-time qPCR  
RNA samples were diluted to 10 ng/μl with DEPC-treated water (LTC46-2224, 
Invitrogen, LTC) and plated in 96-well plates. 20 ng of each RNA sample was 
plated in triplicate in to wells of a 384-well plate. Pre-designed Taqman® gene 
expression assay kits were purchased from Applied Biosystems (Table 2.8, 
2.1.3.3). Samples were processed using the Quantitect Probe RT-PCR kit 
(204445/3, QIA) following manufacturer’s instructions. Briefly, qRT-PCR was 
performed using the omniscript and sensiscript reverse transcriptases and 
HotStarTaq DNA Polymerase within a RT-PCR reaction buffer (Table 2.11). 
Gene expression analysis was performed using an Applied Biosystems 7900HT 
real-time PCR system (QIA). The relative gene expression levels for each tissue 
were calculated using the ∆CT method by normalising data to a geometric 
mean from three independent reference genes. 
Table 2.11: Preparation of one-step qPCR reaction per well of 384-well plate. 
Component Volume (μl) 
RNA 2 
Primer/probe (20X) 0.5 
RT-PCR buffer 5 
RT enzyme 0.1 
RNase free ddH2O 2.4 
Total Volume (μl) 10 
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2.2.2 Cell Culture Methods 
2.2.2.1 Cell line Sources  
The C2C12 muscle skeletal muscle cell line and the 3T3-L1 adipocyte cell line 
and the HEK-293 cell line were purchased from the American Type Culture 
Collection (ATCC). HL1 mouse heart cells (CC) were kindly provided by Dr 
William.C Claycomb (LSU, New Orleans, LA, USA). Platinum-E (Plat-E) cells 
(modified HEK 293 cells) and L6 rat skeletal muscle cells (L6 Bath) were 
provided by Professor David James (Garvan Institute, Sydney, AUS). L6 rat 
skeletal muscle cells (L6 AZ) were a sub-clone of ECACC 83011421 provided 
by and cultured at Astra Zeneca (Astra Zeneca, Alderley Park, Macclesfield, 
UK).  
All cell lines were stored in cryovials and kept in liquid nitrogen tanks. Cells 
were maintained in freeze down medium, normal growth medium supplemented 
with 10% dimethyl sulfoxide (DMSO) (D2650, SIG) with an extra 10% heat 
inactivated FBS (SIG). 
2.2.2.2 HEK-293 cell culture 
Human Embryonic Kidney 293 cells (HEK 293) cells were routinely cultured in 
growth media (Dulbecco Modified Essential Medium (DMEM) (D6546, SIG) 
supplemented with 10% (v/v) heat inactivated FBS (SIG), 50 units/ml penicillin, 
50 μg/ml streptomycin (P4458, SIG) and 2 mM L-glutamine (G7313, SIG) at 
37oC in 10% CO2. HEK 293 cells were grown to 90% confluence and passaged 
every 3-4 days.  
2.2.2.3 Expression of full-length FLAG-tagged TBC1D1 and TBC1D4 in 
HEK 293 cells 
HEK 293 cells were seeded in 90 mm dish (TKT-110-070A, Nunclon, FIS) in 
growth media minus antibiotics and grown overnight to 60% confluence. The 
next day cells were transfected with full-length 1XFLAG-tagged Tbc1d1 or 
3XFLAG-tagged As160/Tbc1d4 using Lipofectamine® LTX reagent (18324-012, 
Invitrogen, LTC). Transfection was performed following manufacturer’s 
instructions. Recombinant proteins were expressed in HEK 293 cells for 18 to 
24 hours at 37oC in 5% CO2. One hour prior to cell lysis the culture media was 
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replenished. Cells were lysed in 2% Sodium Dodecyl Sulphate (SDS) 
supplemented with protease inhibitors (Halt Protease Inhibitor Cocktail, 78430, 
Pierce, FIS). Lysates were pipetted up and down several times, transferred to 
eppendorf tubes and rotated at room temperature for 15 min. Samples were 
briefly sonicated (6 x 1 second at amplitude 10 microns) using a sonicator and 
centrifuged at 14,000 x g for 30 min at 16oC. The cleared supernatant was 
transferred to new eppendorf tubes. Protein concentration was determined as 
detailed in 2.2.3.3. 50 μg of protein lysate was subjected to SDS-PAGE as 
described in 2.2.3.4. All 10 TBC1D1 antibodies (Table 2.3, 2.1.2) were analysed 
for specificity against 1XFLAG-tagged TBC1D1 using western blotting as 
detailed in 2.2.3.5. Preference for TBC1D1 over TBC1D4 was also compared. 
2.2.2.4 Calcium phosphate transfection of HEK 293 cells 
HEK 293 cells were seeded at 2 x 106 cells per 90 mm dish (TKT-110-070A, 
Nuclon, FIS) in growth media minus antibiotics. The next day, three hours prior 
to transfection the media was replenished. For each plate, 20 μg of full-length 
3XFLAG-tagged Tbc1d1 or 3XFLAG-tagged As160/Tbc1d4 DNA were mixed 
with 250 mM CaCl2. The CaCl2/DNA mix was added drop wise to a 2 x HBS 
solution and allowed to stand at room temperature for 30 min until the 
precipitate was formed. The transfection mix was added drop wise to the cells 
and incubated for 16 to 24 hours at 37oC in 10% CO2. The following day the 
media was replenished and incubated for a further 24 hours. Cells were 
harvested 40-48 hours after transfection. 
2.2.2.5 Purification of FLAG-tagged TBC1D1 and TBC1D4 proteins from 
HEK 293 cells 
HEK 293 cells were recovered in PBS and pelleted at room temperature at 400 
x g for 5 min. The cells were washed with PBS and centrifugation was repeated. 
The supernatant was removed and the cells were lysed in HEK 293 cell lysis 
buffer supplemented with protease inhibitors (Halt Protease Inhibitor Cocktail, 
78430, Pierce, FIS). Lysates were pipetted up and down several times, 
transferred to eppendorf tubes and rotated for 1 hour at 4oC. The samples were 
centrifuged at 14,000 rpm for 20 min at 4oC. The cleared supernatant was 
transferred to new eppendorf tubes and incubated with pre-washed anti-FLAG 
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M2 beads (A2220, SIG) and rotated for two hours at 4oC. The unbound fraction 
was removed and the beads were washed three times with cell lysis buffer and 
a further three times with TBS. FLAG-tagged proteins were eluted from the 
beads with 100 μl 200 μg/ml of FLAG-peptide in TBS. A volume of the eluted 
fraction was resolved by SDS-PAGE as described in 2.2.3.4. The concentration 
of recovered purified protein was quantified as detailed in 2.2.3.3. Purified 
proteins were aliquoted and stored at -80oC until required. 
2.2.2.6 C2C12 mouse skeletal muscle cell culture 
The C2C12 mouse myoblast cell line, are a skeletal muscle cell model 
produced by (Blau, et al., 1985). C2C12 cells are a sub-clone of the myogenic 
cell line derived from adult dystrophic mouse muscle (Yaffe & Saxel, 1977).  
Table 2.12: Standardised C2C12 cell culture conditions. 
 
C2C12 methodology Standardised Condition 





/ 6 well 
5 x 10
3 
/ 96 well 
Passaging of myoblasts Every 2-3 days 
Seeding cell density for differentiation 4.0 * 10
3 
/ 96 well 
Myotubes used for experiments 6-8 days post differentiation 
Number of days recovery post infection ~ 10days before seeding  
 
C2C12 myoblasts were cultured in normal growth media, Dulbecco’s Modified 
Essential Medium (DMEM) (D6546, SIG) supplemented with 10% (v/v) foetal 
bovine serum (FBS), antibiotic-antimycotic (AA) solution (S5955, SIG) 
(containing 100 units/ml penicillin, 100 μg/ml streptomycin 250 ng/ml 
amphotericin), 2 mM L-Glutamine (G7313, SIG) at 37oC in 10% CO2. Myoblasts 
were seeded at a density of approximately 2 x 105 cells per T75 flat bottom 
flasks (GRE). The cells have a fast doubling time therefore they were routinely 
passaged every 2 to 3 days. In order to maintain a proliferative phenotype, cell 
cultures were not allowed to reach confluence. Important C2C12 cell culture 
conditions can be found in Table 2.12.  
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2.2.2.7 Pre coating of 96 well micro titre plates 
96-well black micro titre plate with μClear base (655090, GRE) were coated with 
sterile 1% gelatin (214340, Difco, BD) (100 μl/well) for one hour at room 
temperature. Excess gelatin was removed by tipping and wells were fixed with 
0.5% glutaraldehyde (16220, EMS) for 10 min. Plates were washed once with 
PBS then incubated for 5 min with quench solution. Subsequently the plates 
were washed two times with DMEM (200 μl/well) and stored in DMEM at 37oC 
until required. 
2.2.2.8 Differentiation of C2C12 myoblasts to myotubes 
Myoblasts were seeded in pre coated 96-well plates at 5 x 103 cells per well. 
The next day, differentiation was induced by culturing cells in differentiation 
media, DMEM supplemented with 5% horse serum (H1270, SIG), antibiotic 
antimycotic (AA) solution (SIG) and 2 mM L-Glutamine (SIG) at 37oC in 10% 
CO2. The media was replenished every two days. Experiments were conducted 
using myotubes 6-8 days post differentiation. Light microscopy images were 
obtained of C2C12 cell during differentiation using a 4 x objective and were 
documented using digital camera (Motic) (Figure 3.1, 3.4.1). Florescence 
microscopy images were captured using the IN Cell Analyzer system 200 (GE 
Healthvare) confocal imaging plate reader (Figures A1-5, Appendix). 
2.2.2.10 Plat-E cell culture 
Platinum-E (Plat-E) cells are a modified HEK 293T cell line (Morita & Kitamura. 
2000). These were used for efficient and stable packaging of retrovirus. Cells 
were cultured in Plat-E growth media, Dulbecco Modified Essential Medium 
(DMEM) supplemented with 10% (v/v) heat inactivated FBS (SIG), 50 units/ml 
penicillin, 50 μg/ml streptomycin (P4458, SIG), 2 mM L-glutamine (G7313, SIG), 
10 μg/ml blastocidin (15205, SIG) and 1 μg/ml puromycin (540411, Calbiochem, 
MIL) at 37oC in 10% CO2. Cells were grown to 90% confluence and passaged 
every 3-4 days.  
2.2.2.11 Generation of the HA-GLUT4 retrovirus 
The HA-GLUT4 retrovirus was produced in the Plat E cell line as previously 
outlined (Shewan, et al., 2003). Cells were transfected with the pBABE HA-
2 Materials and Methods 
 
~ 80 ~ 
 
GLUT4 construct using Lipofectamine® 2000 reagent (11668-027, Invitrogen, 
LTC) following manufacturer instructions. The transfected cells were incubated 
for 48 hours at 37oC and then transferred to 30oC for a further 24 hours. The 
supernatant (which contains the retrovirus) was collected and filtered. The virus 
was aliquoted and immediately frozen at -80oC.  
2.2.2.12 Stable expression of HA-GLUT4 in C2C12 muscle cells 
C2C12 myoblasts were seeded at 1 x 105 per 90 mm dish (TKT-110-070A, 
Nuclon, FIS) in normal growth media overnight. The next day, cell cultures at 
~30% confluence were infected with 25 μl of HA-GLUT4 retrovirus or 200 μl of 
Empty Vector virus in the presence of 8 μg/ml polybrene (H9268, SIG) for 5 
hours at 37oC in 10% CO2. The amount of virus was determined by performing 
viral titre experiments. The culture media was replenished with normal growth 
media and the cells were left to recover overnight at 37oC in 10% CO2. The 
following day, infected myoblasts were selected for by culturing in normal 
growth media supplemented with 2 μg/ml puromycin (540411, Calbiochem, MIL) 
(HA-GLUT4 growth media). A considerable amount of cell death was noted for 
the HA-GLUT4 cells due to the low viral titre used. The growth media (HA-
GLUT4) was replenished every day to remove dead cells from the cultures. The 
cells were allowed to recover prior to passaging. Once normal growth of the 
cells resumed, myoblasts were seeded and differentiated into myotubes as 
described in 2.2.2.8. 
2.2.2.13 Phosphorylation of AMPK and Akt 
C2C12 myotubes were serum-starved in C2C12 serum free media, DMEM 
(SIG), 0.2% (w/v) BSA (Probumin COHN 5.2 (T) 3220, CEL) and 2 mM L-
glutamine (SIG) overnight at 37oC. The following day, the media was replaced 
with C2C12 serum free media without bicarbonate (11 mg/ml GIBCO® DMEM 
(119 00-073, Invitrogen, FIS), 0.2 % (w/v) BSA (CEL) and 20 mM (w/v) HEPES) 
for two hours before the experiment and were maintained in this throughout 
incubations. Cells were incubated in a water bath at 37oC. Myotubes were 
stimulated with insulin (NOV) at 200 nM, AICAR (A9978, SIG) at 2 mM, 
A769662 (provided by Dr Kei Sakamoto) at 100 μM for indicated times at 37oC. 
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Protein lysates were prepared as described in 2.2.2.14, or cells were used for 
GLUT4 translocation experiments as detailed in 2.2.2.16 and 2.2.2.17.  
2.2.2.14 Preparation of protein lysates from cultured C2C12 cells 
Cells were washed with ice cold PBS, and lysed (15 μl/well) with cell lysis buffer 
supplemented with protease inhibitors (Halt Protease Inhibitor Cocktail, 78430, 
Pierce, FIS) and phosphatase inhibitors (Table 2.13). Lysates were pipetted up 
and down several times and transferred to eppendorf tubes. Samples were 
briefly sonicated (6 x 1 second at amplitude 10 microns) using a sonicator () 
and rotated for 1 hour at 4oC. The samples were centrifuged at 14,000 rpm for 
20 min at 4oC and the cleared supernatant was transferred to new eppendorf 
tubes. The protein concentration was determined by BCA protein assay as 
described in 2.2.3.2. 40 μg of protein lysates were resolved by SDS-PAGE 
(2.2.3.4) and analysed by western blotting (2.2.3.5).  
Table 2.13: List of phosphatase inhibitors. 
Phosphatase  
Inhibitor 
 Target Final 
concentration 
Sodium molybdate NaM Acid phosphatases  
Sodium orthovanadate NaV Protein tyrosine phosphatases  
Sodium fluoride NaF Protein phosphoseryl and 
phosphothreonyl phosphatases (PSPs) 
 
Okadaic acid OA Protein phosphatase 1 (PP1) and 2A 
(PP2A) 
 
Phosphatidic acid PA Protein phosphatase 1 (PP1)  
Nuclear inhibitor of 
protein phosphatase 1 
Nipp1 Protein phosphatase 1 (PP1)  
Cypermethrin Cyp Protein phosphatase 2B (Calcineurin 
PP2A) 
 
Dephostatin Dep Protein tyrosine phosphatases   
 
2.2.2.15 siRNA-mediated knock down 
C2C12 myotubes at day 2-3 of differentiation were transfected with siRNA 
oligonucleotides. One day prior to transfection C2C12 differentiation media was 
replaced with differentiation media minus antibiotics. The following day, the 
media was replenished prior to transfection. Differentiating C2C12 cells were 
either transfected with Tbc1d1-siRNA, As160/Tbc1d4-siRNA or with control 
non-targeting siRNA (Table 2.7, 2.1.3.2) using DharmaFECT 1® transfection 
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reagent (T-2001-02, Dharmacon, FIS). Transfections were performed following 
manufacturer’s instructions. Transfection mix preparation for 20 x wells of 96-
well micro titre plate detailed in Table 2.14. siRNA oligonucleotides were 
prepared at 2 μM in PBS (RNase-free and sterile) and diluted to 1 μM in 
OptiMEM® reduced serum media (31985-062, Invitrogen, FIS), denoted tube 1. 
In a separate tube, DharmaFECT 1® transfection reagent was prepared in 
OptiMEM® reduced serum media to the same final volume as tube 1. This was 
denoted tube 2. The solutions were mixed well and incubated for 5 min at room 
temperature. The contents of both tubes were combined and incubated for 20 
min at room temperature. The mix was diluted with four parts differentiation 
media minus antibiotics. The final siRNA concentration was 100 nM. The 
transfection mix was added to the cells (100 μl/96-well) and incubated at 37oC 
for 24 hours in 10% CO2. The following day the media was replenished. Cells 
were used for experiments at day 7 or 8. Protein lysates were prepared as 
described in 2.2.2.14 and the cells were used for GLUT4 translocation 
experiments as detailed in 2.2.2.16 and 2.2.2.17  
Table 2.14: Preparation of transfection mix for 20x wells of 96-well micro titre plate. 
Contents of Tube 1 Volume (200 μl) Contents of Tube 2  Volume (200 μl) 
2 μM siRNA  100 μl DharmaFECT 1 4 μl 
OptiMEM 100 μl OptiMEM 198 μl 
 
Final Transfection mix 
 
Volume (2000 μl) 
 
Transfection per well 
 
 
Tube 1 + Tube 2 400 μl 100 nM siRNA  
Culture media (minus 
antibiotics) 
1600 μl 0.4 μl DharmaFECT 1  
 
2.2.2.16 HA-GLUT4 translocation assays; transition experiments 
The level of HA-GLUT4 at the plasma membrane in C2C12 myotubes was 
measured as a percentage of the total expressed HA-GLUT4 described 
previously (Govers, et al., 2004) (Fazakerely, et al., 2009).  
The experiments were conducted using myotubes 6-8 days post differentiation. 
Myotubes were serum starved overnight and the next day stimulated with 
agonist as described in 2.2.2.13. After treatment the cells were immediately 
moved to ice to stop the trafficking. The cells were washed three times in ice-
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cold PBS and fixed with 3% paraformaldehyde for 15 min on ice and for a 
further 30 min at room temperature. The cells were quenched with glycine for 5 
min and washed once more with PBS. All residual PBS was removed from cells 
by dipping. Cells were blocked for 20 min with blocking buffer (those wells used 
to calculate total cellular HA-GLUT4 were made permeable by blocking with the 
addition of 0.2 % Saponin). All cells were incubated with primary anti-HA 
antibody at a 1:500 dilution for 45 min. Cells were washed thoroughly in PBS 
(3x 5 min) before re-blocking. Cells were incubated with Alexa 488-conjugated 
goat anti-mouse secondary antibody at 1:100 a dilution for 45 min. Myotubes 
were once again washed thoroughly in PBS. The fluorescence was measured 
at the wavelength 485/520 nm using the bottom reading optics on the 
pheraSTAR micro titre plate reader (BMG).  
 
Figure 2.1: Schematic diagram of HA-epitope tagged GLUT4. HA-GLUT4 inserted in to the 
plasma membrane is detected using anti-HA antibodies and alexa-488 goat anti-mouse. The 
fluorescence is measured at the wavelength 485/520 nm using the bottom reading optics on 
the pheraSTAR micro titre plate reader (BMG). 
The data (transition from the basal to the stimulated steady-state) can be fitted 
to a single-exponential function:  
 ( )  (          )             
The accumulation of GLUT4 at the cell surface over time is denoted by L (t). Y0 
is the initial amount of GLUT4 at the plasma membrane in non-stimulated 
(basal) cells. The amount of GLUT4 at the plasma membrane after long agonist 
treatment (steady-state level) is the plateau. The rate constant for the transition 
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from Y0 to the plateau is k. The half time for the transition (t1/2) can be 
determined using t1/2 = ln2/k. 
2.2.1.17 Anti-HA antibody uptake assays; GLUT4 recycling experiments 
The amount of HA-GLUT4 which recycles with the plasma membrane was 
measured in basal cells or those stimulated with insulin or AICAR. Myotubes 
were serum starved overnight and the next day stimulated with agonist as 
described in 2.2.2.13. After agonist treatment, intact live cells were labelled with 
a saturating concentration of purified anti-HA antibody (50 μg/ml) for 5 to 300 
min at 37oC in the continued presence of agonist. Some cells were kept un-
labelled and these were used to measure total cellular HA-GLUT4. After 
antibody incubations the cells were moved to ice to stop the trafficking and 
washed thoroughly with PBS. Cells were fixed with 3% paraformaldehyde for 15 
min on ice and for a further 30 min at room temperature. Subsequently, cells 
were quenched with glycine for 5 min and washed once more with PBS. All cells 
were incubated with blocking buffer (plus saponin) for 20 min. Cells used to 
calculate total cellular HA-GLUT4 were incubated with anti-HA antibody at a 
1:500 dilution for 45 min at room temperature and washed 3 times in PBS. All 
other pre-labelled cells were maintained in antibody buffer minus antibodies. All 
cells were incubated with Alexa 488-conjugated goat anti-mouse secondary 
antibody at a 1:100 dilution for 45 min and again washed thoroughly in PBS. 
The fluorescence was measured at the wavelength 485/520 nm using the 
bottom reading optics on the pheraSTAR micro titre plate reader (BMG). HA-
GLUT4 labelled with antibody over time was measured in permeabilised cells 
and calculated as a percentage of the total cellular immuno-reactive GLUT4.  
The data (steady-state GLUT4 recycling) can be fitted to a one-phase non-
linear regression (single-exponential equation): 
 ( )  (   )         
The accumulation of labelled GLUT4 over time is denoted by L (t). P is the initial 
plasma membrane level of GLUT4 at Y0. The total amount of the GLUT4 pool 
which is actively recycling with the plasma membrane is T. The rate constant for 
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GLUT4 exocytosis at steady-state is kex. The transition from Y0 to the plateau is 
k. The half time (t1/2) can be determined using t1/2 = ln2/k. 
2.2.3 Biochemical Methods 
2.2.3.1 Preparation of total protein lysates from mouse tissues 
Adult male mice (g) were used for the isolation of tissue samples. Mice were 
sacrificed by cervical dislocation. Tissues were immediately dissected, wrapped 
into aluminium foil and snap frozen in liquid nitrogen. The heart was washed in 
ice-cold PBS prior to freezing to reduce blood from the cleared lysate. Four 
different skeletal muscles were dissected based on fibre type composition 
tibialis anterior (TA), extensor digitorum longus (EDL), gastrocnemius (GN) and 
soleus (SOL) muscles. The anatomical localisation of mouse hind limb muscles 
are depicted (Figure 2.2). All tissues were stored at -80oC until required.  
 
Figure 2.2: Gross anatomical presentation of mouse hind limb muscles after removal of the 
skin. (A) Anterior view of intact hind limb. (B) Anterior/lateral view, (black arrow indicates the 
Tibialis Anterior (TA) muscle). (C) Anterior/lateral view, (black arrow indicates the Extensor 
Digitorum Longus (EDL) muscle. (D) Medial view. (E) Posterior view, (black arrow indicates 
the calf muscle (Gastrocnemius (GN) and Soleus). (F) Excision of the calf muscle at the 
calcaneal tendon, (black arrow indicates the Soleus muscle; white arrow indicates the GN 
muscle. Images were obtained using digital camera.  
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Mouse tissues were removed from -80oC and immediately transferred into a 
glass potter containing ice-cold cell lysis buffer (Table 2.15) and kept on ice. 
Tissues were quickly homogenised (3 x 10 strokes) using a bench top 
homogeniser. Tissue homogenates were transferred to eppendorf tubes and 
further lysed for 30 min on ice. Samples were centrifuged at 13,000 rpm for 20 
min at 4oC and cleared supernatants were transferred in to new eppendorf 
tubes. The protein concentration was determined by BCA protein assay as 
described in 2.2.3.2. 40 μg of protein lysates were resolved by SDS-Page 
(2.2.3.4) and analysed by western blotting (2.2.3.5).  
Tibialis Anterior muscle from recombinant congenic strain (RCS) B6.SJL-
Nob1.10 and transgenic strain FVB/N Tg (MCK-Tbc1d1) were used in order to 
validate the specificity of our TBC1D1 antibodies. These tissues were provided 
by Professor Hadi Al-Hasani (Deutsches Diabetes Zentrum (DDZ), Duesseldorf, 
Germany) (Chadt, et al., 2008). 
Table 2.15: Preparation of mouse tissue lysates. 
 
Mouse tissue  
Heart 1 x heart per ml 
Brain 1 x brain per ml 
Epididymal Fat 1 x fat pad per ml 
Tibialis anterior (TA) 1 x muscle per ml 
Gastrocnemius (GN) 1/2 muscle per ml 
Extensor digitorum longus (EDL) 2 x muscles per ml 
Soleus (SOL) 2 x muscle per ml 
 
2.2.3.2 Determining protein concentration 
The concentration of total protein within cell or tissue lysate was determined by 
the BCA (BiCinchoninic Acid) colorimetric protein assay. BCA reagent A 
(23277, Pierce, FIS) was mixed with BCA reagent B (50:1) following 
manufacturer instructions. 2 mg/ml Bovine Serum Albumin (BSA) (A9418, SIG) 
was used for the generation of a protein standard curve. Samples and 
standards were read in duplicate. The BCA assay was measured at wavelength 
565nm. 
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2.2.3.3 Determining protein concentration using coomassie Blue 
Staining SDS-PAGE gels 
2 mg/ml Bovine Serum Albumin (A9418, SIG) was used for the generation of a 
standard curve. Protein standard samples and a volume of purified protein were 
processed using SDS-PAGE as described in 2.2.3.4. After electrophoresis, the 
SDS-PAGE gel was rinsed once with ddH2O and stained with coomassie dye 
(1610436, BIO) at room temperature for 2-24 hours. The coomassie stain was 
removed and the gel was de-stained in ddH2O. The protein bands were 
visualised using a trans-illuminator (UVP) and documented (camera). A 
standard curve was plotted and the sample protein concentration was 
estimated.   
2.2.3.4 SDS-Polyacrylamide gel electrophoresis SDS-PAGE 
Samples were analysed using the standard method of Laemmli Tris-Glycine 
Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
discontinuous buffer system (Laemmli, 1970).1.5 mm thick SDS-PAGE gels 
were prepared using the Mini protean II system apparatus (BIO) or the Mini 
vertical apparatus (CBS). Gels were composed of acrylamide/bis acrylamide 
(30% (w/v) acrylamide) with resolving or stacking gel buffers. The percentage of 
acrylamide used was determined for each experiment based on the protein of 
interest. Gel polymerisation was initiated by the addition of % (v/v) N,N,N,N’-
tetramethylethylenediamine (TEMED) (T9281, SIG) and 10% (w/v) ammonia 
persulphate (APS) (AP470, FIS). An appropriate amount of protein lysate was 
solubilised in 3X sample buffer. The total sample volume was adjusted with 1X 
sample buffer. Dithiothreitol (DTT) (BP172-5, FIS) was added to the sample at a 
final concentration of 100 mM (w/v). Samples were vortexed and heated for 5 
min at 95oC. Samples were centrifuged at 13,000 rpm for 5 min and loaded onto 
the SDS-PAGE gels. These were run in electrophoresis buffer at 200 Volts for 
approximately 1 hour. The molecular weight of the proteins within samples was 
determined using Novex® Sharp pre-stained protein standards (LC5800, 
Invitrogen, FIS). 
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2.2.3.5 Western Blotting 
Gels were transferred to nitrocellulose using the Trans-Blot® SD Semi-dry 
Electrophoretic Transfer Cell Apparatus (170-3940, BIO). Gels were removed 
from the tanks and immediately placed in transfer buffer. Extra-thick blot 
absorbent filter paper (170-36-69, BIO) and nitrocellulose membrane (P/N 
66485, PAL, VWR) were pre-cut to the dimensions of the gel and allowed to 
soak in transfer buffer for 20 min. One piece of nitrocellulose membrane 
followed by the gel, were sandwiched between sheets of buffer soaked blot 
paper and assembled on to the platinum anode. Air bubbles were removed to 
ensure contact between the layers for a decent transfer. Any excess buffer was 
minimised from around the transfer assembly. Finally, the cathode was fitted on 
top of the stack and secured in place with a lid. The transfer was run at constant 
milliamps (mA) (which was calculated by the area of gel (cm2) X 0.8) for 1 hour 
50 min or for 2 hours 30 min (when studying large proteins of >150 kDa). After 
the transfer was complete, the nitrocellulose was removed, briefly washed in 
ddH2O and stained with ponceau S stain. Excess ponceau stain was removed 
by washing with ddH2O. The molecular weight standards were clearly marked 
on with pencil. The membrane was either processed immediately of left to air 
dry.  
2.2.3.6 Immuno-blotting and Detection 
The nitrocellulose membrane was briefly washed in tris buffered saline 
containing tween-20 (TBS-T) to remove ponceau S stain. Subsequently, 
membranes were blocked by submerging in TBST containing 5% (w/v) Marvel 
milk powder or 5% (v/v) BSA (CEL) (when studying phosphorylated proteins) 
before appropriate primary antibody incubation (Table 2.3, 2.1.2). Primary 
antibodies were incubated overnight at 4oC with continual rocking. Membranes 
were washed 6 times (over the course of one hour) in TBST. The relevant 
secondary antibodies coupled to Horse Radish Peroxidase (HRP) were 
prepared at a 1:4000 dilution in TBST containing 5% Marvel milk powder (Table 
2.4, 2.1.2). Membranes were incubated with secondary antibodies at room 
temperature for 1 hour and then further washed thoroughly 6 times (over the 
course of one hour) in TBST. Bound secondary antibody conjugated to HRP 
was detected using enhanced chemi-luminescence reagent (ECL) which utilises 
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peroxidise catalysed luminal detection method. A working solution of ECL was 
prepared by mixing equal volumes of ECL A and ECL B. Membranes were 
incubated at room temperature for 1 minute. Subsequently, membranes were 
placed between acetate sheets and chemi-luminescence was detected at 
wavelength using a Hamamatsu camera attached on an EpiChemi II Imager 
(UVP) for between 1-5 minutes. If more sensitive detection was required the 
membranes were washed and incubated with Super Signal Dura (34076, 
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3 Characterising TBC1D1 antibodies and 
investigating the expression of TBC1D1 and 
TBC1D4 in muscle 
3.1 Introduction 
The Rab-GAP proteins TBC1D1 and TBC1D4 have been identified as potential 
downstream signalling intermediates which regulate GLUT4 translocation 
(Roach, et al., 2007). They are proposed to function as negative regulators of 
GLUT4 trafficking through maintaining an un-specified rab protein in its in-active 
GDP-bound state. Several studies have demonstrated that TBC1D4 and 
TBC1D1 are phosphorylated in response to insulin and contraction stimulation 
in skeletal muscle (Kramer, et al., 2006) (Bruss, et al., 2005) (Funai & Cartee, 
2008) (Funai & Cartee, 2009) (Vichaiwong, et al., 2010) (Pehmoller, et al., 
2009).  
TBC1D4 and TBC1D1 contain multiple Akt phosphorylation motifs. To date, 
several AMPK phosphorylation sites have been identified in TBC1D1. The most 
well studied site is the consensus AMPK-phosphorylation motif surrounding 
serine 231 on mouse TBC1D1 (Peck, et al., 2009) (Taylor, et al., 2008) (Chen, 
et al., 2008) (Roach, et al., 2007). Studies on TBC1D1 function have led to its 
emergence as a potential signalling protein in regulating GLUT4 trafficking in 
response to contraction and/or AMPK activation (Chavez, et al., 2008) 
At the time this project commenced there were no commercial antibodies 
available against TBC1D1 protein or TBC1D1 phosphorylated at serine 237, so 
specific anti-serum was generated against rat TBC1D1 (AGG Astra Zeneca, 
Macclesfield, UK). The development of TBC1D1 phospho-specific antibodies is 
important as these are key tools for studying phosphorylation events and can be 
used to track the activity of the protein.  
The objectives of this chapter were to analyse the specificity of the TBC1D1 
antibodies for recombinant and endogenous TBC1D1 proteins using western 
blotting. Furthermore, in order to study the importance of TBC1D1 and TBC1D4 
proteins in muscle, we have investigated the relationship between muscle fibre-
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type and TBC1D1/TBC1D4 expression. Lastly, to analyse the usefulness of the 
C2C12 skeletal muscle cell line as a model  
3.2 Characterisation of TBC1D1 specific antibodies 
3.2.1 Development of TBC1D1 specific antibodies 
Three different peptides of rat TBC1D1 were used to generate TBC1D1-specific 
antibodies (Table 2.5, 2.1.2.2) (Figure 3.1). Three or four rabbits were injected 
with each peptide and affinity purified anti-serum from terminal bleeds were 
analysed for specificity against TBC1D1 using western blotting. While this study 
was in progress, another group had developed their own TBC1D1 specific 
antibody in order to functionally characterise TBC1D1 in glucose and fatty acid 
metabolism, this was published in 2008 (Chadt, et al., 2008). This affinity-
purified polyclonal antiserum was raised towards an N-terminal peptide of 
mouse TBC1D1, TBC1D1 H-AH (Figure 3.1). More recently commercial 
antibodies have become available, we have tested TBC1D1 #4629 (Cell 
Signalling Technologies) (Figure 3.1).  
 
Figure: 3.1: Location of antibody recognition epitopes in rat TBC1D1. 10 purified polyclonal 
antisera were raised against three epitopes of rat TBC1D1. Epitope ID AZ 3001724 produced 
antibodies 97, 98 and 99, epitope ID AZ 3001725 for antibodies 00, 01, 02A, 02B and epitope 
ID AZ 3001726 generated antibodies 03, 04 and 05. N-Terminal epitope polyclonal anti - 
TBC1D1 H-AH (Prof. Hadi Al-Hasani) was raised towards Try-Gly-Gln-Pro-Ser-A-Pro-Gly- 
Pro- Arg- Pro-Met-Arg-Lys-SerTGQPSAPGPRPMRKS-CONH2 of mouse TBC1D1. 
Commercial cell signalling anti-TBC1D1 #4629 was raised toward a peptide sequence 
around Val 796 of mouse TBC1D1.  
 
A phospho-peptide matching the sequence around serine 237 was used to 
generate antibodies which would specifically recognise phosphorylated 
TBC1D1 (Table 2.5, 2.1.2.2). Terminal bleeds were purified using a non-
phosphorylated peptide column and examined for specificity in western blots.  
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3.2.2 TBC1D1 antibodies specifically recognise recombinant 
TBC1D1 protein over TBC1D4  
An initial characterisation screen was performed to examine antibody specificity 
for recombinant full-length FLAG-tagged TBC1D1 expressed in HEK cells. 
Preference for TBC1D1 over TBC1D4 was also compared. All 10 generated 
antibodies were tested using western blotting (Figure 3.2). FLAG-tagged 
TBC1D1 and TBC1D4 proteins were both detected at approximately 160 kDa 
by blotting with anti-FLAG antibody. The expression of FLAG-tagged TBC1D1 
was higher than that of TBC1D4; however, it was still possible to determine 
specific immune reactivity against TBC1D1 over TBC1D4. 
Antibodies 03, 04, 05 and 00, 01, 02A and 02B specifically recognise FLAG-
tagged TBC1D1 over TBC1D4. In particular antibodies 04, 05 and 00 strongly 
recognise TBC1D1 and display minimal non-specific immune reactivity with 
other proteins within the HEK cell lysate. 01, 02A and 02B, even though they 
show preferential recognition of TBC1D1 over TBC1D4, they also recognise 
multiple non-specific bands throughout the HEK cell lysate. In contrast, 
antibodies 97, 98 and 99 which are generated against an N-terminal peptide of 
the protein show little specificity for TBC1D1 and strongly recognise numerous 
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Figure 3.2: Selectivity of TBC1D1 antibody for recombinant TBC1D1. 10antibodies generated 
against three different peptides were screened against recombinant FLAG-tagged TBC1D1 
and FLAG-tagged TBC1D4 expressed in HEK 293 cells. Astra Zeneca polyclonal affinity 
purified antibodies generated against three peptides of rat TBC1D1. Antibodies 97, 98 and 99 
were raised against Glu-Pro-Asp-Leu-Arg-Lys-Ser-Gln-Pro-Trp, ID AZ 3001724. Antibodies 
00, 01, 02A, 02B were raised towards Asp-Ser-Pro-Ser-Arg-Tyr-Glu-Asp-Tyr-Ser-Glu, ID AZ 
3001725 and antibodies 03, 04 and 05 were raised against Gln-Lys-Leu-Arg-Pro-Arg-Asn-
Glu-Gln-Arg-Glu-Asn, ID AZ 3001726. Protein load: 50 μg.  
 
3.2.3 Specificity of TBC1D1 antibodies in muscle 
We further characterised the specificity of the TBC1D1 antibodies by western 
blotting of fast-twitch tibialis anterior (TA) muscle lysates generated from four 
different mouse strains (Hadi Al-Hasani, German Institute Human Nutrition, 
Potsdam-Rahbreuche). The recombinant congenic mouse strain (RCS) B6.SJL-
Nob1.10 represents a knock-out model for TBC1D1. TBC1D1 was found to be 
down regulated in skeletal muscle of the Nob1SJL/SJL mouse strain. This was the 
result of a 7bp deletion in exon 18 which resulted in a frame shift mutation and 
premature termination of the protein (Chadt, et al., 2008). The transgenic 
mouse strain, FVB/N-Tg (MCK-Tbc1d1), selectively over-express FLAG-Tbc1d1 
in skeletal muscle and heart. Frozen TA muscle from RCS B6.SJL-Nob1.10, 
wild-type (B6/B6) and mutant (SJL/SJL) and FVB/N-Tg (MCK-Tbc1d1) wild-type 
(Wt) and transgenic (Tg) were directly homogenised and lysates were resolved 
by SDS-PAGE. 9 antibodies were directly compared with an already 
characterised polyclonal antibody raised towards an N-terminal peptide of 
mouse TBC1D1, TBC1D1 H-AH (Hadi Al-Hasani) using western blot techniques 
(Figure 3.3). Purified antibody TBC1D1 H-AH is specific for TBC1D1 protein as 
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it recognised two distinct protein bands within B6/B6, Wt and Tg muscle 
samples at approximately 150 kDa and 160 kDa. The slightly reduced 
electrophoretic mobility of the 160 kDa band detected in the Tg muscle sample 
is due to the presence of over-expressed 3XFLAG-TBC1D1. As expected, 
TBC1D1 protein was not detected in muscle lysate from SJL mice. TBC1D1 
was also detected in C2C12 myotube cell lysate but was not detected in TA or 
cardiomyocyte rat muscle lysates.  
Similar western blot profiles were observed with antibodies 00, 01 and 02A, 
which recognised a distinct full-length TBC1D1 protein band at approximately 
160 kDa which was absent from muscle lysate of SJL mice and rat muscle 
lysates. In addition, western blotting with antibody 02A led to the detection of a 
band at 150 kDa. Antibodies 97, 98 and 99 show no specificity for endogenous 
mouse TBC1D1 protein this further confirmed the lack of specificity of these 
antibodies.  
Interestingly, antibodies 04 and 05 which strongly recognised FLAG-tagged rat 
TBC1D1 detected a distinct but faint protein band of 160 kDa in Tg muscle 
lysate but did not specifically recognise the endogenous TBC1D1 protein in 
B6/B6 or Wt mouse muscle lysates. However, antibody 04 faintly detected a 
band at approximately 160 kDa, which is absent from SJL mice. Intriguingly, 
antibody 04 strongly identified a protein band of 150 kDa in differentiated 
C2C12 cells and rat muscle lysates. This was the approximate molecular weight 
of the smaller TBC1D1 protein band detected in mouse muscle lysates with 
TBC1D1 02A and H-AH antibodies. An amino acid sequence alignment 
between rat and mouse TBC1D1 was performed. As detailed in Table 2.5 
(2.1.2.2), there were no sequence differences between the two rodents within 
the antibody recognition epitopes. This cannot therefore explain the different 
protein band pattern detected by immuno-blotting with TBC1D1 04. The 
antibody TBC1D1 02A (AZ 3001725) that was generated (AGG, Astrazeneca, 
Macclesfield, UK), specifically recognises TBC1D1. It was therefore selected 
and used in all further experiments.  
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Figure 3.3: Screening of TBC1D1 antibodies using lysates from tibalis anterior (TA) muscle 
from different mouse strains. C2C12 myotubes, cardiomyocyte and TA muscle from rat. Nine 
polyclonal TBC1D1 antibodies generated against three peptides of rat TBC1D1. Antibodies 
97, 98 and 99,  ID AZ 3001724, Antibodies 00, 01, 02A,  ID AZ 3001725 and antibodies 03, 
04 and 05 ID AZ 3001726 were screened against TA muscle from recombinant congenic 
mouse B6.SJL-Nob1.10, and muscle specific transgenic mouse FVB/N-Tg(MCK-Tbc1d1). 
Astra Zeneca generated antibodies were directly compared with a polyclonal anti -TBC1D1 
H-AH antibody raised towards Try-Gly-Gln-Pro-Ser-A-Pro-Gly-Pro-Arg-Pro-Met-Arg-Lys-Ser-
TGQPSAPGPRPMRKS-CONH2 of mouse TBC1D1. Protein load: 30 μg.   
 
3.2.4 Characterising the specificity of TBC1D1 antibody 02A in 
insulin-responsive cells 
The TBC1D1 antibody 02A was further tested for specificity by western blotting 
cell lysates prepared from a selection of insulin-responsive cell models. These 
included L6 myotubes, C2C12 myotubes, HL1 cells, 3T3 adipocytes and flexor 
digitus brevis (FDB) muscle cells. The results shown in Figure 3.4 are 
representative western blots derived from different experiments.  
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As shown in Figure 3.4A, blotting with antibody 02A led to the detection of a 
distinct protein band which migrated at approximately 140 kDa in L6 myotubes. 
It is apparent that the protein band detected in L6 myotubes does not 
correspond to the protein bands at 150 kDa and 160 kDa in C2C12 myotubes 
(Figure 3A).   
HL1 cells are a clonal cell line derived from AT-1 mouse atrial cardiomyocyte 
tumour cells. HL1 cells retain a differentiated adult cardiomyocyte phenotype 
when cultures are grown to confluence (Claycomb, et al., 1998). Cell lysates 
were prepared from both confluent (HL1 Heart cells CC) and sub-confluent 
(HL1 Heart cells) cultures and immuno-blotted with TBC1D1 antibody 02A 
(Figure 3.4B). Two proteins bands are detected in both HL1 heart cell lysates. 
These bands migrate at the expected molecular weights of 150 kDa and 160 
kDa. Interestingly, in cells maintained at high confluence, the higher molecular 
weight protein was more abundant than the lower molecular weight protein. In 
comparison, this was not the case for HL1 cells grown to sub-confluence. In sub 
confluent cultures the smaller TBC1D1 protein band was most abundant (Figure 
3.4B).  
In addition, western blotting with antibody 02A led to the detection of a faint 
protein at approximately 150 kDa in differentiated 3T3-L1 adipocytes (Figure 
3.4B). Furthermore, as shown in Figure 3.4C, a single TBC1D1 protein band at 
160 kDa is detected in rat FDB muscle cells.   
It is important to note that blotting with antibody 02A led to the detection of a 
protein band at ~260 kDa in HL1 cell lysates and 3T3-L1 adipocytes. Based on 
the known molecular weight of TBC1D1 it is likely that this protein band is non-













Figure 3.4: Western blot analysis of TBC1D1 across a selection of insulin-responsive cells 
derived from rodent using total TBC1D1-specific antibody 02A. (A)  Protein lysates from 
transformed cell lines L6 rat myotubes load: 15 μg, Day 7 C2C12 mouse myotubes load: 25 
μg - loading control: anti-β tubulin. (B) HL1 mouse heart cells (CC-Batch of cells direct from 
Claycomb) and 3T3-L1 mouse adipocytes load 20 μg - loading control: anti-β tubulin. (C) 
Flexor digitus brevis (FDB) muscle cells from rat load: 50 μg - loading control: anti-AMPK. (A-
C) All cell lysates were immuno-blotted with anti-TBC1D1 02A. The western blots are derived 
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3.2.5 Phospho-specific TBC1D1 antibody recognises TBC1D1 
phosphorylated at serine 231  
Three antibodies were generated against TBC1D1 phosphorylated at serine 
237. Terminal bleeds of different rabbits injected with a phospho-peptide the 
sequence is detailed in Table 2.5 (2.1.2.2). These antibodies have been shown 
to display specificity by western blotting towards an in vitro phosphorylated 
recombinant TBC1D1 N-terminal construct containing the two PTB domains of 
the protein (Fazakerely, 2010). Following on from this the specificity of 
phospho-TBC1D1 91p antibody for endogenous phosphorylated TBC1D1 was 
assessed in the C2C12 skeletal muscle cell model. These cells were subjected 
to AMPK activation (Figure 3.5). Stimulation of C2C12 myotubes with AMPK 
activators AICAR or oligomycin resulted in a marked increased phosphorylation 
of TBC1D1 at serine 231. Western blotting with phospho-TBC1D1 91p antibody 
led to the detection of two distinct protein bands of TBC1D1 at approximately 
150 and 160 kDa. AMPK activation was assessed by confirming AMPK 
phosphorylation at threonine 172 and ACC phosphorylation at serine 79 by 
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Figure 3.5: Antibody recognition of phosphorylated TBC1D1 by phospho-TBC1D1 (serine 
237) 91p antibody in lysates following AMPK activation in C2C12 cells. C2C12 myotubes 
were maintained under basal conditions or stimulated with AMPK activators Oligomycin at 5 
mg/ml for 60 min, 2 mM AICAR for indicated times or Insulin at 200 nM for 5 min. AMPK 
activation was assessed by immuno-blotting for anti-phospho-AMPK (threonine 172), and 
down-stream signalling proteins anti-phospho-ACC (serine 79) and anti-phospho-TBC1D1 
(serine 237) 91p. AKT activation by insulin stimulation was confirmed by blotting with anti-
phospho-AKT (serine 473). Cell lysates were immuno-blotted with anti-TBC1D1 02A, anti-
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3.3 Tissue-specific expression pattern of TBC1D1 and 
TBC1D4 
3.3.1 Relative Tbc1d1 and Tbc1d4 mRNA expression by 
quantitative real-time PCR 
In order to characterise the importance of Rab-GAPs TBC1D1 and TBC1D4, 
the pattern of gene expression across a panel of tissues was determined by 
Taqman® quantitative real-time PCR. Tbc1d1 and Tbc1d4 gene expression 
profiles were generated for rat, mouse and human tissues. Absolute 
quantification was not performed; therefore only the relative expression levels 
between the tissues for each gene could be determined separately. All 
Taqman® probes used are detailed in Table 2.8 (2.1.3.3). Relative gene 
expression levels were normalised against a calculated genomic mean of three 
reference genes (Vandesompele, et al., 2002). The ∆Ct method was 
implemented to express normalised relative expression levels. Ct values relate 
to the real-time PCR signal and determine the amount of a target that is present 
in the sample. PCR efficiency was evaluated by performing template dilution 
series experiments for all Taqman® expression assays.  
3.3.1.1 TBC1D1 and TBC1D4 expression in human tissues 
A broad-coverage panel of 26 human tissue cDNAs was purchased from 
Clontech. Pre-designed gene expression assay kits were purchased from 
Applied Biosystems and were used to amplify TBC1D1 and TBC1D4 by two-
step real-time qPCR. The relative gene expression levels for each tissue were 
calculated by normalising data to three independent reference genes, 
cyclophilin A (CypA), β2 microglobulin (B2m) and beta-glucuronidase (Gusβ). 
The expression profile for human TBC1D1 is depicted in Figure 3.6 (top panel) 
and human TBC1D4 Figure 3.6 (bottom panel). TBC1D4 was most highly 
expressed in skeletal muscle, with distinguishable levels detected in the heart 
and brain. The expression of TBC1D1 was significantly pronounced in muscular 
tissues, including, skeletal muscle, heart, uterus and colon. The data revealed 
that both genes were ubiquitously expressed in most of the other tissues 
analysed, however, TBC1D4 expression was primarily within insulin-responsive 
tissues. The identification of the skeletal muscle is not known.  
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Figure 3.6: Relative TBC1D1 and TBC1D4 mRNA expression across a panel of human 
tissues-using real-time quantitative PCR. A selection of human tissue cDNAs were purchased 
from Clontech. TBC1D1 and TBC1D4 cDNAs were amplified by two-step Taqman® real-time 
PCR using gene expression kits purchased from Applied Biosystems. Relative expression 
was calculated using the delta ∆Ct method by normalising the data to three reference genes 
by geometric averaging of three internal control genes GUS B, B2M, CYPA. Top panel: The 
expression of TBC1D1. Bottom panel: the expression of TBC1D4. 
 
3.3.1.2 Tbc1d1 and Tbc1d4 gene expression in mouse and rat tissues 
A gene expression analysis of mouse tissues was performed. 31 separate 
tissue cDNAs were analysed for the expression of Tbc1d1 and Tbc1d4 (these 
were kindly pre-made by Alison Davies, CVGI group, Astra Zeneca, 
Macclesfield, UK) using two-step real-time PCR. Relative gene expression 
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levels were normalised against a calculated genomic mean of three reference 
genes, hypoxanthine phosphoribosyltransferase (Hprt), TATA-binding protein 
(Tbp) and beta-glucuronidase (Gusβ). The expression profiles for mouse 
Tbc1d1 and Tbc1d4 are displayed in Figure 3.7A. As shown in Figure 3.7A (top 
panel), Tbc1d1 was prominently expressed in the testes, muscle and brown 
adipose tissue (BAT). Notable expression of Tbc1d1 was found in many of the 
tissues analysed, in particular tissues within the gastro-intestinal tract. The 
expression of Tbc1d4 was most highly expressed in BAT, skeletal muscle and 
heart (Figure 3.7A, bottom panel). Interestingly, the expression of Tbc1d4 in 
skeletal muscle was approximately three to four-fold greater than that 
expressed in mature epididymal adipose tissue (Epi mature fat). The type of the 
mouse skeletal muscle and muscle is not known.  
At the time this project commenced, the relative expression of Tbc1d1 and 
Tbc1d4 mRNA within different muscles had not been determined. Therefore, 
the expression of Tbc1d1 and Tbc1d4 was determined in five rat skeletal 
muscles which were chosen due to their fibre-type composition. tibialis anterior 
(TA) and extensor digitorum longus (EDL) and gastrocnemius (GN) are fast-
twitch oxidative/glycolytic muscles which contain type IIA/IIX/IIB fibres. Flexor 
digitus brevis (FDB) is a fast-twitch oxidative muscle which contains 90% type 
IIA fibres. The soleus is a slow-twitch oxidative skeletal muscle which expresses 
~90% type I fibres (Bloemberg & Quadrilatero, 2012). Total RNA was isolated 
from a panel of 26 rat tissues including the five different skeletal muscles. 
Tbc1d1 and Tbc1d4 mRNA expression levels within these tissues were 
analysed using Taqman® one-step quantitect probe real-time qPCR. The 
relative gene expression levels were calculated for each tissue by normalising 
the data to three reference genes hypoxanthine phosphoribosyltransferase 
(Hprt), β2 microglobulin (B2m) and beta glucuronidase (Gus β).  The expression 
results for Tbc1d1 and Tbc1d4 are presented in Figure 3.7B. Tbc1d1 shows the 
highest level of expression in skeletal muscle. The expression of Tbc1d1 in FDB 
muscle was approximately 2-fold higher than that detected in TA, EDL, GN or 
soleus muscles (Figure 3.7B top panel). In contrast, Tbc1d4 was most highly 
expressed in the TA, EDL and GN muscles (Figure 3.7B bottom panel). The 
expression of Tbc1d4 in these muscles was greater than that expressed in the 
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soleus or FDB muscles. The data revealed that both genes were ubiquitously 





~ 104 ~ 
 
 
Figure 3.7: Determination of relative Tbc1d1 and Tbc1d4 mRNA expression levels in rodent 
tissues-using real-time quantitative PCR. (A) Expression levels were compared across a 
panel of mus musculus (Mu) tissues. The selection of cDNAs analysed were kindly donated 
by Allison (Research Scientist, Astra Zeneca, Alderley Park). Tbc1d1 and Tbc1d4 cDNAs 
were amplified by two-step Taqman® real-time PCR using gene expression assays 
purchased from Applied Biosystems. Relative expression was calculated based on delta ∆Ct 
method by normalising the data to three reference genes by geometric averaging of three 
internal control genes, Hprt, Tbp and Gus B (B) mRNA abundances were compared across a 
panel of rattus norvegicus (Rn) tissues. Total RNA was extracted from tissue homogenates 
(except muscle and adipose) using the RNA Easy Mini Kit (QIA). Muscle and adipose 
homogenates were subjected to phenol-based RNA extraction to maximise RNA yield. RNAs 
were processed using one-step quantitect probe real-time PCR. Gene expression assays kits 
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3.3.2 Quantification of TBC1D1 and TBC1D4 protein levels in 
insulin-responsive tissues 
To further understand the role of TBC1D1 and TBC1D4 within skeletal muscle, 
the pattern of protein expression was analysed by western blotting. Absolute 
protein expression of both TBC1D1 and TBC1D4 was compared within different 
skeletal muscle tissues and other insulin-responsive tissues (Figure 3.8). 
Tissues were dissected from mice, homogenised and protein lysates were 
resolved by SDS-PAGE. Skeletal muscle tissues were selected based on fibre-
type composition. tibialis anterior (TA), extensor digitorum longus (EDL) and 
gastrocnemius (GN) are fast-twitch glycolytic muscles which contain 
predominately type IIX/IIB. The soleus is a slow-twitch oxidative skeletal muscle 
which expresses ~80% type I/IIA fibres. Anatomical localisation of mouse hind 
limb muscles are depicted in Figure 2.2 (2.2.3.1). Expression levels were 
obtained by extrapolating against the standard curves of purified rat FLAG-
tagged TBC1D1 and FLAG-tagged TBC1D4 recombinant proteins. Estimated 
protein levels were expressed in terms of femto-moles of protein per microgram 
of tissue lysate.  
Quantitative immuno-blot analysis of three independent experiments revealed 
that all skeletal muscle tissues analysed as well as differentiated C2C12 
myotubes expressed the highest levels TBC1D1 protein. EDL muscle (24.8 ± 
1.2 femto-moles) and TA muscle (22.9 ± 3.3 femto-moles) expressed slightly 
higher levels of TBC1D1 compared with GN (17.4 ± 2.0) and soleus muscle 
(18.6 ± 1.3 femto-moles). Heart tissue expressed significantly lower levels of 
TBC1D1 (8.1 ± 0.5 femto-moles) compared with skeletal muscle, approximately 
three-fold lower than EDL muscle. TBC1D4 was most highly expressed in 
adipose tissue, brain, heart muscle and the soleus muscle. The expression of 
TBC1D4 in the soleus muscle (2.7 ± 0.6 femto-moles) was significantly more 
than that detected in the TA, EDL and GN muscles. Quantitative western 
blotting allows us to directly compare the levels of different proteins expressed 
within the same tissue sample. Our data revealed that within all types of skeletal 
muscle analysed and in heart the level of TBC1D1 protein expressed was 
significantly higher than the level of TBC1D4 protein (Figure 3.8A). We were 
unable to detect any defined TBC1D1 protein bands in epididymal adipose (epi 
3 Results 
 
~ 106 ~ 
 
fat) tissue and the amount detected in brain tissue by western blotting was very 
low under the conditions tested (Figure 3.8B). Even though we were unable to 
accurately quantify the expression of TBC1D1 in these tissues, it is reasonable 
to conclude that TBC1D4 is more highly expressed in brain and adipose than 
TBC1D1.  
3.3.3 Expression analysis of Tbc1d1 and Tbc1d4 splice variants 
There appears to be two major splicing variants of Tbc1d1 and Tbc1d4 that can 
be determined from the online sequencing database ENSEMBL. Comparative 
intron-exon distribution data for Tbc1d1 and Tbc1d4 have been extracted for 
rat, mouse and human and these are depicted in Appendix, Figure 1A, B.  
Rat and mouse online sequencing data indicated that a short variant of Tbc1d1 
exists as well as a longer form. These two splice variants translate in to proteins 
with estimated molecular weights of 132 kDa and 142-143 kDa. Alignments 
clearly indicate that the long variant of the Tbc1d1 gene codes for an additional 
segment (which corresponds to exon 11 and 12) within the center of the protein 
(Figure 1A, Appendix). Interestingly, Tbc1d4 also has two alternative splice 
variants. These correspond to proteins with estimated molecular weights of 139-
140 kDa and 146-147 kDa. The longer splice variant occurs because of the 
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Figure 3.8: Quantification of TBC1D1 and TBC1D4 protein within insulin-responsive tissues 
as determined by quantitative western blotting. Known amounts of recombinant FLAG-tagged 
TBC1D1 or FLAG-tagged TBC1D4 that had been expressed in HEK 293 cells were western 
blotted and probed with anti-TBC1D1 02A or anti-AS160 antibodies to generate calibration 
curves. Tibialis anterior (TA), gastrocnemius (GN), extensor digitorum longus (EDL) and 
Soleus muscles, Heart, Epididymal adipose (Epi Fat) and Brain tissue from mouse were 
excised and homogenised. Tissue protein lysates were western blotted and relative 
expression of TBC1D1 and TBC1D4 was quantified. (A) Data are expressed as the means ± 
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In order to understand more about the expression pattern of Tbc1d1 splice 
variants within skeletal muscle and other insulin-responsive tissues, we 
performed qualitative RT-PCR analysis. Exon-splicing primers which flank the 
predicted insertion exons 11 and 12 of the long variant of Tbc1d1 were 
designed (Table 2.6, 2.1.3.1) (Figure 3.9). To determine the tissue specific 
distribution of splice variants within skeletal muscles and other tissues, two 
different sets of primers (primers 1 and primers 2) were used to amplify Tbc1d1 
by PCR. The resulting PCR products were resolved using gel electrophoresis 
and visualised (Figure 3.10).  
 
Figure 3.9: Exon flanking Tbc1d1 PCR primers for qualitative reverse transcription (RT)-PCR 
experiments. Regions of the rat Tbc1d1 sequence containing the exon-splicing primer 
sequences. Two sets of primers were designed against the regions flanking exons 11-12 
(highlighted in green) Exon flanking primers 1 (F1-R1) and primers 2 (F2-R2); forward (F) and 
reverse (R) primer sequences are underlined with arrowhead for orientation. A PCR product 
containing an extra 286-bp would indicate the presence of exons 11-12 and therefore the 
expression of the longer splice variant.   
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Figure 3.10: Relative distribution of Tbc1d1 splice variants within a selection of rat tissues. 
Expression of Tbc1d1 splice variants within tibialis anterior (TA), soleus, flexor digitus brevis 
(FDB) muscles, Heart, Epididymal adipose, Brain Cortex, Testes, Colon and Liver, along with 
the relative distribution in differentiated L6 Myotubes.  RNA was isolated and reverse 
transcribed to cDNA. Tbc1d1 cDNA was amplified by PCR using exon-flanking PCR primers. 
Resulting products were resolved by agarose gel electrophoresis and imaged by SYBR safe 
staining. PCR fragment size was quantified against a 100bp ladder, (PRO).  
The skeletal muscles were selected based on differences in their muscle fibre-
type composition. Tibialis anterior (TA) muscle is a fast-twitch 
oxidative/glycolytic muscle that contains predominately type II fibres, soleus is a 
slow-twitch oxidative type I skeletal muscle and flexor digitus brevis (FDB) is a 
fast-twitch oxidative skeletal muscle and so contains predominately type IIA 
fibres. TA, soleus and FDB muscles and brain from rat expressed two defined 
PCR products, indicating the expression of both isoforms of Tbc1d1. Only one 
shorter PCR product was expressed in heart, epididymal adipose, testes and 
colon. A Tbc1d1 PCR product could not be detected within the liver. These data 
together with the quantitative real time PCR data confirms that Tbc1d1 is not 
expressed in the liver (Figure 3.7B, top panel). We also investigated the 
expression of the two splice variants in the L6 rat muscle cell line. One PCR 
was detected in differentiated L6 myotubes. This corresponded to the short 
splice variant of Tbc1d1.  
The two PCR fragments were calculated as 730 bp and 445 bp (Figure 3.10, 
primers 1, top panel). The difference calculated between these fragments is 285 
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bp, which is approximately 10 kDa. These PCR based data correspond with the 
size difference between the splice variants of Tbc1d1 from online sequencing 
databases (Figure 3.9A) and also to the difference between two distinct 
TBC1D1 protein bands detected within mouse TA muscle by western blotting 
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3.4 C2C12 skeletal muscle cells as a model for 
studying the function of TBC1D1 
The C2C12 mouse myoblast cell line, are a skeletal muscle cell model 
produced by Blau et al., 1985. They are a sub-clone of the myogenic cell line 
derived from adult dystrophic mouse muscle (Yaffe & Saxel, 1977). C2C12 cells 
can be differentiated for 6-8 days in culture by the addition of horse serum. 
Myoblasts fuse to form a heterogeneous population of multi-nucleated tubes 
with distinct morphology (Yoshida, et al., 1998). Light microscopy images of un-
differentiated C2C12 cells (Day 0) and differentiating cells at various time points 
are shown in Figure 3.11. After 48 hours of differentiation, many of the cells 
began to elongate. By Day 4, there are greater numbers of elongated cells as 
myoblasts fuse to become multi nucleated myotubes. After Day 4, C2C12 
myotubes became larger and more pronounced. However, not all of the cells 
within the population will differentiate to form myotubes. Some remain in a 
quiescent state and have been designated ‘reserve cells’ (Yoshida, et al., 
1998).  
3.4.1 Tbc1d1 and Tbc1d4 mRNA expression in C2C12 cells 
The relative Tbc1d1 and Tbc1d4 gene expression levels were analysed in 
C2C12 cells during differentiation using Taqman® real-time quantitative PCR. 
The expression of Myod was also analysed. Myod is a transcription factor that 
activates muscle-specific genes and regulates myogenic differentiation The 
Taqman® probes used are detailed in Table 2.8 (2.1.3.3). Gene expression 
levels were normalised against a calculated genomic mean of three reference 
genes, Hprt, Tbp, Gus β. The fold change in gene expression during C2C12 
differentiation was determined using the ∆∆Ct  method.  
As shown in Figure 3.12A, Tbc1d1 mRNA expression is up-regulated in C2C12 
cells during differentiation. Tbc1d1 mRNA levels were approximately three-fold 
higher in myotubes on day 7 than in myoblasts on day 0 (Figure 3.12A). The 
expression of TBC1D4 did not change (Figure 3.12B). The up-regulation of 
Tbc1d1 during myotube formation correlates with the increased expression of 
Myod (Figure 3.12C).  
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Figure 3.11: Morphology of C2C12 cells during differentiation. Light microscopy images were 
obtained using a 4x objective and were documented using digital camera (Motic). The images 
represent C2C12 cells at Day 0 and during differentiation at day 1, 2, 3, 4, 5, 6, 7 and 8.  
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Figure 3.12: Relative Tbc1d1, Tbc1d4 and Myod mRNA expression levels in C2C12 cells 
during differentiation as determined using real-time quantitative PCR. Expression levels were 
compared in C2C12 cells at day 0 and during differentiation at day 1, 2, 4, 5, 6 and 7. Total 
RNA was extracted using the RNA Easy Micro Kit (QIA) and reverse transcribed to cDNA. 
Tbc1d1, Tbc1d4 and MyoD cDNAs were amplified by two-step Taqman® real-time PCR 
using gene expression kits (purchased from Applied Biosystems). Relative expression was 
calculated based on the delta ∆∆Ct method.  The data was normalised to three reference 
genes by geometric averaging of three internal control genes, Hprt, Tbp and Gus B. The 
expression units are relative to C2C12 Day 0 reference sample. (A) Gene expression of 
Tbc1d1 (B) Gene expression of Tbc1d4 (C) Gene expression of Myod. Data are expressed 
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3.4.2 Quantification of TBC1D1 and TBC1D4 protein in C2C12 
cells during differentiation in C2C12 cells  
The protein expression levels of both TBC1D1 and TBC1D4 were estimated in 
C2C12 myoblasts and in myotubes during differentiation. Expression levels 
were calculated within protein lysates by extrapolating against the standard 
curves of purified rat FLAG-tagged TBC1D1 and FLAG-tagged TBC1D4 
recombinant proteins. Estimated protein levels were expressed in terms of 
femto-moles of protein per microgram of tissue lysate.  
Quantitative immuno-blot analysis of three independent experiments revealed 
that TBC1D1 protein levels were approximately three-fold greater in fully 
differentiated myotubes (Day 7) (28.7 ± 13.7) compared to myoblasts (Day 0) 
(7.7 ± 0.6). This appeared to correspond with the up-regulation of the longer 
splice variant of TBC1D1 of 160 kDa (Figure 3.13A). Conversely, TBC1D4 
protein levels were slightly down-regulated in C2C12 myotubes during 
differentiation. Quantitative western blotting allows us to directly compare the 
levels of different proteins expressed within the same sample. Our data 
revealed the level of TBC1D1 protein in myoblasts was higher than the level of 
TBC1D4 protein in either C2C12 myoblasts (3.6 ± 0.5 femto-moles) or 
myotubes (2.6 ± 0.2 femto-moles) (Figure 3.13).  
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Figure 3.13: Quantification of TBC1D1 and TBC1D4 protein in C2C12 cells during 
differentiation as determined using quantitative western-blotting. Known amounts of 
recombinant FLAG-tagged TBC1D1 or FLAG-tagged TBC1D4 that had been expressed in 
HEK 293 cells were western blotted and probed with anti-TBC1D1 02A or anti-AS160 
antibodies to generate calibration curves. C2C12 cells were differentiated and protein lysates 
were extracted at day 0 and during differentiation at day 1, 2, 4, 5 and 7. Protein lysates were 
western blotted and relative expression of TBC1D1 and TBC1D4 was quantified. Data are 
expressed as the means ± SE of n=3 experiments. (A) Expression of TBC1D1. (B) 
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3.4.3 Distribution of Tbc1d1 splice variants 
Further characterisation of the C2C12 cell line was performed to determine 
whether these cells can represent a useful model for studying the function of 
TBC1D1 in skeletal muscle. It was therefore necessary to determine by 
qualitative RT-PCR the relative expression of Tbc1d1 splice variants within 
C2C12 cells. Exon-splicing primers were used to amplify Tbc1d1 by PCR 
(Figure 3.9), the resulting products were separated by agarose gel 
electrophoresis and visualised. The relative levels of the splice variants were 
determined in C2C12 myoblasts (day 0) and during differentiation at days 1-2, 
4-7.  
 
Figure 3.14: Relative distribution of Tbc1d1 splice variants within C2C12 cells during 
differentiation as determined by using qualitative RT–PCR. Expression of Tbc1d1 splice 
variants in HL1 Heart cells and in C2C12 cells at day 0 and during differentiation at day 1, 2, 
4, 5, 6 and 7. RNA was isolated and reverse transcribed to cDNA. Tbc1d1 cDNA was 
amplified by PCR using exon-flanking PCR primers. Resulting products were resolved by 
agarose gel electrophoresis and imaged by SYBR safe staining. PCR fragment sizes were 
quantified against 100bp ladder (PRO), 
Differentiation of C2C12 myoblasts to myotubes led to the induction of the 
expression of the long splice variant form of Tbc1d1 (Figure 3.14). This form of 
Tbc1d1 was first expressed at day 4 of differentiation and coincides with a 
distinct morphological change which occurs within the cell culture at around day 
4 (Figure 3.14, Figure 3.11). On day 4 there appears to be a greater number of 
elongated and fused myoblasts. This seems to be associated with the initiation 
of a rapid differentiation process and distinct morphological changes leading to 
a myotube population at around day 7. The shorter transcript was highly 
expressed in C2C12 myoblasts and remains present in the myotubes. The 
increased abundance of Tbc1d1 mRNA determined by quantitative real-time 
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PCR could be due to the up regulation of the long splice variant. Differentiated 
C2C12 myotubes display a Tbc1d1 splice variant expression pattern similar to 
that of primary rat muscle. HL1 heart cells also express both splice variant 
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3.5 Discussion 
It is not fully understood whether TBC1D1 and TBC1D4 are both essential in 
muscle. In order to address this question we have investigated the tissue-
specific expression pattern of TBC1D1 and TBC1D4 within different tissues 
using quantitative real-time PCR and western blotting techniques. We have 
found that both Tbc1d1 and Tbc1d4 were highly expressed in skeletal muscle 
and heart. In addition, we have shown that TBC1D1 protein is more highly 
expressed than TBC1D4 in all types of skeletal muscle analysed (TA, EDL, GN 
and soleus muscles). Finally, we have reported that two distinct TBC1D1 
protein bands were detected in primary muscle and C2C12 mouse myotubes at 
approximately 160 kDa and 150 kDa. Interestingly, the longer variant of 
TBC1D1 is predominately expressed in muscle and this is up-regulated during 
C2C12 differentiation. In comparison to L6 muscle cells, C2C12 myotubes 
display a TBC1D1 splice variant expression pattern which is similar to that of 
primary muscle. Therefore, C2C12 myotubes may represent a useful muscle-
like model to further investigate GLUT4 trafficking in response to insulin 
stimulation and contraction-mediated signalling.  
TBC1D1 (tre-2/USP6, BUB2, cdc16 domain family member 1) and TBC1D4 
belong to the TBC Rab-GTPase (Rab-GAP) domain family of proteins. The two 
proteins are 47% identical and share similar protein domains. These include two 
N-Terminal phospho-tyrosine binding (PTB) domains and a Ca2+/calmodulin 
binding domain (CBD) situated adjacent to the C-terminal GAP domain. It is well 
established that TBC1D4 is phosphorylated in response to insulin stimulation 
and this is important for the regulation of GLUT4 translocation and glucose 
uptake (Sano, et al., 2003) (Zeigerer, et al., 2004) (Eguez, et al., 2005) (Ramm, 
et al., 2006) (Thong et al., 2007) (Ishikura, et al., 2007) (Ishikura & Klip, 2008). 
In addition, several studies have demonstrated that TBC1D1 and TBC1D4 are 
phosphorylated in response to insulin- and contraction-mediated stimuli in 
skeletal muscle (Kramer, et al., 2006) (Bruss, et al., 2005) (Funai & Cartee, 
2008) (Funai & Cartee, 2009). It has been recently proposed that TBC1D1 
could be primarily responsible for regulating contraction-mediated glucose 
uptake in muscle (Funai & Cartee, 2009) (An, et al., 2010) (Pehmoller, et al., 
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2009) (Vichaiwong, et al., 2010). However, whether TBC1D1 and TBC1D4 are 
both essential in muscle it is not yet fully understood. Furthermore, studies 
using TBC1D1 deficient mice (B6.SJL-Nob1.10) have demonstrated TBC1D1 is 
involved in the regulation of both glucose and fatty acid metabolism (Chadt, et 
al., 2008). In addition, TBC1D1 has been identified as a candidate gene for 
obesity predisposition (Stone, et al., 2006). Therefore, a key issue which 
remains to be addressed is the role and the importance of TBC1D1 and 
TBC1D4 in skeletal muscle function. 
To address this issue, we first examined the tissue-specific mRNA expression 
of Tbc1d1 and Tbc1d4 genes using quantitative real-time RT-PCR. We 
analysed tissue-specific gene expression profiles in human, mouse and rat 
systems (Figures 3.6 and 3.7). We have found that Tbc1d1 and Tbc1d4 were 
highly expressed in skeletal muscle and heart. This is in support of previous 
studies (Stone, et al., 2006) (Nagase, et al., 1998). However, we observed a 
broad rather than tissue-specific expression pattern of Tbc1d1. There was 
notable gene expression in uterus, colon and brown adipose tissue. In contrast, 
Tbc1d4 was primarily expressed in insulin-responsive tissues. However, the 
mRNA expression of Tbc1d4 was relatively low in adipose tissue (Figure 3.7A, 
B bottom panels).  
In this present study we observed that the individual gene expression profiles 
for Tbc1d1 and Tbc1d4 were similar in rat, mouse and human. This suggests 
that there may be evolutionary conservation of Tbc1d1 and Tbc1d4 expression 
in mammals. Phylogenetic data has indicated that Tbc1d4 emerged after 
Tbc1d1 in evolution during vertebrate development (Chen, et al., 2008). The 
expression of Tbc1d4 presumably reflects the acquisition of new genes to 
increase the complexity among vertebrate species.  
It has been reported that two protein coding splice variants of the Tbc1d1 and 
Tbc1d4 genes exist (Taylor, et al., 2008). Sequence alignments clearly indicate 
that the long variant codes for an additional segment within the center of the 
protein (Figure 3.9). The additional exons translate to an extra ~10 kDa in 
TBC1D1 and ~7 kDa in TBC1D4. 
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In this current study we have analysed the distribution of Tbc1d1 splice variants 
in several tissues and insulin-responsive cell lines using qualitative RT-PCR 
(Figure 3.10). Taylor et al., 2008 reported that both isoforms were expressed in 
skeletal muscle and white adipose tissue. We have shown here that the short 
splice variant of Tbc1d1 was expressed in the majority of tissues analysed. In 
addition, the long splice variant was strongly detected in skeletal muscle and 
brain. The long variant was expressed at low levels in white epididymal adipose 
tissue.  
In this present study we have shown that the relative expression of the long 
splice variant of TBC1D1 was increased in HL1 cardiac mouse cells cultured in 
high cell-density conditions compared to cells grown in low density cultures 
(Figure 3.4). Confluent HL1 cells maintain a differentiated cardiac phenotype in 
culture. The cells express the genes for cardiac alpha-myosin heavy chain (α-
MHC) and atrial natriuretic factor (ANF) which are expressed in adult heart 
(Claycomb, et al., 1998). Another important observation in this present study is 
that the differentiation of C2C12 myoblasts to myotubes led to the up-regulation 
of the long splice variant form of TBC1D1 (Figure 3.13A) (Figure 3.14). This 
finding is in support of those of Peck et al., 2009. Interestingly, the expression of 
the long isoform in C2C12 myotubes is concurrent with the development of 
sarcomere structure and contractile activity (Nedachi & Kanzaki, 2006). These 
findings support the hypothesis that the long splice variant may be important for 
the regulation of TBC1D1 function in muscle.  
Similarly to Tbc1d1, there is a long and short (AS160_V2) splice variant of 
Tbc1d4 (Baus, et al., 2008). The expression of both variants in human tissues 
has been analysed by quantitative RT-PCR (Baus, et al., 2008). Interestingly, 
the full-length transcript of Tbc1d4 is predominately expressed in human 
skeletal muscle and heart. By contrast, the short splice variant of the Tbc1d4 
gene (transcript variant 2 (AS160_v2)) is ubiquitously expressed in most human 
tissues (Baus, et al., 2008). Both TBC1D1 and TBC1D4 Rab-GAPs contain a 
Ca2+/calmodulin binding domain (CBD). There is growing evidence implicating 
Ca2+/calmodulin in the regulation of contraction-mediated glucose uptake into 
skeletal muscle (Kramer, et al., 2007) (Funai & Cartee, 2009) (Witczak, et al., 
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2010). The CBD is not affected by the lack of exons 11 and 12 in the short 
splice variant. However, it cannot be ruled out that this region may be required 
for Ca2+/calmodulin binding to the CBD. Furthermore, the splice region may also 
be important for the potentiation of contraction-mediated responses. The protein 
region corresponding to the splice region of Tbc1d1 contains two AMPK 
consensus motifs (serine 660 and serine 700). These have been shown to be 
phosphorylated in response to AICAR-treatment in skeletal muscle (Frosig, et 
al., 2010) (Taylor, et al., 2008). Therefore, it is likely that the long splice variants 
of TBC1D1 and TBC1D4 are the forms that may act as points of convergence 
between the insulin and contraction signalling pathways leading to GLUT4 
translocation and glucose uptake in skeletal muscle.  
The mRNA expression level of a gene is thought to provide a rough estimate 
about the relative abundance within a tissue. However, with no information 
about mRNA stability or mRNA translation efficiency, it is more reliable to 
determine protein expression.  
At the time this project commenced there were no commercial antibodies 
available against TBC1D1. Therefore, specific anti-serum against TBC1D1 and 
TBC1D1 phosphorylated at serine 237 were generated as part of the CASE 
studentship with Astra Zeneca (AGG Astra Zeneca, Macclesfield, UK) (Figure 
3.1). Subsequently, a number of research groups have reported on the 
generation and use of anti-TBC1D1 antibodies (Chen, et al., 2008) (Chadt, et 
al., 2008) (Chavez, et al., 2008) (Taylor, et al., 2008).  
In our preliminary antibody characterisation studies, we have shown that the 
antibody 02A (which has been raised against the rat peptide Asp-Ser-Pro-Ser-
Arg-Thr-Glu-Asp-Tyr-Ser-Glu corresponding with TBC1D1 amino acids 766-
776), specifically recognises endogenous TBC1D1 (Figure 3.3). We have 
shown that use of these antibodies led to the detection of a distinct protein band 
with the expected molecular weight of ~160 kDa in mouse skeletal muscle and 
heart (Figure 3.3, 3.4 and 3.8). A number of previous studies have reported that 
the long isoform of TBC1D1 in mouse and human skeletal muscle lysates 
migrates at an apparent molecular mass of 150~160 kDa (Taylor, et al., 2008) 
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(Pehmoller, et al., 2009)  (Frosig, et al., 2010) (Jessen, et al., 2011). We could 
not detect TBC1D1 in rat TA muscle lysates when immuno-blotted using 
TBC1D1 02A antibody (Figure 3.3). This was surprising because the polyclonal 
antibodies were raised against synthetic peptides of rat TBC1D1 protein. It is 
possible that the level of TBC1D1 protein is relatively low compared with the 
abundance of connective tissue and contractile proteins within muscle tissue. In 
support of this, we could detect TBC1D1 in isolated rat FDB muscle cells. 
Further work is required to establish this. Furthermore, we have reported that 
two distinct protein bands were detected in C2C12 mouse myotubes at 
approximately 160 kDa and 150 kDa (Figures 3.3 and 3.4A). In addition, we 
have shown that identical protein bands are detected in C2C12 myotubes 
lysates immuno-blotted with two other primary antibodies raised towards 
different epitopes in TBC1D1 (Figure 3.3 and data not shown). TBC1D1 H-AH is 
previously described in (Chadt, et al., 2008), TBC1D1 #4629 (Cell Signalling 
Technologies) is previously described in (Taylor, et al., 2008). The presence of 
the higher molecular weight band of 160 kDa detected in muscle corresponded 
with the expression of the long splice variant (Figure 3.3 and 3.4). 
The phosphorylation of TBC1D1 at serine 231 in C2C12 myotubes occurs in 
response to AMPK activation. Western blotting with phospho-specific TBC1D1 
antibody led to the detection of two distinct protein bands at approximately 150 
and 160 kDa. Therefore, it is reasonable to conclude that both bands 
correspond to the major isoforms of TBC1D1.  
In contrast to earlier findings by Taylor et al., 2008, we could not detect a 
distinct TBC1D1 protein band in white epididymal adipose tissue. A possible 
explanation could be that the polyclonal antibody TBC1D1 02A preferentially 
detects the long TBC1D1 isoform. In this current study we found that epididymal 
adipose tissue predominately expressed the short splice variant of the Tbc1d1 
gene (Figure 3.10). However, the antibody 02A recognition epitope corresponds 
to amino acids 764-774 of the mouse TBC1D1. This region is located close to 
the C-terminal region of the splice site (amino-acids 631-723 of TBC1D1). In 
addition, two isoforms are detected in C2C12 myotubes and HL1 cardiac 
muscle cells. Furthermore, a faint band corresponding to the shorter isoform of 
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TBC1D1 was detected in 3T3-L1 mouse adipocytes (Figure 3.4B). Another 
more plausible explanation is that the western blot technique is not sensitive 
enough to detect the level of TBC1D1 protein expressed in adipose tissue. RT-
PCR is a very sensitive technique in which low numbers of RNA transcripts can 
be detected. 
In this study we have used quantitative western blotting to estimate the amount 
of TBC1D1 and TBC1D4 in different types of mouse muscle. This is in contrast  
to several studies which have investigated the relationship between the 
expression levels of TBC1D1 and TBC1D4 with respect to muscle type using 
relative quantification techniques (Taylor, et al., 2008) (Szekeres, et al., 2012). 
Relative quantification is limited as it only allows the expression levels of 
TBC1D1 and TBC1D4 to be determined between the tissues separately. Using 
a quantitative approach in this study, we have shown here that within all types 
of skeletal muscle analysed (TA, EDL, GN and soleus muscles) the amount of 
TBC1D1 protein expressed (femto-moles of protein per microgram of tissue 
lysate) was significantly more than the level of TBC1D4 protein. In addition, the 
amount of TBC1D1 in TA and EDL muscles (which consist of >60% type IIB/IIX 
fast-twitch glycolytic muscle fibres (Bloemberg & Quadrilatero, 2012)) was 
slightly higher than that in GN muscle (mixed fibre-type) or in soleus muscle 
(which consists of ~80% type I/IIA oxidative muscle fibres (Bloemberg & 
Quadrilatero, 2012)).The results reported by Taylor et al., 2008, are in 
accordance with ours since they observed a higher expression of TBC1D1 in 
TA muscle compared with in the soleus muscle. In addition, we have found that 
the expression of TBC1D4 was significantly higher in the soleus muscle 
compared with the other muscle types. TBC1D4 protein expression was similar 
in the soleus muscle, heart, adipose tissue and brain. Furthermore, TBC1D4 
expression in the soleus, GN, EDL and TA is positively correlated with the 
skeletal muscle content of oxidative fibres (Type I and IIA). Henriksen et al., 
1990, reported that insulin-stimulated glucose transport was higher in the rat 
soleus muscle compared with the EDL muscle and this was correlated with the 
increased expression of GLUT4 protein in the soleus muscle (Henriksen, et al., 
1990). Therefore, the larger insulin-responsive pool of GLUT4 in the soleus 
muscle could to be associated with the increased level of TBC1D4. However, it 
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is important to note that in contrast to mouse soleus muscle, the rat soleus 
muscle has been shown to consist of predominately type I slow twitch fibres 
(Bloemberg & Quadrilatero, 2012). 
Finally, C2C12 myotubes display a TBC1D1 splice variant expression pattern 
which is similar to that of primary muscle. This is in contrast to what we have 
found for the L6 muscle cell model (Figure 3.4A and Figure 3.10). However, 
several studies have reported the expression the both the long and short splice 
variants of TBC1D1 in L6 myotubes (Chen, et al., 2008).  
It has been reported that C2C12 cells can be classified as ‘hybrid’ muscle cells. 
This is because they express both fast and slow MHC isoforms (Zebedin, et al., 
2004). In support a ‘hybrid’ phenotype, our data has revealed that C2C12 
myotubes express both TBC1D1 and TBC1D4 proteins. Interestingly, the 
amount of TBC1D1 and TBC1D4 proteins expressed (femto-moles of protein 
per microgram of cell lysate) demonstrated that cultured C2C12 myotubes do 
not represent either fast or slow twitch muscle types but are a hybrid type of 
muscle cell. Therefore, C2C12 myotubes could represent a unique model for 
investigation of the importance of TBC1D1 and TBC1D4 for the regulation of 
GLUT4 trafficking in response to insulin stimulation and contraction-mediated 
signalling in muscle in general.  
In conclusion, the development of TBC1D1 specific antibodies especially the 
phospho-specific antibody provide useful tools for investigating TBC1D1 leading 
to GLUT4 trafficking. In this study we have highlighted the importance for 
extensive antibody characterisation studies. By evaluating cross-species 
reactivity of the antibodies in both rat and mouse tissue lysates and analysing 
the validity of antibodies using knockout mice. Our data support that there are 
variations between the expression levels of TBC1D1 and TBC1D4 within 
different fibre-type muscles. Furthermore, that the longer variant of TBC1D1 is 
predominately expressed in muscle and that this is up-regulated during C2C12 
differentiation. However, to what reason and extent these differences affect 
insulin- and contraction-mediated glucose uptake in muscle is still unknown. 
Further work is required to determine the roles for TBC1D4 and TBC1D1 in 
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GLUT4 trafficking. Considering that most skeletal muscles are composed of a 
mixture of muscle fibres, it will be of importance for future studies to investigate 
GLUT4 trafficking with respect to muscle fibre-type. Furthermore, there may be 
slight differences in the fibre-type composition of the same muscle from different 
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4 Characterising GLUT4 trafficking in the C2C12 
muscle cell culture model 
4.1 Introduction 
Glucose transport into adipose and muscle cells is controlled through processes 
which regulate the rate at which GLUT4 is trafficked and inserted in to the 
plasma membrane and the rate GLUT4 is retrieved from the cell surface. In the 
absence of insulin stimulation, GLUT4 is rapidly removed from the cell surface 
and slowly recycled. Thus, the net effect is that the majority of GLUT4 
transporters are actively retained within intracellular compartments and absent 
from the plasma membrane pool.  
The intracellular trafficking route for GLUT4 can be simplified into discrete 
trafficking steps (Figure 1.3, 1.3.2.6). These are the biogenesis of GSV (this 
includes the release of GSV from sequestration mechanisms), the translocation 
of GSVs to the cell surface, tethering, docking, fusion events and GLUT4 
endocytosis (Larance, et al., 2008). However, the question is which of these 
steps of GLUT4 trafficking are the major sites of insulin action. Furthermore, the 
dysregulation of insulin-stimulated glucose uptake into peripheral tissues is a 
major feature of T2DM. However, exercise-mediated GLUT4 translocation and 
glucose disposal appears to be normal in insulin-resistant individuals. 
Therefore, it is of importance also to understand the effects of contraction-
mediated signalling on GLUT4 trafficking.  
The development of exofacial epitope-tagged GLUT4 fusion proteins have been 
important for studies of GLUT4 trafficking in both adipose and muscle cells. 
These GLUT4 reporter constructs contain a hemagglutinin (HA) or Myc tag in 
the first exofacial loop (which enables the rapid detection of GLUT4 which has 
been inserted into the plasma membrane) and can also have a C-Terminal GFP 
tag (HA/Myc-GLUT4-GFP). Using these reporter proteins the rate at which 
GLUT4 arrives at the cell surface can be measured as a function of time 
(transition kinetics). Secondly, several studies have used these reporter 
proteins to study the effect of insulin on GLUT4 exocytic pathways at steady-
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state (Martin, et al., 2006) (Karylowski, et al., 2004) (Govers, et al., 2004) 
(Fazakerely, et al., 2009). For these studies intact live cells are labelled with a 
saturating concentration of purified anti-HA antibody. The concentration of 
antibody used is sufficient to label all HA-GLUT4 that appears at the cell 
surface. Thus, anti-HA accumulation (uptake) over time is a function of the rate 
of GLUT4 exocytosis (kex). In addition, the size of the GLUT4 actively cycling 
pool can be determined. Therefore, the effect of insulin on the release of 
GLUT4 from an intracellular storage compartment can be resolved. 
Two different models of GLUT4 retention have been proposed. These models 
are illustrated in Figure 1.4 (1.3.2.6). The first model details that intracellular 
GLUT4 traffic is governed by a dynamic system (Figure 1.4B, 1.3.2.6). In this 
‘dynamic equilibrium retention’ model the actively cycling GLUT4 pool is 
regulated by a very slow cycling rate under basal conditions. Importantly, this 
model states that GSVs are in continual exchange with the endosomal 
compartment and so the entire insulin-responsive GLUT4 pool can eventually 
recycle with the plasma membrane in basal cells. Stimulation with insulin 
concurrently increases the rate of GLUT4 exocytosis (kex) and decreases 
GLUT4 endocytosis (ken), thus redistributing GLUT4 to the cell surface (Martin, 
et al., 2006) (Karylowski, et al., 2004).  
The second model is known as the ‘static retention model’ (Figure 1.4C, 
1.3.2.6). GLUT4 is stored within specialised non-cycling GSVs sequestered 
away from the ERC (Govers, et al., 2004) (Coster, et al., 2004) (Muretta, et al., 
2008) (Fujita, et al., 2010). Insulin stimulates the release of GLUT4 from a 
‘static retention mechanism to the plasma membrane and thus increasing the 
size of the GLUT4 cycling pool. Furthermore, insulin stimulation increases the 
exocytic rate (kex) of this pool at steady-state. No effect on ken was observed. 
The actual mechanism for how insulin regulates GLUT4 recycling is still 
disputed. However, it is likely that a combination of both ‘static retention’ and 
‘dynamic recycling’ mechanisms will contribute to the regulation of GLUT4 
trafficking (Muretta, et al., 2008) (Xu, et al., 2011).  
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There are only a few studies which address this question in muscle cells. 
Further support for the ‘dynamic recycling’ model comes from experimental 
studies carried out in L6 myoblasts stably expressing Myc-tagged GLUT4 
(Foster, et al., 2001). Additionally, partial GLUT4 static retention has been 
proposed for L6 skeletal muscle cells expressing HA-GLUT4 (Fazakerely, et al., 
2009).  
The aim of these investigations is to address whether immortal muscle cell lines 
can provide an alternative in vitro model system for accurately measuring the 
kinetics of GLUT4 trafficking. These muscle cell lines are advantageous to use 
as they can be readily sourced and cultured. and so have great potential for 
industry applications. For these studies we have chosen to utilise the C2C12 
skeletal muscle cell model. In comparison to L6 cells, C2C12 develop partially 
formed transverse (T) -tubules (which is an important site for glucose uptake in 
muscle) (Rudich & Klip, 2003). Furthermore, we have shown that C2C12 
myotubes display a TBC1D1 splice variant expression pattern which is similar to 
that of primary muscle. Therefore, C2C12 myotubes may represent a useful 
muscle-like model to further investigate GLUT4 trafficking in response to insulin 
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4.2 Establishing the model for studying GLUT4 
trafficking 
For these studies an immortal myoblast cell line was used. Myoblasts can be 
readily differentiated in culture and in contrast to primary muscle cells they can 
be efficiently infected and transfected. We have employed the C2C12 skeletal 
cell culture model to study GLUT4 trafficking. The main focus of this research 
was to understand the importance of TBC1D1 and TBC1D4 in muscle cells. As 
discussed above (3.4.3), and in contrast to L6 cells, C2C12 myotubes display a 
TBC1D1 splice variant expression pattern similar to that of primary muscle.  
Two major problems are faced when using C2C12 or L6 muscle cells. Firstly, 
the differentiated cell phenotype is highly dependent on the differentiation 
conditions and culture conditions used. It was necessary to standardise C2C12 
culture conditions for both growth and differentiation of the cells. This is 
documented in Table 2.12 (2.2.2.6). It was important to grow these cells in sub-
confluent cultures, in order to maintain a proliferative phenotype. Secondly, 
C2C12 cells express low levels of endogenous GLUT4 and therefore 
biotinylated photolabels (which have been developed to monitor GLUT4 
trafficking events) cannot be used with these cells. Instead, myoblasts are 
infected with a GLUT4 reporter construct containing a HA epitope tag inserted 
within the first exofacial loop of the protein. HA-GLUT4 can be stably expressed 
within C2C12 myoblasts using this retroviral expression system. Cell surface 
GLUT4 can then be detected by labelling with cell impermeant anti-HA 
antibodies. The methods developed for studies of GLUT4 trafficking using the 
C2C12 muscle cell model were based on previous experiments carried out 
within our group in L6 skeletal muscle cells (Fazakerely, et al., 2009). 
Experiments using epitope-tagged GLUT4 reporter proteins were adapted from 
initial studies developed to observe GLUT4 trafficking in 3T3-L1 adipocytes 
(Govers, et al., 2004) (Muretta, et al., 2008) (Martin, et al., 2006) (Karylowski, et 
al., 2004).   
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4.2.1 Retroviral expression of HA-GLUT4  
It has been reported that over expression of GLUT4 in adipose cells interferes 
with insulin-stimulated GLUT4 translocation to the plasma membrane (Al 
Hasani, et al., 1999). C2C12 cells express low levels endogenous GLUT4, so 
over-expression could over load the trafficking machinery. It was therefore 
important to consider whether the expression of HA-GLUT4 in C2C12 cells 
would affect GLUT4 trafficking.   
C2C12 myoblasts were infected with either increasing concentrations of 
pBABE-puro HA-GLUT4 retrovirus (HAG4 0.025-0.2 ml) or the corresponding 
pBABE-puro empty vector control virus (EV). A viral concentration-dependant 
increase in the expression of HA-GLUT4 was observed by western blotting of 
protein lysates with anti-GLUT4 and -HA antibodies (Figure 4.1A). Expression 
of GLUT4 reporter protein was substantially higher than the endogenous levels 
of GLUT4 within these cells. Endogenous GLUT4 could be faintly detected in 
EV cells by a longer western blot exposure.  
A sample of rat adipose cell, low-density microsomal (LDM) (containing a 
known amount of GLUT4) was used as a standard to quantify the expression of 
GLUT4 in C2C12 cells that were infected with increasing volumes of HA-GLUT4 
virus. The mean results are depicted in Figure 4.1B. Cells infected with 0.1 or 
0.2 ml of virus expressed significantly more GLUT4 compared with cells 
infected with 0.025 ml (Figure 4.1B). This over-expression resulted in an 
increased level of GLUT4 at the cell surface in basal cells and affected insulin-
stimulated GLUT4 translocation (Figure 4.1C).  
The lowest amount of retrovirus (0.025ml) was used to infect C2C12 cells for all 
subsequent experiments. The amount of GLUT4 expressed was calculated to 
be 6.6 ± 1.4 femto-moles per microgram of cell lysate (Figure 4.1B). The 
amount of GLUT4 expressed in non-infected myotubes was calculated to be 
0.017 ± 0.003 femto-moles per microgram (Figure 4.1D). Therefore, the level of 
over-expression was calculated to be approximately 400 times greater than the 
amount of GLUT4 expressed in non-infected differentiated C2C12 myotubes 
(Figure 4.1D).  
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Figure 4.1: Increasing HA-GLUT4 viral titre on cell and plasma membrane GLUT4 expression 
levels. (A) C2C12 myoblasts were infected with increasing volumes of HA-GLUT4 retro-virus 
(0.025 - 0.2 ml) or empty vector (EV) virus as a control. HA-GLUT4 expression levels were 
determined compared to EV cells by western blotting with anti-GLUT4, HA and β –Tubulin 
antibodies. Expression of GLUT4 was quantified by western blotting against a calibration 
curve generated using known amounts of rat adipocyte low density microsome (LDM) 
fraction.  (1μg of LDM is equivalent to 60 femto-moles of GLUT4) Protein load: 10 μg. (B) 
Quantification of HA-GLUT4 in C2C12 myoblasts was determined by densitometry analysis of 
five experiments. (C) C2C12 myotubes were maintained under basal conditions (dark grey 
bars) or stimulated with insulin at 200 nM for 5 min (light grey bars), The plasma membrane 
levels of GLUT4 were determined by incubating fixed cells with anti-HA primary antibodies 
and anti-mouse Alexa 488 secondary antibodies. The results are expressed as a percentage 
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of total HA-GLUT4 in permeabilised cells. (D) The expression of endogenous GLUT4 in 
C2C12 myoblasts and C2C12 myotubes. Repeated measures analysis of variance (ANOVA) 
test was used with Tukey multiple comparison test at p=0.05. * p≤0.05, ** p≤0.01, *** 
p≤0.005. 
4.2.2 Investigating the change in phosphorylation of TBC1D1 in 
response to AMPK activation of C2C12 cells 
Several studies have demonstrated that AMPK is a key mediator of contraction-
stimulated signalling responses that regulate glucose uptake in muscle (Mu, et 
al., 2001) (Wright, et al., 2005) (Jessen, et al., 2002) (Jensen, et al., 2008). 
Therefore, to investigate the regulation of GLUT4 trafficking with respect to 
AMPK-activation we have utilised the AMP-mimetic, 5-Aminoimidazole-4-
carboxamide 1-β-D-ribofuranoside (AICAR). AICAR is a cell-permeable 
adenosine analogue that can be phosphorylated to ZMP (an AMP analogue) in 
the target cell. In muscle, treatment with AICAR has been shown to activate 
AMPK-α2 which increases cell surface levels of GLUT4 transporters and 
enhances glucose transport (Koistinen, et al., 2003) (Hayashi, et al., 1998) 
(Sajan, et al., 2010). We also examined the response to direct AMPK activator, 
A-769662. A-769662 is a small-molecule thienopyridone which was identified by 
Abbott laboratories (Cool, et al., 2006). A-769662 has been reported to 
stimulate glucose uptake and GLUT4 translocation in L6 myotubes (Guigas, et 
al., 2009) (Fazakerely, et al., 2009). A-769662 lacks the off-target effects 
described for AICAR as it is not an AMP-analog (Viollet, et al., 2009). Further, 
use of this compound is discussed in  (Goransson, et al., 2007).  
Under serum starvation conditions, C2C12 myotubes were treated either with 
AICAR, or insulin-stimulated or stimulated with both in combination. C2C12 cell 
lysates were prepared and immuno-blotted with phospho-specific antibodies. 
Changes in the phosphorylation status of AMP-activated protein kinase 
(AMPK), its down-stream targets acetyl-CoA carboxylase (ACC) and TBC1D1 
and Akt all were assessed. The basal phosphorylation levels of signalling 
proteins varied between experiments, even though optimised serum-starvation 
conditions were followed. This affected the calculated fold-change above the 
basal phosphorylation and induced large un-avoidable error in this ratio. The 
expression of AMPK was also assessed using western blotting. In addition, the 
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specificity of antibodies towards Rab-GAPs TBC1D1 and TBC1D4 were also 
evaluated (Figure 4.2). 
We first determined the expression of TBC1D1 and TBC1D4 in C2C12 mouse 
myotubes. Western blotting with TBC1D1 02A antibody led to the detection of 
two distinct protein bands in C2C12 mouse myotubes at approximately 150 and 
160 kDa (Figure 4.2A) (Figure 3.3, 3.2.3; Figure 3.4A, 3.2.4). Furthermore, 
TBC1D4 was detected in C2C12 cells migrating at the expected molecular 
weight ~160 kDa. 
AICAR-treatment alone or in combination with insulin resulted in a marked 
increase in phosphorylation of AMPK at threonine 172 and the downstream 
kinase ACC at serine 79 (Figure 4.2A, C, D). AMPK activation resulted in an 
increase in the phosphorylation of TBC1D1 at serine 237 (Figure 4.2A, B). We 
compared the effect of a short-time exposure of AICAR for 5 min with a longer 
treatment for 45 min on the activation of AMPK in C2C12 cells. We did not 
observe a time-dependant increase in the relative phosphorylation of AMPK 
threonine 172, ACC serine 79 and TBC1D1 serine 237. As expected, AICAR-
treatment did not increase the phosphorylation of Akt at serine 473 (Figure 
4.2A, E).  
Interestingly, treatment with the direct AMPK activator A-769662 did not activate 
AMPK in C2C12 cells. There were no detectable increases in the 
phosphorylation of AMPK at threonine 172, ACC at serine 79 or TBC1D1 at 
serine 237 over basal phosphorylation levels (Figure 4.2A). As expected, 
treatment with A-769662 did not increase the phosphorylation of Akt at serine 
473. Recently, it has been reported that A-769662 exclusively activates β1-
subunit containing AMPK hetero-trimeric complexes (Scott, et al., 2008) 
(Treebak, et al., 2009). Therefore it is likely that C2C12 myotubes lack or 
express a very low proportion of β1-containing AMPK complexes. In support of 
this, it has been reported that mouse skeletal muscle expresses predominately 
α2β2γ3 hetero-trimeric complexes (O'Neill, et al., 2011). Furthermore, no β1-
containing complexes have been reported to be present in human skeletal 
muscle (Wojtaszewski, et al., 2005).  
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Insulin stimulation induced the phosphorylation of Akt at serine 473 in C2C12 
cells. Furthermore, C2C12 cells stimulated with insulin and AICAR in 
combination did not further enhance the phosphorylation status of either AMPK 












Figure 4.2: Characterisation of the signalling responses in C2C12 myotubes following insulin 
stimulation and/or treatment with AICAR. C2C12 myotubes were maintained under basal 
conditions or stimulated with insulin at 200 nM and/or treated with AICAR at 2 mM or A-
769662 at 100 μM for the indicated times. (A) Representative western-blot analysis. Insulin-
stimulated Akt activation was detected by blotting with anti-phospho-Akt (serine 473). AMPK-
activation was assessed by immuno-blotting with anti-phospho-AMPK (threonine 172), anti-
phospho-ACC (serine 79) and anti-phospho-TBC1D1 91p (serine 237). Cell lysates were 
immuno-blotted with anti-TBC1D1 02A, anti-AMPK and anti-AS160. Protein load: 30 μg. (B-
E) Quantification analysis of phosphorylated TBC1D1 at serine 237 p=3147, AMPK at 
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threonine 172 p=0.0361, ACC at serine 79 p=0.0798 and Akt at serine 473 p=0.0002 
respectively. Repeated measures analysis of variance (ANOVA) test was used with Tukey 
multiple comparison at p=0.05.  * p≤0.05, ** p≤0.01.  
 
 
4.2.3 Investigating the insulin-stimulated phosphorylation of Akt 
and TBC1D4 in C2C12 cells 
C2C12 cells were serum starved and incubated in the absence or presence of 
insulin (200 nM) for 2 to 60 min. Cell lysates were then prepared and immuno-
blotted with phospho-specific antibodies towards Akt and TBC1D4. The relative 
phosphorylation levels of Akt and TBC1D4 proteins were normalised to total 
Akt. The results were then expressed as a fold-change above basal 
phosphorylation levels.  
Insulin increased the phosphorylation of Akt at serine 473 and TBC1D4 at 
threonine 642. The pattern of insulin-induced phosphorylation of Akt and 
TBC1D4 were similar. Peak Akt phosphorylation was reached after 5 min (26.2 
± 5.6 fold) of insulin stimulation (Figure 4.3A, B). The phosphorylation of Akt 
was sustained throughout the 60 min time course. Insulin induced a rapid and 
transient phosphorylation of TBC1D4/AS160 at threonine 642 (2-15 min), 
although this did not reach statistical significance. The phosphorylation of 
TBC1D4 returned to near basal levels within 30 min of insulin stimulation 
(Figure 4.3A, C). 
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Figure 4.3: Activation of Akt and Rab-GAP TBC1D4 after insulin stimulation in C2C12 
myotubes. C2C12 myotubes were maintained under basal conditions (t=0) or stimulated with 
Insulin at 200 nM for 2, 3, 5, 10, 15, 30 and 60 min. (A) Representative western-blot showing 
the time course of Akt and TBC1D4 phosphorylation using anti-phospho-Akt (serine 473) and 
anti-phosho-AS160 (threonine 642) antibodies respectively. (B, C) Densitometry units were 
normalised to total Akt protein in the sample by immuno-blotting with an anti-Akt antibody. 
Results are expressed relative to the basal value. Results represent the mean ± SE of 3 
experiments. (B) Time course of serine 473 Akt phosphorylation. (C) Time course of 
threonine 642 TBC1D4 phosphorylation. Repeated measures analysis of variance (ANOVA) 
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4.3 HA-GLUT4 trafficking assays in C2C12 myotubes 
The methods developed for the studies of GLUT4 trafficking using the C2C12 
muscle cell model were based on previous experiments carried out within our 
group in L6 muscle cells (Fazakerely, et al., 2009). The assay which were 
implemented are based on those developed by Govers et al, for the studies of 
GLUT4 trafficking in 3T3-L1 adipocytes. The aim of these studies was to 
analyse the trafficking kinetics of HA-tagged GLUT4 in C2C12 cells in response 
to insulin or AMPK activation.  
C2C12 myoblasts were infected with either HA-GLUT4 (GLUT4 reporter 
construct containing a HA epitope tag) retrovirus (0.025 ml) or the 
corresponding empty vector (EV) control virus. Infected myoblasts were seeded 
in 96-Well plates and then differentiated for 6-8 days. C2C12 myoblasts fuse to 
form a heterogeneous population of multi-nucleated myotubes (Figure 3.11, 
3.4.1).  
In this study, AICAR was used to activate AMPK. Treatment of C2C12 cells with 
the direct AMPK-activator A-769662 did not induce AMPK activation (Figure 
4.2A). Or increase the cell surface levels of GLUT4 above basal levels (data not 
shown). 
4.3.1 Insulin stimulation and AMPK-activation increase cell 
surface GLUT4 levels; Transition experiments  
C2C12 myotubes were serum-starved and incubated with either insulin (200 
nM) or AICAR (2 mM) or stimulated with both in combination for 2 to 60 min. 
The time-dependant accumulation of GLUT4 (HA-GLUT4) at the plasma 
membrane was measured. HA-GLUT4 at the cell surface was determined by 
immuno-labelling with anti-HA antibodies. HA-GLUT4 at the cell surface was 
calculated as a percentage of total cellular GLUT4. Total cellular immuno-
reactive GLUT4 was measured in permeabalised cells. The results were 
normalised to cells infected with the pBABE-puro empty vector control virus. For 
each experiment a minimum of three intra-assay replicates for at each time 
point were analysed.   
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The transition from the basal to the stimulated steady-state data can be fitted to 
a single-exponential function:  
 ( )  (          ) (   )             
The accumulation of GLUT4 at the cells surface over time is denoted by L (t). 
Y0 is the initial amount of GLUT4 at the plasma membrane in non-stimulated 
(basal) cells. The amount of GLUT4 at the plasma membrane after long agonist 
treatment (steady-state level) is the plateau. The rate constant for the transition 
from Y0 to the plateau is k. The half time for the transition (t1/2) can be 
determined using t1/2 = ln2/k. The observed rate constant (k) for the transition is 
a function of the initial translocation of GLUT4 to the plasma membrane (kout) 
and the rate constant for GLUT4 endocytosis (ken) (Brewer et al., 2012).  
In non-stimulated C2C12 myotubes, approximately 15% of the total cellular 
GLUT4 was present at the cell surface. Treatment with AICAR (which activates 
AMPK) increased the plasma membrane levels of GLUT4 in a time-dependant 
manner. AICAR stimulated a 2- to 3-fold increase in the level of GLUT4 
transporters at the cell surface. Within 30 min a new steady-state was reached 
and this was maintained for at least a further 30 min (Figure 4.4A, B). AICAR 
stimulated the accumulation of HA-GLUT4 at the cells surface with a t1/2 of ~7 
min (k = 0.099 ± 0.035 min-1), fitting the transition data to a single exponential 
association (r2 value: 0.610) (Figure 4.4C). The transition from basal to AICAR-
stimulated steady-state was significantly slower than that measured from basal 
to insulin-stimulated steady-states (p=0.0068).  
Insulin stimulation resulted in a rapid and transient accumulation of GLUT4 at 
the plasma membrane. The maximum level of cell surface GLUT4 was reached 
after 5 min (2- to 3-fold increase) (Figure 4.4A-C). This returned to near basal 
levels within 60 min after insulin stimulation. As expected, the time-course could 
not be accurately fitted to a one-phase association curve (r2 value: 0.240). 
Therefore, just the data representing the transition from the basal steady-state 
to the maximum insulin‐stimulated state were used, fitting a one-phase 
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exponential curve (r2 value: 0.847) (Figure 4.4C). This transition occurred with a 
t1/2 of ~1.24 min (k=0.559 ± 0.110 min
-1) (Figure 4.4D).  
Finally, we investigated whether insulin and AICAR had an additive effect on 
GLUT4 translocation. In C2C12 myotubes, stimulation with insulin and AICAR in 
combination resulted in a 5-fold increase in cell surface GLUT4. The 
combination of insulin plus AICAR significantly increased the steady-state 
GLUT4 level compared with AICAR treatment alone. A new steady-state level 
was reached within 20 min and this remained for at least 60 min (Figure 4.4A, 
B). The transition from basal steady-state plasma membrane GLUT4 levels 
occurred with a t1/2
 of 4.7 min (k=0.148 ± 0.021 min-1), fitting a single 
exponential curve (r2 value: 0.899) (Figure 4.4C, D). The synergistic effect of 
insulin and AICAR to increase GLUT4 at the cell surface was not due to 
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Figure 4.4: The transition of HA-GLUT4 levels from the basal to the stimulated state in 
C2C12 myotubes. C2C12 myotubes were maintained under basal conditions (t=0) or 
stimulated with insulin at 200 nM (solid triangles), AICAR at 2 mM (open squares) or insulin 
plus AICAR (solid circles) for 2 to 60 min. (A) The plasma membrane levels of GLUT4 were 
determined by incubating fixed cells with anti-HA primary antibodies and anti-mouse Alexa 
488 secondary antibodies. The results are expressed as a percentage of total HA-GLUT4 in 
permeabilised cells. The results represent the mean + SE from 5-7 experiments. The data 
was fitted to a single-exponential function. (B) Cell surface levels of GLUT4 at t=0 (Y0) (dark 
grey bars) and at t=∞ (plateau) (light grey bars) were calculated from curve fitting. (C) Cell 
surface levels of GLUT4 were expressed as a fraction of long-time agonist stimulation. Curve 
fitting was performed through indicated data points. (D) Transition rate constant were 
determined for Insulin, AICAR and with Insulin plus AICAR in combination. Un-paired student 
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4.3.2 Measuring GLUT4 recycling in C2C12 myotubes; Anti-HA 
antibody uptake assays. 
When the transition phase from basal steady-state is over a new steady-state 
level of GLUT4 at the cell surface is reached, as discussed in 4.3.1. GLUT4 
levels at the plasma membrane remain unchanged when the system is in 
steady-state. As this is a dynamic system GLUT4 at the cell surface is 
continually exchanging with GLUT4 within intracellular compartments. The rates 
at which GLUT4 moves into and out of the plasma membrane are equal. 
Therefore, steady-state GLUT4 trafficking kinetics can be investigated in cells 
stimulated with agonists. Anti-HA antibody uptake assays were developed by 
Govers et al, to measure the rate of HA-GLUT4 exocytosis (kex) and the size of 
the GLUT4 cycling pool (T) in 3T3-L1 adipocytes (Govers, et al., 2004). These 
were further developed to study GLUT4 traffic in L6 myotubes (Fazakerely, et 
al., 2009). Both of these studies used a saturating concentration of anti-HA 
antibodies at 50 μg/ml in order to accurately determine the GLUT4 cycling pool. 
To validate that this is a saturating antibody concentration in our system, anti-
HA uptake assays were performed in non-stimulated C2C12 myotubes. Cells 
were labelled with increasing concentrations of anti-HA antibody (5-120 μg/ml) 
for 180 min. The labelling of HA-GLUT4 saturated at approximately 40 μg/ml of 
antibody. Therefore, all anti-HA antibody uptake assays were performed using a 
final anti-HA antibody concentration of 50 μg/ml. 
Anti-HA antibody uptake assays were based on the assumption that antibody 
binding is instantaneous. Thus, anti-HA accumulation (uptake) over time would 
be a function of the rate of the exchange of GLUT4 between intracellular 
compartments and the plasma membrane (kex).  
4.3.2.1 Analysis of anti-HA uptake curve fits 
For these studies, C2C12 myotubes were serum-starved and either insulin-
stimulated or treated with AICAR or treated with both in combination. In 
addition, some cells remained un-stimulated (basal). Subsequently, intact live 
cells were labelled with a saturating concentration of purified anti-HA antibody 
for 5 to 300 min in the continued presence of agonist. HA-GLUT4 labelled with 
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antibody over time was measured in permeabilised cells and calculated as a 
percentage of the total cellular immuno-reactive GLUT4 (Figure 4.5).  
Anti-HA antibody uptake data can be fitted to a one-phase non-linear regression 
(single-exponential equation): 
 ( )  (   )         
This model is based on the assumption that GLUT4 is trafficked to the plasma 
membrane from one intracellular compartment. This is an over-simplification as 
many GLUT4 compartments are likely to contribute to the overall GLUT4 
trafficking rates. However, we can use this model to estimate several steady-
state kinetic parameters.  
The accumulation of labelled GLUT4 over time is denoted by L (t). P is the initial 
plasma membrane level of GLUT4 at Y0. The total amount of the GLUT4 pool 
which is actively recycling with the plasma membrane is T. The rate constant for 
GLUT4 exocytosis at steady-state is kex. The half time (t1/2) can be determined 
using t1/2 = ln2/kex. 
The analysis of P values from the one-phase non-linear regression analysis of 
anti-HA uptake data revealed that approximately 10% of the total cellular 
GLUT4 was present at the cell surface in non-stimulated C2C12 myotubes 
(Figure 4.5C). This result was consistent with the result measured from the 
transition experiments (Figure 4.4A, B). However, in cells treated with insulin or 
AICAR the P fit parameter values inferred from these curve-fits were not 
significantly different to non-stimulated cells (Figure 4.5C). This is in contrast to 
the transition data analysis which revealed that stimulation with insulin or 
AICAR resulted in a ~2- to 3-fold increase in GLUT4 at the plasma membrane. 
In addition, a ~5 fold increase of cell surface levels of GLUT4 was observed in 
cells stimulated with insulin and AICAR in combination (Figure 4.4A, B). 
The standard error (SE) values for the P and kex fit parameters were >20% of 
the predicted values, indicating large variation within the data sets. In addition, 
the r2 of the fits were low which suggested that a single exponential function 
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may not be the most appropriate. However, the data could not be fitted to a two-
phase non-linear regression (multiple exponential treatments). Conversely, the 
SE values for the T fit parameter were less than 5 % of the predicted values. 
4.3.2.2 Insulin stimulation and AICAR-treatment increase the size of the 
GLUT4 cycling pool 
In non-stimulated (basal) C2C12 myotubes, 64% of the total cellular GLUT4 is 
actively recycling with the plasma membrane within 300 min (Figure 4.5A, B). 
This was increased with insulin stimulation and AICAR-treatment to 75% and 
78%, respectively. In C2C12 cells, stimulation with insulin and AICAR in 
combination further increased the amount of GLUT4 recycling with the cell 
surface to 85%. However, insulin and AICAR treated in combination did not 
significantly increase the amount of GLUT4 that is actively recycling compared 
with AICAR-treatment alone. In addition, the estimated values indicated that not 
all of the GLUT4 available actively recycles with the plasma membrane. There 
appears to be a residual ‘latent GLUT4 pool’ that remains within intracellular 
compartments, which is not mobilised in response to insulin stimulation or 
treatment with AICAR. 
In cells stimulated with insulin, the total amount of GLUT4 in the recycling 
system reached maximum levels within 150 min. Conversely, in non-stimulated 
cells or cells treated with AICAR alone, the maximum level of GLUT4 in the 
recycling system was reached within approximately 200 min.  
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Figure 4.5: Time courses of anti-HA antibody labelling of the actively recycling GLUT4 pool in 
live C2C12 myotubes. C2C12 myotubes expressing HA-GLUT4 were maintained in basal 
conditions (open inverted triangles) or either stimulated with insulin at 200 nM (solid triangles) 
or AICAR at 2 mM (open squares) or insulin plus AICAR in combination (solid circles) for 
indicated times to reach maximum GLUT4 cell surface levels, then incubated with 50 μg/ml of 
anti-HA antibody for 5-300 min at 37
o
C, in the continued presence of agonist. The cells were 
fixed, permeabilised and incubated with anti-mouse Alexa 488 secondary antibody. (A) 
Results are calculated as a percentage of the total cellular immuno-reactive HA-GLUT4. 
Results represent the mean + SE of four non-paired experiments. A one-phase non-linear 
regression curve was fitted to determine kinetic parameters. (B) The total amount of the 
GLUT4 pool which is actively recycling with the plasma membrane (T) (C) The initial plasma 
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4.3.2.3 Insulin stimulates GLUT4 exocytosis 
Anti-HA antibody data for each condition was expressed as a fraction of the 
maximum amount of GLUT4 labelled within 300 min in order to infer a more 
accurate estimation of the rate of GLUT4 exocytosis (kex) at steady-state 
(Figure 4.6A). The SE values for the kex parameter were <15% of the predicted 
value and the r2 for the curve-fits were improved to >0.90 in all cases.  
In basal C2C12 myotubes, we observed an exocytosis rate constant (kex) of 
0.016 ± 0.003 for GLUT4 (t1/2 of ~40 min) (Figure 4.6B). Insulin stimulates a 
relatively small increase in the kex for GLUT4 to 0.023 ± 0.003 (t1/2 of ~30 min). 
In contrast, AICAR slightly decreased kex for GLUT4 to 0.013 ± 0.002 (t1/2 of ~50 
min). Interestingly, the exocytosis rate constant (kex) for GLUT4 was 2-fold 
higher in cells treated with insulin and AICAR in combination (kex 0.031 + 0.005, 
t1/2 ~20 min) compared with basal cells (Figure 4.6A).  
 
Figure 4.6: Kinetic parameters of anti-HA antibody labelling surface GLUT4 in C2C12 
myotubes. C2C12 myotubes expressing HA-GLUT4 were maintained in basal conditions 
(open inverted triangles) or either stimulated with insulin at 200 nM (solid triangles), AICAR at 
2 mM (open squares) or insulin plus AICAR in combination (solid circles) for indicated times 
to reach maximum surface GLUT4 levels, then incubated with anti-HA antibody (final 
concentration of 50 μg/ml) for 5-300 min at 37
o
C in the continued presence of agonist. The 
cells were fixed, permeabilised and incubated with anti-mouse Alexa 488 secondary 
antibody. (A) Results are calculated as a percentage of the total cellular immuno-reactive HA-
GLUT4. Results represent the mean + SE from four experiments. A one-phase non-linear 
regression curve was fitted to determine kinetic parameters. (B) The exocytosis rate constant 
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4.3.2.4 AMPK-activation inhibits GLUT4 endocytosis 
In the current study the effect of agonist treatment on the rate of GLUT4 
endocytosis at steady-state was not directly measured. However, as the system 
is in steady-state, the rate at which GLUT4 appears at and is retrieved from the 
plasma membrane is balanced. Therefore, the rate constant for GLUT4 
endocytosis (ken) can be estimated using parameters derived from the uptake 
data. 
    
    (   )
 
                              
    
 
 
Where (T-P) is the proportion of cycling GLUT4 pool in intracellular 
compartments and P is the proportion of GLUT4 at the plasma membrane and 
kex is the rate constant for exocytosis at steady-state (Coster, et al., 2004). This 
can be simplified and written where P which equals the partitioning co-efficient.   
P=(P/(P-T)) 
Using this model we found that insulin stimulation alone increased the endocytic 
rate constant (ken) for GLUT4 (ken ~0.112 min
-1 for basal to ~0.150 min-1 for 
insulin-stimulated cells). In contrast, AICAR-treatment alone led to a reduction 
in ken to ~0.047 min
-1. However, the ken for GLUT4 was only slightly reduced in 
cells treated with insulin and AICAR in combination compared to basal cells 
(~0.106 min-1).  
The SE values for the P fit parameter derived from the anti-HA uptake data 
indicated that there were large variations within the data sets at early time 
points. Furthermore, the most striking observation was the amount of GLUT4 at 
the cell surface (P) in cells treated with either insulin or AICAR derived from the 
curve fits, were not significantly different to basal cells. Therefore, we are 
underestimating the proportion of GLUT4 at the plasma membrane and 
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4.3.2.5 The labelling efficiency of anti-HA antibody  
When anti-HA antibody uptake data was expressed as a percentage of total 
cellular immuno-reactive GLUT4, large variability was observed between the 
repeated data-sets, this was particularly evident within the early time points 
(Figure 4.5A, C). The accuracy and reliability of kinetic parameter estimations 
depends on the curve-fits to the data especially within the early time points, 
which is further discussed in 4.3.2.1. 
All uptake assays were carried out using a final concentration of anti-HA 
antibody at 50 μg/ml. This was determined experimentally as a saturating 
antibody concentration required to label the entire GLUT4 cycling pool within 
180 min.  
Anti-HA antibody uptake assays are based on the assumption that antibody 
binding is instantaneous. Thus, the concentration of antibody is sufficient to 
label all of the GLUT4 at the plasma membrane. We therefore wanted to test 
this to determine whether the entire plasma membrane pool can be labelled at 
shorter incubation times with a final concentration of anti-HA antibody at 50 
μg/ml. 
C2C12 myotubes were serum starved and then either maintained under basal 
conditions or insulin-stimulated. Subsequently, intact live cells were labelled 
with increasing concentrations of purified anti-HA antibody (36-120 μg/ml) for 5 
and 180 min in the continued presence of agonist. The results are represented 
as a percentage of the GLUT4 labelled with maximum antibody concentration 
tested.  
Our data confirmed that the minimum concentration of purified anti-HA antibody 
required to saturate the labelling of surface GLUT4 was between 36-50 μg/ml 
during 180 min of labelling (Figure 4.7). This was observed for cells maintained 
in basal conditions or cells stimulated with insulin. However, incubating cells for 
just 5 min with saturating concentration of antibody, only labelled a fraction of 
the GLUT4 present at the cell surface. Antibody concentrations below 120 μg/ml 
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(maximum tested), labelled significantly lower levels of GLUT4. Similar antibody 
dose response values were observed in basal and insulin-stimulated cells.  
 
 
Figure 4.7: Labelling efficiency of cell surface HA-GLUT4 at short incubation time points is 
dependent on anti-HA antibody concentration. C2C12 myotubes were maintained in basal 
conditions (A) or stimulated with Insulin at 200 nM for 5 min (B).  Cells were incubated with 
increasing concentrations of anti-HA antibodies (36-120 μg/ml) for 5 (dark grey bars) or 180 
min (light grey bars) at 37
o
C. Cells were then fixed, permeabilised and incubated with anti-
mouse Alexa 488 secondary antibody. Results are calculated as a percentage of the total 
HA-GLUT4 available and expressed as a percentage of the 120 μg/ml values. Results 
represent the mean ± SE from 3-4 experiments. Repeated measures analysis of variance 
(ANOVA) test was used with Tukey multiple comparison at p=0.05. * p≤0.05, ** p≤0.01. 
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4.4 Discussion  
There have been many technical challenges which have impeded the detailed 
kinetic analysis of endogenous GLUT4 trafficking in primary skeletal muscle. 
Therefore, the C2C12 cell culture model provides an alternative in vitro model 
system. These cells can be readily sourced and easily manipulated and so have 
great potential for industry applications. In this chapter we have optimised a 96-
Well plate assay to investigate GLUT4 trafficking in C2C12 myotubes. We 
provide evidence for the use of C2C12 myotubes as a model system to 
measure the kinetics of GLUT4 trafficking in response to insulin and 
contraction-mediated signalling. Our findings support current concepts that 
insulin stimulates the rapid release of GLUT4 to the plasma membrane. 
Interestingly, the effect of insulin alone to increase cell surface GLUT4 levels 
was transient. In addition, treatment with the AMPK-activator, AICAR stimulates 
the slow accumulation of GLUT4 at the cell surface through the inhibition of 
GLUT4 endocytosis. Of importance, we have shown that the combination of 
AICAR and insulin treatments was synergistic to increase GLUT4 at the plasma 
membrane and the combined treatment significantly increases the rate of 
GLUT4 exocytosis (kex) at steady state. These findings support the presence of 
more than one distinct intracellular GLUT4 pool and provides evidence that 
multiple and complex mechanisms exist to enhance glucose disposal in muscle 
cells.  
In the basal to agonist transition experiments, the exponential rise of cell 
surface GLUT4 can be measured over time. In C2C12 myotubes, insulin 
stimulation resulted in a rapid and transient 2- to 3–fold accumulation of GLUT4 
at the plasma membrane (k ~0.559, t1/2 ~1.2 min) (Figure 4.4). Subsequently, 
cell surface GLUT4 levels rapidly declined and returned to near steady-state 
basal levels within 15 to 30 min after insulin stimulation. Similarly, insulin has 
been found to stimulate a rapid 2- to 3-fold increase in GLUT4 at the cell 
surface in L6 myotubes expressing HA-GLUT4 (t1/2 ~1.2 min) (Fazakerely, et 
al., 2009). Furthermore, comparable transition response kinetics, have been 
observed in L6 myotubes stably expressing Myc-tagged GLUT4 (t1/2 ~2.5 min) 
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(Somwar, et al., 2001). However in contrast to C2C12 cells, within 10 min a new 
steady-state level of cell surface GLUT4 is reached.  
A similar insulin-stimulated ‘overshoot’ of cell surface GLUT4 expression has 
been reported in several studies in both 3T3-L1 fibroblasts (Govers, et al., 
2004) (Bogan, et al., 2001) and 3T3-L1 adipocytes (Zeigerer, et al., 2002) 
(Bogan, et al., 2001) (Huang, et al., 2005). However, in 3T3-L1 cells an insulin-
dependent biphasic response is observed. Generally, studies in 3T3-L1 cells 
report that insulin stimulates a pronounced 5- to 12-fold increase in GLUT4 at 
the plasma membrane. After the initial transient peak in cell surface GLUT4 
over basal levels, cell surface levels reduce (approximately 30-40%) and a new 
insulin-stimulated steady-state level is reached. It has been proposed that this 
‘transient overshoot’ corresponds with the mobilisation of GLUT4 from highly 
insulin-responsive vesicles which are rapidly depleted upon insulin addition 
(Bogan, et al., 2001). The initial GLUT4 exocytosis rate during the transition is 
greater than the rate of GLUT4 exocytosis at steady-state. GLUT4 exocytosis at 
steady-state is rate-limited at steps during its trafficking through endosomal 
recycling compartments. This mechanism of action is similar to one that has 
been proposed to describe first-phase insulin secretion from pancreatic β-cells. 
This results from the rapid fusion of insulin granules present in a readily 
releasable pool (RRP) that are pre-docked at the cell surface (Wang & 
Thurmond, 2009). Recently, TIRF-imaging of HA-GLUT4-GFP has been used to 
characterise the dynamics of GLUT4 trafficking in live muscle fibres from 
transgenic mice. Interestingly, it was discovered that the majority of GLUT4 
exocytic events at the plasma membrane in response to insulin stimulation in 
muscle were from the fusion of pre-tethered GLUT4 vesicles rather than the 
recruitment and tethering of GLUT4 vesicles from intracellular cell depots 
(Lizunov, et al., 2012). Therefore, from our present results it seems reasonable 
to conclude that C2C12 myotubes appear to possess a small insulin-responsive 
GLUT4 compartment. In support of this, the insulin-regulated amino peptidase 
(IRAP) is up-regulated during differentiation of C2C12 myotubes. IRAP is a 
major constituent of GLUT4 storage vesicles (Malide, et al., 1997) (Kandror, et 
al., 1995). The insulin-stimulated transient accumulation of GLUT4 at the cell 
surface in C2C12 myotubes could be the result of the rapid exocytosis of a pool 
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of fusion-ready GLUT4 vesicles. However, C2C12 cells lack other mechanisms 
which regulate the robust insulin-stimulated increase in cell surface GLUT4 
levels as demonstrated in 3T3-L1 cells. Additionally, C2C12 cells appear to lack 
efficient pathways which control the steady-state level of cell surface GLUT4 
present in other insulin-responsive cells.  
Our present findings are in contrast to an earlier study which reported that 
GLUT4 is not targeted to an insulin-sensitive compartment in C2C12 myotubes 
(Tortorella & Pilch, 2002). For this study the investigators treated C2C12 cells 
with dexamethasone to induce GLUT4 gene expression. Sub-fractionation 
based experiments were used to determine GLUT4 translocation from a low-
density microsomal fraction (LDM) to a plasma membrane fraction upon insulin 
stimulation. However, only a single time-point measurement for insulin (15 min) 
was analysed. Based on our data, insulin stimulation for 15 min would be too 
long and the initial peak in insulin-stimulated cell surface GLUT4 would have 
been overlooked. 
Several studies have reported that insulin stimulation results in only a small 
increase in glucose uptake in C2C12 cells (1.2- to 1.5-fold) (Kumar & Dey, 
2002) (Niu, et al., 2010) (Tortorella & Pilch, 2002). The lack of insulin-stimulated 
glucose uptake could be due to a deficiency of endogenous GLUT4 expression 
or the transient presence of GLUT4 at the cell surface. It has been reported that 
there is a time delay between the presence of GLUT4 at the cell surface and 2-
deoxyglucose uptake in L6 muscle cells (Somwar, et al., 2001). The transient 
(2- to 3-fold) increase in cell surface GLUT4 would be too rapid and as a 
consequence a similar increase in glucose transport would not be measured. 
Conversely, a possible explanation could be that the presence of GLUT4 at the 
cell surface is masked by the action of other glucose transporters. For example, 
GLUT1 and GLUT3 are expressed at different stages of muscle cell 
differentiation (Yamamoto, et al., 2008).  
Using anti-HA antibody uptake assays, the GLUT4 steady-state recycling 
kinetics can be measured. By using this experimental method two separate 
effects on GLUT4 exocytosis (the size of the actively recycling GLUT4 pool and 
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the intrinsic rate of cycling (kex)) can be determined (Brewer, et al., 2011). We 
found that ~85% of the insulin-stimulated steady-state pool (64% of the total 
GLUT4 pool) is actively recycling with the plasma membrane in non-stimulated 
C2C12 myotubes (Figure 4.5). This result is in agreement with previous data 
described in L6 myotubes expressing HA-GLUT4 (Fazakerely, et al., 2009). 
Together these findings suggest that differentiated muscles cells possess a 
small GLUT4 pool ~15% of the insulin-stimulated GLUT4 pool (~21% of the 
total pool) that is statically retained/sequestered away from the general 
endosomal recycling pathway (ERC) in the absence of insulin.  
The concept of GLUT4 ‘static retention’ was first reported in studies using 
confluent quiescent 3T3-L1 adipocytes (Govers, et al., 2004) (Coster, et al., 
2004) (Muretta, et al., 2008). However, in 3T3-L1 cells only ~15-25% of the 
insulin-stimulated GLUT4 recycling pool (~10-15% of the total GLUT4 pool) is 
actively engaged in recycling with the plasma membrane in adipocytes under 
basal conditions. The majority of GLUT4 is sequestered within specialised ‘non-
cycling/slow cycling’ GLUT4 storage vesicles (GSVs). This retention mechanism 
in part is responsible for maintaining the low cell surface GLUT4 levels in the 
absence of insulin. Conversely, McGraw and colleagues have shown that 
GLUT4 retention is exclusively regulated by a ‘dynamic-recycling’ mechanism in 
3T3-L1 adipocytes (Martin, et al., 2006) (Karylowski, et al., 2004). These 
studies have observed that over-time the total ‘insulin-responsive’ GLUT4 pool 
can access the plasma membrane in the absence of insulin. The GLUT4 
storage compartment is continually recycling with the general ERC, albeit very 
slowly. However, Muretta et al., discovered that the lifting and re-plating of 
confluent differentiated 3T3-L1 adipocytes (as performed in Martin et al, for 
microscopy based studies) has been shown to increase the size of the basal 
GLUT4 recycling pool (Muretta, et al., 2008). The exact mechanism for this 
dramatic effect on GLUT4 recycling is yet to be determined. However, it is 
possible that re-plating of 3T3-L1 cells affects adipogenic differentiation. In 
support of this, Govers et al. observed that the ‘static retention’ mechanism is 
acquired during adipocyte differentiation. Furthermore, direct analysis of GLUT4 
dynamics using quantum dot technology has revealed that the majority of 
GLUT4 (64%) is present within a stationary GLUT4 compartment in 
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differentiated 3T3-L1 basal cells and this is absent in fibroblasts (Fujita, et al., 
2010). Although, this study revealed that ‘replating’ 3T3-L1 adipocytes did not 
affect GLUT4 stationary behaviour. Further support for the ‘dynamic recycling’ 
model comes from experimental studies carried out in L6 myoblasts stably 
expressing Myc-tagged GLUT4 (Foster, et al., 2001). These findings suggest 
that un-differentiated myoblasts may not possess a ‘statically retained’ GLUT4 
compartment that has been proposed here for differentiated muscle cells.  
Fundamental differences between adipose and muscle may explain the 
substantial; GLUT4 ‘static retention’ in 3T3-L1 adipocytes compared with in 
muscle cell lines. However, it is more likely that L6 and C2C12 myotubes do not 
recapitulate the complex mechanisms which regulate GLUT4 trafficking as L6 
and C2C12 muscle cells do not fully differentiate. Compared to mature muscle 
fibres, skeletal muscle cell lines do not develop mature sub-cellular 
compartments or establish full contractile activity. Mature transverse (T) -
tubules (an important site for glucose uptake in muscle) are only partially 
formed in differentiated C2C12 cells and are deficient in L6 myotubes (Rudich & 
Klip, 2003). Furthermore, both L6 and C2C12 skeletal muscle cell lines express 
low endogenous levels of GLUT4 and exhibit reduced insulin-responsive 
glucose uptake compared to primary muscle (1.5- to 2-fold in muscle cells 
compared with 3- to 9-fold in primary muscle) (Kramer, et al., 2006) (Karlsson, 
et al., 2009).  
In this study we have highlighted an important technical issue associated with 
the anti-HA antibody uptake assay as a model for studying GLUT4 recycling. 
The model assumes that antibody binding is instantaneous. Therefore, anti-HA 
accumulation (uptake) over time would be a function of GLUT4 exocytosis (kex). 
However, this can only true if antibody accumulation is not dependent on 
antibody concentration. We report here that an antibody concentration of 50 
μg/μl (which is a saturating antibody concentration required to label the entire 
GLUT4 cycling pool within 180 min) is insufficient to label the entire GLUT4 pool 
at the plasma membrane in 5 min. Therefore, it appears that antibody 
accumulation is a function of both antibody binding and the rate for GLUT4 
exocytosis (kex). As a consequence, it is important to note that this model may 
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not accurately determine the true exocytosis rate constant for GLUT4 at steady-
state. However, we did not directly measure whether the rate of antibody 
accumulation was dependant on antibody concentration. Furthermore, the 
accuracy of the curve-fits to the data especially within the early time points is 
required for the correct estimation of P (the initial plasma membrane level of 
GLUT4 at Y0). The correct value for P is necessary for calculating the 
partitioning coefficient (P). This is a ratio between GLUT4 at the cell surface and 
GLUT4 within intracellular pools at steady-state. Therefore, a correct 
partitioning coefficient (P) is required for the accurate estimation of the rate for 
GLUT4 endocytosis (ken).  
In C2C12 cells, we have found that in addition to increasing the size of the 
GLUT4 recycling pool (64% to 75%), insulin-stimulated a slight increase in the 
steady-state exocytic rate constant (kex) ~1.5-fold, from 0.016 to 0.023 min
-1 
(half-time ~30 min) (Figure 4.6). However, the effect of insulin on steady-state 
GLUT4 recycling kinetics was unable to sustain plasma membrane GLUT4 
levels. In 3T3-L1 adipocytes expressing HA-GLUT4, insulin has been shown to 
stimulate a similar modest increase in kex for GLUT4 from 0.014min
-1 to 0.03 
min-1 (Govers, et al., 2004) (Coster, et al., 2004). This is further supported by 
Mastick and colleagues who have observed a similar effect of insulin on the rate 
of anti-HA antibody uptake (kobs) (0.012 min
-1 basal to 0.036 min-1 insulin-
stimulated) (Muretta, et al., 2008). However, in these studies insulin was found 
to regulate the release of a large pool of GLUT4 from a ‘static’ storage 
compartment in to the general recycling pathway, thus, substantially increasing 
cell surface GLUT4 levels. It has been proposed that the release of GLUT4 from 
a retention compartment is the major rate-limiting step for GSV translocation in 
3T3-L1 adipocytes (Brewer, et al., 2011) (Xu, et al., 2011). Therefore, the lack 
of a substantial GLUT4 storage compartment may account for the inadequate 
transition from basal to insulin-stimulated steady-states in C2C12 myotubes. 
Conversely, in other studies insulin elicits a greater fold increase in the intrinsic 
steady-state GLUT4 exocytic rate (kex). In 3T3-L1 adipocytes, Mcgraw and 
colleagues have shown that insulin markedly increases kex for GLUT4 ~7-13 
fold from 0.006-0.007 min-1 to 0.05-0.08 min-1. Furthermore, insulin significantly 
inhibited ken (Karylowski, et al., 2004) (Martin, et al., 2006). In this ‘dynamic 
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retention’ model, insulin solely regulates the rate of GLUT4 movement between 
the intracellular compartments and the plasma membrane. The action of insulin 
to stimulate GLUT4 exocytic pathways is consistent with earlier studies in both 
primary muscle and adipose cells. In rat muscle, insulin stimulation has been 
shown to markedly increase GLUT4 exocytosis rate (kex 0.01 to 0.067 min
-1) 
(Karlsson, et al., 2009). Similarly, insulin stimulates an increase in kex (0.01 to 
0.086 min-1) in primary adipocytes (Jhun, et al., 1992). However, in these 
systems the effect of insulin on the release of GLUT4 from storage 
compartment to increase the total amount of GLUT4 which is able to recycle 
with the cell surface could not be measured.  
In this study the observed rate constant that is calculated from the single 
exponential fitting of anti-HA antibody uptake data is assumed to be a measure 
of kex. This is interpreted based on a ‘two pool’ model (Holman, et al., 1994) 
(Figure 1.4, 1.3.2.6). This model assumes that GLUT4 is trafficked between an 
intracellular compartment and the plasma membrane as one kinetic pool. 
However, it is likely that multiple pools contribute to the overall GLUT4 
trafficking kinetics. For instance the rapid transition kinetics in response to 
insulin stimulation and the slower recycling kinetics at steady-state can only be 
explained based on a multiple-pool model (Muretta, et al., 2008). Furthermore, 
the current intracellular retention models propose that there at least two 
intracellular pools of GLUT4 (Figure 1.4, 1.3.2.6). In support of this, it has been 
recently observed that after acute insulin stimulation (3-6 min), GLUT4 is 
predominately carried on smaller vesicles (50 nm) (GSVs) which translocate to 
the cell surface in 3T3-L1 adipocytes. Insulin stimulates the release of 
specialised GSVs which are sequestered in basal cells. In addition, insulin 
promotes the exocytosis of a pool of fusion-competent vesicles at the cell 
surface. However, during continued insulin stimulation typically larger GLUT4 
vesicles (150 nm) translocate to the plasma membrane. These vesicles are 
identical to those which transport TfR (Xu, et al., 2011). Therefore, it has been 
proposed that insulin also functions to switch GLUT4 traffic between two distinct 
circuits. This model for insulin-stimulated GLUT4 translocation has been named 
the dual brake-accelerator model and is depicted in Figure 4.8 (Xu, et al., 2011).  
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Figure 4.8: The dual brake-accelerator model for insulin-stimulated GLUT4 translocation. This 
schematic has been adapted from (Xu, et al., 2011). Insulin mediates the release of GLUT4 
from an intracellular retention pool (brake) and stimulates the exocytosis of a fusion-ready 
pool of GSVs at the cell surface (acceleration). During continual insulin stimulation GLUT4 is 
trafficked to the plasma membrane on larger vesicles which bypass the GSV compartment. 
Insulin regulates the switching of GLUT4 traffic between two cycles.  
The dual brake-accelerator model unites the static retention and dynamic 
recycling models which describe basal intracellular GLUT4 retention. Our 
experimental data support the presence of a small insulin-responsive GSV 
compartment in C2C12 myotubes. Therefore are consistent with an accelerator 
mode of insulin action. However, our results revealed that C2C12 cells lack a 
substantial GSV retention compartment. The release of an intracellular brake is 
essential for a robust insulin-stimulated response in 3T3-L1 adipocytes. 
Interestingly, the removal of this brake through the knockdown of TUG (a 
protein which is required for GSV intracellular retention) resulted in only a 
transient 2-fold pulse of GLUT4 exocytosis in 3T3-L1 adipocytes in response to 
insulin stimulation (Xu, et al., 2011). These results were remarkably similar to 
what we have reported here in C2C12 myotubes. 
In the current study the effect of insulin stimulation on the rate of GLUT4 
endocytosis (ken) was not determined experimentally. However, we cannot rule 
out this as a site of insulin action. Several reports in 3T3-L1 adipocytes (Martin, 
et al., 2006) (Yang & Holman, 1993) and rat adipocytes (Jhun, et al., 1992) 
4 Results 
 
~ 160 ~ 
 
have reported that insulin reduces the rate constant for GLUT4 endocytosis 
(ken). In L6 myotubes it has been reported that the predominant effect of insulin 
was on the inhibition of GLUT4 endocytosis (ken ~0.4 min
-1 to 0.2 min-1) as 
opposed to stimulating GLUT4 exocytosis (kex ~0.06 min
-1 to 0.07 min-1) 
(Fazakerely, et al., 2009). Although, in contrast to other kinetic studies in this L6 
cell system the rate for GLUT4 recycling was very fast under basal conditions. 
Conversely, studies in 3T3 L1 adipocytes (Govers, et al., 2004). L6 myoblasts 
(Foster, et al., 2001) and rat cardiomyocytes (Yang & Holman, 2005) have 
observed that insulin has little effect on the rate of GLUT4 internalisation.  
It is well established that exercise is important and beneficial for overall fitness, 
body weight and for the management of T2DM, in part through the activation of 
metabolic processes which increase glucose uptake into skeletal muscle 
(Defronzo, et al., 1981). Importantly, exercise-mediated GLUT4 translocation 
appears normal in people with type II diabetes despite impaired insulin 
responses (Zierath, et al., 1997). Therefore, it is of importance to investigate the 
effect of contraction-mediated stimuli in the regulation of GLUT4 trafficking in 
muscle. Although the AMP-mimetic (AICAR) activates AMPK, it is important to 
note that AICAR does not recapitulate the full extent of contraction-induced 
responses. AICAR-mediated glucose uptake is impaired in skeletal muscle from 
AMPK-α2 knockout (AMPK-α2 KO) although contraction-stimulated glucose 
uptake is not affected (Jorgensen, et al., 2004). However, AICAR is a useful tool 
to study the role of AMPK-signalling in regulating GLUT4 trafficking. 
Furthermore, numerous studies have reported additive effects of both AMPK-
activators and insulin on glucose uptake and/or GLUT4 translocation in to 
muscle (Hayashi, et al., 1998) (Yang & Holman, 2005) (Yang & Holman, 2006) 
(Bergeron, et al., 1999).   
In this present study, we find that AICAR stimulates a maximal 2- to 3-fold 
increase in the level of GLUT4 transporters at the cell surface in C2C12 cells 
(basal to AICAR steady-state transition rate k ~0.099 min-1, t1/2 ~7 min) (Figure 
4.4). The magnitude of the effect of AICAR treatment on cell surface GLUT4 
levels is comparable with data previously reported for C2C12 myotubes (Niu, et 
al., 2010), L6 myotubes (Fazakerely, et al., 2009) (Sajan, et al., 2010) and in 
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isolated primary skeletal muscle (Koistinen, et al., 2003). Furthermore, the 
accumulation of cell surface GLUT4 is slow and reaches maximum levels 30 
min after AICAR-treatment. This is in contrast to when cells are stimulated with 
insulin (insulin stimulates a rapid and transient increase in GLUT4 at the cell 
surface). The increase in AMPK-phosphorylation in response to AICAR 
treatment is comparable at 5 and 45 min. Therefore, the slow response is not 
due to a slow onset of AMPK activation. We find that the exocytic rate constant 
for GLUT4 does not increase above basal levels following treatment with AICAR 
(kex ~0.016 min
-1 for basal versus ~0.013 min-1 for AICAR) (Figure 4.6). These 
values are surprisingly similar to those reported for the exocytosis of GP15-
labelled GLUT4 in rat skeletal muscle (Karlsson, et al., 2009). Treatment with 
AICAR increases the size of the GLUT4 cycling pool compared to basal cells 
(64% to 78%) (Figure 4.5). This data suggests that AMPK-activation may 
regulate the mobilisation of an intracellular GLUT4 pool. We cannot therefore, 
exclude the possibility that AICAR stimulates exocytosis directly. However, this 
may be just a transient pulse release of GLUT4 that occurs shortly after 
treatment with AICAR. It is unlikely that these responses alone are sufficient to 
account for the sustained increase of cell surface GLUT4 levels observed. In 
cardiomyocytes, AMPK-activation following metformin treatment (Yang & 
Holman, 2006), hypoxia or the inhibition of mitochondrial H+-ATP synthase 
using oligomycin (Yang & Holman, 2005) led to the inhibition of endocytosis. 
Furthermore, exposing L6 myotubes to 2, 4 dinitrophenol (DNP) which 
simultaneously activates both AMPK and PKC reduces GLUT4 internalisation. 
Additionally, AICAR or direct AMPK activator A-769662 treatment alone, have 
been shown to reduce endocytosis in L6 myotubes (Fazakerely, et al., 2009). 
Here, we find treatment with AICAR reduced the rate constant for GLUT4 
endocytosis (ken ~0.112 min
-1 basal versus ~0.043 min-1 AICAR). However, a 
degree of caution must be applied as this parameter was estimated from the 
uptake data and has not been determined experimentally. Alternatively, the rate 
for GLUT4 endocytosis can be directly measured using internalisation assay 
Interestingly, we find that insulin and AICAR when added simultaneously result 
in a 4- to 5-fold increase of cell surface GLUT4 levels over basal levels (basal to 
Insulin + AICAR steady-state transition rate k ~0.148 min-1, t1/2 ~4.7 min) 
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(Figure 4.4). This data revealed that the combined effect of insulin stimulation 
and AMPK-activation was synergistic to increase GLUT4 cell surface levels. 
This finding supports that at least two distinct mechanisms may regulate GLUT4 
accumulation at the cell surface. In support of this, we report that treatment with 
insulin and AICAR resulted in a partially additive effect on the size of the 
actively recycling GLUT4 pool compared to basal cells (64% to 85%) (Figure 
4.5). These findings support the existence of distinct pools of GLUT4 in muscle 
(Douen, et al., 1990) (Fazakerely, et al., 2009). Furthermore, the results support 
the concept that insulin stimulation and contraction-mediated signalling promote 
the release of GLUT4 into the actively recycling pool through distinct signalling 
mechanisms. Intriguingly, we observed that 15% of the total GLUT4 pool is not 
mobilised in response to combined treatment with insulin and AICAR, similar to 
what has been reported in L6 myotubes (Fazakerely, et al., 2009). In support of 
this, a comparable sized non-cycling pool has been observed in 3T3 
adipocytes. Here, it has been speculated that this small ‘latent GLUT4 pool’ 
represents GLUT4 transporters that are synthesised early which are not 
mobilised in response to insulin stimulation (Coster, et al., 2004) (Govers, et al., 
2004).  
In addition, we have found that co-stimulation with insulin and AICAR increase 
the steady-state rate constant for exocytosis (kex) ~2-fold, from 0.016 to 0.031 
min-1 (half-time ~20 min) (Figure 4.6). This effect is more pronounced compared 
with the measured rate constant for insulin-stimulated GLUT4 exocytosis (kex). 
Thus, it is conceivable that the activation of both AMPK and Akt signalling 
pathways simultaneous may converge on a single signalling intermediate to 
enhance GLUT4 exocytosis. Furthermore, the concurrent slowing of GLUT4 
internalisation in response to AMPK-activation is likely to contribute to the 
sustained cell surface levels of GLUT4. However in this current study the effect 
of insulin and AICAR treatment in combination on the rate of GLUT4 
endocytosis could not be accurately determined. Together, these findings 
suggest that multiple and complex mechanisms may exist in muscle cells in 
response to different agonist treatment to regulate GLUT4 trafficking. 
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In conclusion, we have optimised a 96-Well plate assay for the study of GLUT4 
trafficking in C2C12 myotubes. In these studies our data revealed that insulin-
stimulation and treatment with the AMPK-activator (AICAR) increased the levels 
of GLUT4 at the plasma membrane by two-fold. Insulin-stimulation and 
activation of AMPK mobilised GLUT4 from a non-cycling compartment in to the 
actively cycling pool. Furthermore, insulin increased GLUT4 exocytosis (kex) of 
this cycling pool. By contrast activation of AMPK inhibited GLUT4 internalisation 
(ken). The combined effect of insulin-stimulation and AMPK-activation was 
synergistic and led to increased GLUT4 cell surface levels above those 
obtained with either treatment alone. Furthermore, Insulin-stimulation and 
AMPK activation in combination resulted in a partially additive effect on the size 
of the actively recycling GLUT4 pool and further enhanced kex of this cycling 
pool. These results provide evidence to further enhance our understanding of 
how GLUT4 trafficking is regulated in response to insulin and AMPK-activation.  
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5 Role of TBC1D1 and TBC1D4 in the regulation 
of GLUT4 trafficking in muscle cells 
5.1 Introduction 
TBC1D1 and TBC1D4 are related Rab-GTPase activating proteins (Rab-GAP). 
The two proteins are 47% identical and share similar protein domains including 
a TBC domain at the C-Terminus along with two N-Terminal phosphotyrosine 
binding (PTB) domains (Roach, et al., 2007). TBC1D4 is highly expressed in 
insulin-responsive tissues which include adipose tissue, brain and heart and in 
oxidative soleus muscle. In contrast, TBC1D1 is primarily expressed in skeletal 
muscle (Taylor, et al., 2008) (Szekeres, et al., 2012) (Figure 3.8, 3.3.2). They 
exhibit similar catalytic activity towards the rab proteins 2A, 8, 10 and 14 
(Roach, et al., 2007). TBC1D4 has been found to regulate rab proteins involved 
in the mobilisation of GLUT4 to the plasma membrane (Miinea, et al., 2005) 
(Sano, et al., 2007) (Ishikura, et al., 2007). They are proposed to function as 
negative regulators of GLUT4 trafficking through maintaining an un-specified 
rab proteins in its in-active GDP-bound state.  
TBC1D4 and TBC1D1 contain multiple Akt phosphorylation motifs. Two Akt 
phosphorylation motifs in mouse TBC1D1 threonine 590 (596) and serine 501 
(507) are conserved phosphorylation sites on TBC1D4 threonine 642 (649) and 
serine 570 (577) (Peck, et al., 2009) (Taylor, et al., 2008) (rat sequences are 
displayed in brackets). The phosphorylation of TBC1D4 in response to insulin 
stimulation is important for the regulation of GLUT4 translocation and glucose 
uptake (Sano, et al., 2003) (Zeigerer, et al., 2004) (Roach, et al., 2007) (Eguez, 
et al., 2005) (Ramm, et al., 2006) (Thong et al., 2007) (Ishikura, et al., 2007) 
(Ishikura & Klip, 2008). TBC1D4 phosphorylation leads to the in-activation of its 
GAP activity and therefore allows the rab to switch to an activate GTP bound 
state.  
Several studies have demonstrated that TBC1D4 and TBC1D1 are 
phosphorylated in response to insulin and contraction stimulation in skeletal 
muscle (Kramer, et al., 2006) (Bruss, et al., 2005) (Funai & Cartee, 2008) 
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(Funai & Cartee, 2009) (Vichaiwong, et al., 2010) (Pehmoller, et al., 2009). 
Therefore they may be important downstream intermediates regulating glucose 
transport in response to both insulin and contraction signalling. The over-
expression of TBC1D4 4P (TBC1D4 mutated to alanine at four phosphorylation 
sites serine 318, serine 588, threonine 642 and serine 751, therefore removing 
its capacity to undergo phosphorylation) in TA muscle inhibited insulin- and 
contraction-stimulated glucose uptake (Kramer, et al., 2006). The inhibition was 
reversed when GAP activity was simultaneous disrupted with the R/K mutation. 
Although, the over expression of wild-type TBC1D4 also reduced contraction-
mediated glucose uptake. TA muscle expresses a very low level of endogenous 
TBC1D4 protein and so the over-expression may result in some aberrant 
effects.   
Multiple AMPK phosphorylation sites have been identified in TBC1D1. These 
are serine 231, serine 660, serine 700 and threonine 499 (Peck, et al., 2009) 
(Taylor, et al., 2008) (Chen, et al., 2008) (Roach, et al., 2007). The identification 
of TBC1D1 as an AMPK substrate supports a role for TBC1D1 as a 
downstream signalling intermediate of contraction. Moreover, AMPK-dependent 
signaling mechanisms are essential for contraction-mediated glucose transport 
and phosphorylation of TBC1D1 in type II glycolytic skeletal muscles (EDL and 
EPI) (Funai & Cartee, 2009) (Pehmoller, et al., 2009). In contrast, one predicted 
AMPK site has been identified in TBC1D4 at serine 711 and this site is 
phosphorylated in response to AICAR and contraction in mouse muscle. 
However, mutation of this site to alanine does not affect glucose uptake.  
The over expression of TBC1D1 4P (mutation to alanine at four Akt/AMPK 
phosphorylation sites serine 231, serine 499, threonine 590, serine 621) in TA 
muscle decreased contraction and not insulin-stimulated glucose transport (An, 
et al., 2010). Therefore, it has been proposed that TBC1D1 could be primarily 
responsible for regulating contraction-mediated glucose uptake in muscle 
(Funai & Cartee, 2009) (An, et al., 2010) (Vichaiwong, et al., 2010) (Pehmoller, 
et al., 2009). However, the over expression of a TBC1D1 R125W mutant protein 
has been found to impair insulin-induced glucose transport in TA muscle (An, et 
al., 2010). This mutation tryptophan at arginine 125 in TBC1D1 has been 
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identified as a candidate causing severe familial obesity predisposition in 
humans (Stone, et al., 2006) (Meyre, et al., 2008). Therefore, it has been 
suggested that the presence of TBC1D1 R125W could affect insulin-responsive 
glucose disposal in skeletal muscle and thus consequently lead to the 
associated manifestation of obesity. The exact mechanism for how this mutation 
affects TBC1D1 function is unknown. Furthermore, precisely how TBC1D1 is 
involved in insulin-regulated GLUT4 trafficking is still to be determined.  
The objective of these studies was to investigate the importance of TBC1D1 
and TBC1D4 for the regulation of GLUT4 trafficking in response to insulin and 
AMPK-activation in muscle. To investigate this, we have performed siRNA-
mediated knockdown of Tbc1d1 and Tbc1d4 in C2C12 myotubes expressing 
HA-GLUT4. Using these cell models we were able to directly monitor the 
transition kinetics for HA-GLUT4 translocation. Furthermore, in the previous 
chapter of this thesis, our data support the existence for distinct pools of GLUT4 
in muscle cells. We have observed that insulin and AICAR regulate the release 
of GLUT4 in to the actively recycling pool. Therefore, utilising these knockdown 
cell models we can examine the effect of silencing TBC1D1 and TBC1D4 on the 
GLUT4 recycling pool.  
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5.2 siRNA-mediated knockdown of Tbc1d1 and Tbc1d4 
in C2C12 myotubes 
5.2.1 Characterisation  
C2C12 myoblasts were seeded in 96-well plates and differentiation was induced 
the following day. Two days post differentiation; the cells were transfected with 
Tbc1d1-specific, Tbc1d4-specific or non-targeting control siRNA 
oligonucleotides (Dharmacon ‘SMARTpool’ or individual oligonucleotides as 
indicated in Table 2.7, 2.1.3.2). Six days after transfection, the transfection 
efficiency was directly assessed using western blotting techniques to measure 
the protein expression level of TBC1D1 and TBC1D4 within a population of 
transfected cells. As illustrated in Figure 5.1, lipid-based transfection of C2C12 
cells with Tbc1d1-specific siRNA resulted in a ~75% knockdown of TBC1D1 
protein compared with non-targeting control siRNA treated cells. In addition, 
TBC1D4 protein was reduced ~50% in cells transfected with Tbc1d4-specific 
siRNA. Importantly, Tbc1d1-specific siRNA did not reduce the protein 
expression of closely related Rab-GAP TBC1D4 or vice versa. These results 
demonstrate that endogenous TBC1D1 and TBC1D4 can be knocked down in 
differentiated C2C12 myotubes using siRNA. Of note, the efficiency of TBC1D1 
knockdown was reduced (~50%) when cells were transfected with Tbc1d1-
specific siRNA and Tbc1d4-specific siRNA simultaneously compared to the 
single targeting of TBC1D1 alone. In contrast, the level of TBC1D4 protein 
knockdown was the same or slightly improved in TBC1D4/TBC1D1 double 
knockdown cells compared with TBC1D4 single knockdown cells.  
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Figure 5.1: Efficiency of knockdown by siRNA Tbc1d1 (single oligo) and Tbc1d4 
(SMARTpool). HA-GLUT4 expressing C2C12 cells were transfected with 100 nM siRNA 
specific for Tbc1d1 or 50 nM Tbc1d4 siRNA or non-targeting siRNA (control) on day 2. Cells 
were cultured for a further 6 days. TBC1D1 and TBC1D4 protein expression was analysed by 
western blotting with anti-TBC1D1 02A and anti-TBC1D4. β tubulin was used as a control. 
Protein load: 30μg. (A) Representative western-blot (B) TBC1D1 and TBC1D4 protein levels 
were quantified in TBC1D1 depleted cells (dark grey bars) compared to control cells (open 
bars); results represent the mean ± SE from 6 experiments. (C) Representative western blot 
(D) TBC1D1 and TBC1D4 protein levels were quantified in TBC1D4 depleted cells (dark grey 
bars) and TBC1D4/TBC1D1 double knockdown cells (light grey bars) compared to control 
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The differentiated C2C12 myotube phenotype is highly dependent on the 
culture conditions for both growth and differentiation of the cells, as outlined 
previously (4.2). Therefore, it was important to assess transfection toxicity. Cell 
viability and morphology was assessed in transfected cultures compared to 
non-transfected control cells. Furthermore, it was essential to investigate 
whether the specific knockdown of TBC1D1 or TBC1D4 in C2C12 myotubes 
would affect myotube differentiation. siRNA transfected and non-transfected 
control cells were cultured in 96-well plates. Light microscopy images were 
taken at various time points during differentiation to myotubes. Several wells for 
each cell type were tracked throughout differentiation. Representative images 
are depicted in Figure 5.2. We found that lipid-transfection in C2C12 cells on 
day 2 of differentiation did not affect the ability of cells to differentiate. In all 
cases, cells had formed distinct multi-nucleated myotubes by day 6. However, 
on day 4, transfected wells did appear to contain a greater number of rounded 
cells. This indicated a level of transfection toxicity. In addition, transfected 
myotubes appeared to be more defined, slightly longer and developed a 
‘stringy’ appearance compared to non-transfected control cells. Furthermore, 
we find that the specific knockdown of TBC1D1 or TBC1D4 in C2C12 myotubes 
did not appear to affect cell morphology compared to cells transfected with non-
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Figure 5.2: Morphology of TBC1D1-depleted, TBC1D4-depleted and control C2C12 cells 
during differentiation. C2C12 myotubes were lipid-transfected with Tbc1d1-specific or 
Tbc1d4-specific or non-targeting control siRNA. Cells were cultured for a further 3 days. Light 
microscopy images were obtained using a 4x objective and were documented using a digital 
camera (Motic). The images represent C2C12 cell morphology at day 0 and during 
differentiation at day 2, 3, 4 and 6. Several wells of a 96-well plate were tracked throughout 
myotube differentiation for each condition. Representative images from one well are depicted.  
5.2.2 siRNA-mediated knockdown of Tbc1d1 increases cell 
surface GLUT4 levels in non-stimulated C2C12 myotubes but does 
not affect insulin-induced GLUT4 translocation 
In this study we examined the effect of knockdown of TBC1D1 on the relative 
amount of GLUT4 at the cell surface in C2C12 myotubes. C2C12 myotubes 
were serum starved and incubated with either insulin (200 nM) or AICAR (2 
mM) for 2 to 60 min. We investigated the time-dependant accumulation of 
GLUT4 (HA epitope-tagged GLUT4) at the plasma membrane. HA-GLUT4 at 
the cell surface was determined by immuno-labelling with anti-HA antibodies. 
HA-GLUT4 at the cell surface was calculated as a percentage of total cellular 
immuno-reactive GLUT4. To note, TBC1D1 knockdown did not affect the level 
of expression of the HA-tagged GLUT4.  
The results were normalised to cells infected with the pBABE-puro empty vector 
control virus. For each experiment three intra-assay replicates for at each time 
point and condition were analysed. Knockdown of TBC1D1 protein expression 
was determined for each experiment using western blot analysis of C2C12 
myotubes cell lysates. We observed a consistent ~75% knockdown of TBC1D1 
protein in a population of cells transfected with Tbc1d1-specific siRNA 
compared with cells transfected with non-targeting control siRNA (Figure 5.1A, 
B). Importantly, knockdown of TBC1D1 in C2C12 myotubes did not affect 
TBC1D4 protein levels. 
The basal cell surface level of HA-GLUT4 was increased in TBC1D1 
knockdown cells compared with control siRNA treated cells (Figure 5.3A-C) 
(Figure 5.4A-C). The cell surface GLUT4 levels in basal TBC1D1 knockdown 
cells were between 30-60% higher compared with basal control cells.  
The depletion of TBC1D1 had little effect on the maximum level of GLUT4 
transporters at the cell surface in the presence of AICAR (~32.5 ± 2.1, siRNA 
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Tbc1d1 versus ~34.4 ± 7.8, Control) (Figure 5.3A, B). Therefore, there was a 
reduction in the net gain of cell surface HA-GLUT4 above basal levels in 
TBC1D1 knockdown cells compared with control cells. The knockdown of 
TBC1D1 was only partially AICAR-mimetic. Treatment with AICAR promoted 
the time-dependant elevation in cell surface GLUT4 levels in both knockdown 
and control cells. By fitting the transition data to a single-exponential function, 
the observed rate constant and t1/2 for the transition from the basal to the 
AICAR steady-state was determined. The r2 goodness-of-fit measure indicated 
that a single-exponential curve does not fit well the data obtained in TBC1D1 
knockdown cells (r2 values: control, 0.933; siRNA Tbc1d1, 0.679). The basal to 
AICAR transition appreared to be slower in the TBC1D1 knockdown cells (k 
~0.031 ± 0.022 min-1, t1/2 ~22 min) than in the control cells (k ~0.055 ± 0.010 
min-1, t1/2 ~13 min) although the were not significantly different p = 0.3769.  
(Figure 5.3C, D). 
We next investigated whether TBC1D1 was involved in the regulation of insulin-
stimulated GLUT4 translocation in C2C12 myotubes. In insulin-stimulated 
TBC1D1 knockdown cells the level of cell surface HA-GLUT4 reached a slightly 
higher level compared with insulin-stimulated control cells. Therefore, the net 
gains in cell surface HA-GLUT4 above basal levels were unaffected by TBC1D1 
knockdown in C2C12 myotubes. Insulin promoted a rapid and transient 2-fold 
accumulation of GLUT4 at the cell surface in TBC1D1 knockdown cell similar to 
control cells (Figure 5.4A). The observed transition rate constant (k) from basal 
steady-state to maximal insulin-stimulated level in TBC1D1 knockdown cells 
was not significantly different compared with control cells (k = 0.537 ± 0.342 
min-1, t1/2 ~1.29 min, siRNA Tbc1d1 versus  k ~0.379 ± 0.276 min
-1, t1/2 ~1.82 
min, Control) (Figure 5.4C, D). However, there was substantial variation in the 
level of HA-GLUT4 at the surface over time. This is reflected in the low r2 values 
for both curves (r2 values: control, 0.569; siRNA Tbc1d1, 0.494). In both cell 
types, GLUT4 at the cell surface rapidly declined and returned to their 
respective basal levels within 60 min after insulin stimulation. Accordingly, cell 
surface GLUT4 levels were significantly elevated in TBC1D1 knockdown cells 
compared to control cells, 60 min after insulin addition (Figure 5.4B).  
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The magnitude of the knockdown effect (evaluated using the plate-based assay 
result) could not be correlated with the level of protein knockdown. Both results 
represent an average from a population of cells. Furthermore, we did not 
directly determine the number of transfection positive cells within a population. 
Therefore, we could not directly normalise results for each condition to the level 







~ 174 ~ 
 
 
Figure 5.3: Knockdown of TBC1D1 increases cell surface levels of GLUT4 in basal C2C12 
myotubes. C2C12 cells were transfected with 100nM siRNA specific for Tbc1d1 (siRNA 
Tbc1d1) or non-targeting control siRNA (control) 2 days after the initiation of differentiation. 
Cells were cultured for a further 6 days. C2C12 myotubes were maintained under basal 
conditions (t=0) or stimulated with AICAR at 2 mM for 2 to 60 min. (A) The cell surface levels 
of HA-GLUT4 in control (open squares) and TBC1D1 knockdown cells (solid squares) was 
determined by incubating fixed cells with anti-HA primary antibodies and anti–mouse Alexa 
488 secondary antibody. The results are expressed as a percentage of total immuno-reactive 
HA-GLUT4 within in permeablised cells. Results represent the mean + SE from 3 
experiments. An unpaired t-test was performed at p=0.05. * p≤0.05 (B) The cell surface levels 
of GLUT4 at t=0 (Y0) and at t=∞ (plateau) were calculated from the data sets. (C) The cell 
surface levels of GLUT4 were expressed as a fraction of maximum AICAR (long-time) 
stimulation. A single-exponential function was fitted to determine the observed rate constant 
(kobs) for the transition.  Two-way analysis of variance (ANOVA) test was used with Bonferroni 
post test at p=0.05. *** p≤0.001 (D) The observed rate constant (kobs) for the transition from 
the basal to the AICAR stimulated steady-state were determined for TBC1D1 knockdown 
(siRNA Tbc1d1) and control cells.  
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Figure 5.4: TBC1D1 knockdown affects cell surface levels of GLUT4 in basal and insulin-
stimulated C2C12 myotubes. C2C12 cells were transfected with 100nM siRNA specific for 
Tbc1d1 or non-targeting siRNA (control) on day 2 of differentiation. The cells were cultured 
for a further 6 days. C2C12 myotubes were maintained under basal conditions (t=0) or 
stimulated with insulin at 100 nM for 2 to 60 min. (A) The cell surface levels of HA-GLUT4 in 
control (open squares) and TBC1D1 knockdown cells (solid squares) were determined in 
fixed cells using anti-HA primary antibodies and anti–mouse Alexa 488 secondary antibody. 
The results are expressed as a percentage of total immuno-reactive HA-GLUT4 within 
permeabilised cells. Results represent the mean + SE from 3 experiments. (B) The cell 
surface levels of GLUT4 at t=0 (Y0) and at t=∞ (plateau) were calculated from the data sets. 
An unpaired t-test was performed at p=0.05. * p≤0.05 (C) The cell surface levels of GLUT4 
were expressed as a fraction of maximum insulin (long-time) stimulation. A single-exponential 
function was fitted to determine the observed rate constant (kobs) for the transition. (D) The 
observed rate constant (kobs) for the transition from the basal to the insulin-stimulated state 
were determined for TBC1D1 knockdown (siRNA Tbc1d1) and control cells  
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5.2.3 siRNA-mediated knockdown of Tbc1d4 does not affect basal 
cell surface levels of GLUT4 in C2C12 myotubes 
In this next study we examined the effect of knockdown of TBC1D4 on the 
relative amount of GLUT4 at the cell surface in C2C12 myotubes. Endogenous 
TBC1D4 protein expression was reduced ~50% in myotubes transfected with 
siRNA-Tbc1d4 compared with cells transfected with non-targeting control siRNA 
(Figure 5.1C, D). 
C2C12 myotubes were serum starved and either kept under basal conditions or 
incubated with AICAR (2 mM) for 2 to 60 min. We investigated the time-
dependant accumulation of GLUT4 (HA epitope-tagged GLUT4) at the plasma 
membrane. HA-GLUT4 at the cell surface was calculated as a percentage of 
total cellular immuno-reactive GLUT4. Importantly, the depletion of TBC1D4 did 
not affect total cell expression of HA-GLUT4.  
Knockdown of TBC1D4 did not affect the basal levels of cell surface HA-GLUT4 
compared with basal control cells. Thus, in contrast to TBC1D1, TBC1D4 is not 
required for regulating GLUT4 retention in basal C2C12 myotubes (Figure 5.5A, 
B). Furthermore, the depletion of TBC1D4 did not prevent the elevation of 
GLUT4 transporters at the cell surface following AICAR-treatment. However, it 
is important to note that knockdown of TBC1D4 was not highly efficient. 
Therefore, residual protein levels of TBC1D4 may be enough for normal 
function.  
Additionally, we examined the effect of TBC1D4/TBC1D1 double knockdown 
cells. Surprisingly, the double knockdown of TBC1D1 and TBC1D4 did not 
result in an elevation of basal cell surface GLUT4 expression compared to 
control cells (Figure 5.5A, B). This may have been due to the reduced efficiency 
of TBC1D1 knockdown in siRNA Tbc1d4/Tbc1d1 double knockdown cells 
compared with the single targeting of TBC1D1 alone. The difference may be 
due to residual levels of TBC1D1 protein persisting which prevented a 
noticeable reduction in TBC1D1 function.  
5 Results 
~ 177 ~ 
 
It was apparent from the r2 goodness-of-fit measures that the data obtained in 
control non-targeting siRNA cells did not fit a single-exponential curve (r2 
values: control, 0.29; siRNA Tbc1d4, 0.81; siRNA Tbc1d4/Tbc1d1, 0.74) (Figure 
5.5C). Therefore, this ambiguous control data has made the results from these 
experiments difficult to interpret. The transition rate constant from basal to 
AICAR steady-state in the TBC1D4 knockdown cells was seemingly slow (k 
~0.02 ± 0.01 min-1, t1/2 ~33 min). Whereas, a more normal transition response 
curve was observed in the TBC1D4/TBC1D1 double knockdown cells (k ~0.06 ± 
0.02 min-1, t1/2 ~12 min). These interpretations have been made in comparison 
to cells transfected with non-targeting control siRNA from the previous set of 
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Figure 5.5: Knockdown of TBC1D4 does not affect cell surface levels of GLUT4 in basal 
C2C12 myotubes. C2C12 cells were transfected with 50 nM siRNA specific for Tbc1d4 
(siRNA Tbc1d4) or with 50 nM siRNA specific for Tbc1d4 and 100 nM of siRNA specific for 
Tbc1d1 (siRNA Tbc1d4/Tbc1d1) or non-targeting control siRNA (control) on day 2 of muscle 
cell differentiation. Cells were cultured for a further five days. C2C12 myotubes were 
maintained under basal conditions (t=0) or stimulated with AICAR at 2 mM for 2 to 60 min. (A) 
The cell surface levels of HA-GLUT4 in control (open squares), TBC1D4 knockdown cells 
(solid squares) and TBC1D4/TBC1D1-knockdown cells (grey squares) were determined by 
incubating fixed cells by with anti-HA primary antibodies and anti–mouse Alexa 488 
secondary antibody. The results are expressed as a percentage of total immuno-reactive HA-
GLUT4 within in permeabilised cells. Results represent the mean + SE from 3 experiments. 
(B) The cell surface levels of GLUT4 at t=0 (Y0) and at t=∞ (plateau) were calculated from 
the data sets. (C) The cell surface levels of GLUT4 were expressed as a fraction of maximum 
AICAR (long-time) stimulation. A single-exponential function was fitted to determine the 
observed rate constant (k) for the transition. (D) The observed rate constant (k) for the 
transition from the basal to the AICAR stimulated steady-state were determined for 




~ 179 ~ 
 
5.2.4 TBC1D1 regulates the release of GLUT4 from a non-
cycling/slow cycling pool in to the actively recycling pool 
C2C12 myotubes were serum starved and stimulated with insulin at 200 nM or 
maintained in basal conditions. Subsequently, live cells were incubated at 37oC 
in the presence of anti-HA antibody for 300 min to measure the amount of HA-
GLUT4 actively recycling with the plasma membrane. The amount of GLUT4 
actively recycling within 300 min was calculated as a percentage of total cellular 
immuno-reactive GLUT4. The results were expressed as a percentage of the 
maximum amount of GLUT4 labelled within 300 min in insulin-stimulated control 
cells (Figure 5.6C).  
In C2C12 myotubes, knockdown of TBC1D1 increased the size of the actively-
cycling GLUT4 pool in both basal and insulin-stimulated cells compared with 
control cells, although this did not reach statistical significance (Basal, p=1366; 
Insulin, p=1872) (Figure 5.6C). Conversely, knockdown of TBC1D4 did not 
affect the amount of GLUT4 in the cell surface recycling pool in basal or insulin-
stimulated C2C12 myotubes. 
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Figure 5.6: Knockdown of TBC1D1 increases the size of the actively cycling GLUT4 pool in 
basal and insulin-stimulated C2C12 myotubes. HA-GLUT4 expressing C2C12 cells were 
transfected with 100 nM siRNA specific for Tbc1d1 or 50 nM siRNA specific for Tbc1d4 or 
non-targeting siRNA (control) on day 2. Cells were cultured for a further 5 days. (A) TBC1D1 
and TBC1D4 protein expression was analysed by western blotting with anti-TBC1D1 02A and 
anti-TBC1D4. β tubulin was used as a control. A representative western blot is shown. (B) 
TBC1D1 and TBC1D4 protein levels were quantified in TBC1D1 knockdown cells (dark grey 
bars) and TBC1D4 knockdown cells (light grey bars) compared to control cells (open bars); 
results represent the mean ± SE from 3 experiments. (C) siRNA transfected C2C12 
myotubes were maintained in basal conditions or stimulated with Insulin at 200 nM for 5 min. 
Cells were incubated with agonist + 50 μg/ml of anti-HA antibody for 300 min at 37
o
C, then 
fixed, permeabilised and incubated with anti–mouse Alexa 488 secondary antibody. Results 
are calculated as a percentage of the GLUT4 labelled in insulin-stimulated control cells. 
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5.3 Discussion 
Cell culture models provide alternative in vitro model systems to study. In 
contrast to primary muscle cells, these cells can be readily sourced, cultured 
and large populations of cells can be obtained for robust investigations and so 
have great potential for industry applications. In this chapter we have 
established a lipid-transfection based protocol for siRNA-mediated knockdown 
of Tbc1d1 and Tbc1d4 in differentiated C2C12 myotubes. Using these 
knockdown muscle cell models we were able to investigate the role for Rab-
GAPs in the regulation of GLUT4 trafficking. We have shown that knockdown of 
TBC1D1 increases GLUT4 at the plasma membrane in basal cells therefore 
may play an important role in regulating GLUT4 intracellular retention 
mechanisms. Interestingly, TBC1D1 depleted cells remain insulin responsive. 
Insulin stimulates the rapid and transient accumulation of GLUT4 at the cell 
surface. This suggests that TBC1D1 may not be directly regulated by insulin 
alone. The experimental data presented here supports the effect of knockdown 
on the release of GLUT4 from storage compartments. However, due to 
experimental constraints, time course recycling data could not be investigated 
and so the effect of TBC1D1 and TBC1D4 knockdown on the intrinsic rate of 
GLUT4 recycling (kex) could not be distinguished.  
Here, we show that siRNA mediated knockdown of TBC1D1 increased basal 
cell surface levels of HA-GLUT4 in C2C12 myotubes (Figure 5.3 and Figure 
5.4) (Figure 5.7A,B). This is similar to observations made in L6 myotubes, 
where silencing TBC1D1 significantly elevated basal cell surface levels (50%) of 
GLUT4myc (Ishikura & Klip, 2008). Together these results suggest that 
endogenous TBC1D1 is required for basal GLUT4 intracellular retention. 
TBC1D1 has been found to be more effective at regulating GLUT4 retention in 
L6 myotubes compared to myoblasts (Ishikura & Klip, 2008). Consistent with 
this, the expression of TBC1D1 is up-regulated during differentiation of L6 
(Chavez, et al., 2008) and C2C12 muscle cells (Peck, et al., 2009) (3.4.3).  
5 Results 
~ 182 ~ 
 
5 Results 




~ 184 ~ 
 
Figure 5.7: A role for TBC1D1 in GLUT4 trafficking in C2C12 myotubes. In the three-pool 
model GLUT4 recycles through two intracellular compartments (endosomal recycling 
compartment (ERC) and GLUT4 storage vesicular compartment (GSV)) and the plasma 
membrane. The additional pool can account for the initial rapid stimulation of GLUT4 
translocation to the plasma membrane following insulin stimulation and the slower steady-
state t1/2 value for GLUT4 exocytosis in the continued presence of insulin. (A) In the basal 
state, cell surface levels of GLUT4 are kept low from the slow movement of GLUT4 to the 
plasma membrane and the rapid retrieval back to endosomal recycling compartment (ERC). 
A small fraction of GLUT4 transporters are sequestered to a stationary non-cycling GSV 
compartment. A pool of GSVs are retained through the action of TBC1D1. (B) Knockdown of 
TBC1D1 removes this retention and releases GLUT4 stored in static storage vesicles (GSVs) 
in to the endosomal recycling compartment and increases cell surface levels. (C, D) Insulin 
simulates the release of a GSV pool to the plasma membrane in control and TBC1D1 
knockdown cells. This pool is not retained through the action of TBC1D1. (E) Treatment with 
AICAR leads to the phosphorylation of TBC1D1 and releases a GSV pool in to the 
endosomal recycling compartment and increases cell surface levels. (F) Knockdown of 
TBC1D1 in addition to AICAR treatment has no further effect on the cell surface levels of 
GLUT4. Key: Arrows– indicate the movement of GLUT4 between compartments. Heavy 
weighted arrows indicate increased movement. Green 1D1: TBC1D1 with active GAP 
domain, Red 1D1: TBC1D1 with inactive GAP domain, Red crosses: Indicate the knockdown 
of TBC1D1.  
The silencing of TBC1D1 in C2C12 myotubes acts as a partial AICAR-mimetic. 
However, the depletion of TBC1D1 alone does not completely prevent AICAR-
mediated responses. Interestingly, siRNA-mediated knockdown of TBC1D1 did 
not affect the maximum cell surface levels of GLUT4 attained following AICAR-
treatment. However, the basal to AICAR transition rate appeared to be slightly 
slower in the TBC1D1 knockdown cells (k ~0.03 ± 0.02 min-1, t1/2 ~22 min) than 
in the control cells (k ~0.06 ± 0.01 min-1, t1/2 ~13 min) (Figure 5.3). It is likely that 
the retention mechanism governed by TBC1D1 is released upon 
phosphorylation by AMPK. This is illustrated in Figure 5.7. In support of this, we 
have shown here that TBC1D1 is phosphorylated on serine 237 in response to 
AMPK-activation. This is in support of data presented in other studies (Peck, et 
al., 2009) (Pehmoller, et al., 2009) (Roach, et al., 2007) (Chen, et al., 2008) 
(Taylor, et al., 2008). In 3T3-L1 adipocytes an insulin-dependent association 
between 14-3-3 and phosphorylated TBC1D4 plays an important role in the 
inactivation of TBC1D4 Rab-GAP activity and the regulation of GLUT4 
trafficking (Ramm, et al., 2006) (Koumanov, et al., 2011). In contrast, the 
phosphorylation of TBC1D1 on threonine 596 in response to insulin stimulation 
is insufficient to induce 14-3-3 binding in muscle (Chen, et al., 2008) 
(Pehmoller, et al., 2009). Instead, the binding of TBC1D1 to 14-3-3 is regulated 
through the phosphorylation of TBC1D1 on serine 237 in response to AMPK-
activation (Chen, et al., 2008) (Pehmoller, et al., 2009).  
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We have shown here that TBC1D1 knockdown increased the level of GLUT4 at 
the plasma membrane in basal C2C12 myotubes did not affect insulin-
stimulated GLUT4 translocation to the plasma membrane. The insulin-
stimulated net gains in cell surface HA-GLUT4 above respective basal levels 
were unaffected by TBC1D1 knockdown (Figure 5.4). The proposed mechanism 
for this finding is illustrated in Figure 5.7C, D. These results are consistent with 
those described for L6 myotubes and support the concept that endogenous 
TBC1D1 may also function to restrict insulin-stimulated responses (Ishikura & 
Klip, 2008). The over expression of wild-type TBC1D1 or the dominant-negative 
mutant TBC1D1 4P (TBC1D1 mutated to alanine at four Akt/AMPK 
phosphorylation sites serine 231, threonine 499, threonine 590 and serine 621, 
therefore removing its capacity to undergo phosphorylation) in mouse tibialis 
anterior muscle does not abrogate normal insulin-stimulated glucose transport 
(An, et al., 2010). The authors speculated that either TBC1D1 is not required for 
insulin-stimulated glucose transport or that other Akt phosphorylation sites on 
TBC1D1 are critical for insulin-induced responses. Our results support the 
former, as insulin-stimulated net gains in cell surface HA-GLUT4 were un-
affected following depletion of TBC1D1 from C2C12 myotubes. Taken together, 
these findings may suggest that the expression of endogenous TBC1D1 may 
function to constrain the extent to which insulin alone can induce the release of 
GLUT4 to the cell surface in muscle. In contrast, the ectopic expression of wild-
type TBC1D1 (active GAP) in 3T3 L1 adipocytes had an inhibitory effect on 
insulin-stimulated GLUT4 at the plasma membrane. This was rescued 
completely when TBC1D1 was simultaneously mutated to lysine at arginine 
941, which inactivated GAP activity (Peck, et al., 2009) (Chavez, et al., 2008). 
Interestingly, the inhibitory effect of wild-type TBC1D1 on insulin-stimulated 
responses in 3T3-L1 adipocytes was partially rescued when cells were treated 
with AICAR (Peck, et al., 2009). Therefore, it is reasonable to conclude that the 
ectopic expression of TBC1D1 in fat cells may lead to aberrant effects in part 
due to the absence of signalling pathways regulating TBC1D1 activity. A role for 
AMPK under basal conditions has been suggested. In muscle-specific α2-
inactive AMPK transgenic (AMPKα2iTG), α2AMPK kinase dead (α2AMPK KD) 
and β1β2 knockout (AMPKβ1β2KO) mice basal phosphorylation of TBC1D1 
was significantly reduced (Vichaiwong, et al., 2010) (Pehmoller, et al., 2009) 
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(O'Neill, et al., 2011). Furthermore, in α2AMPK KD mice TBC1D1 association 
with 14-3-3 is impaired (Pehmoller, et al., 2009). Thus, the regulation of 
TBC1D1 by AMPK in basal muscle cells could somehow regulate insulin-
responsiveness. In support of this, AMPK is required for insulin-stimulated 
phosphorylation of TBC1D1 at threonine 596 (Pehmoller, et al., 2009). Although 
signalling via PI 3-kinse is important for mediating insulin-stimulated TBC1D1 
phosphorylation. However, full alleviation of TBC1D1-induced retention (through 
in-activation of TBC1D1 GAP activity) could be dependent on other factors 
specific in muscle. Conversely, the expression of TBC1D1 may dominantly 
inhibit the endogenous proteins and interfere with insulin-induced responses 
which would normally function in adipose cells.  
Additionally, we have shown here that silencing TBC1D1 does not significantly 
affect the observed transition rate constant (k) from basal steady-state to a 
maximal insulin-stimulated state compared with control cells (k = 0.537 ± 0.342 
min-1, t1/2 ~1.29 min, siRNA Tbc1d1 versus k ~0.379 ± 0.276 min
-1, t1/2 ~1.82 
min, Control) (Figure 5.4). In view of a concept first proposed by Bogan et al, 
this ‘transient overshoot’ of cell surface GLUT4 levels observed following acute 
insulin stimulation corresponds with the rapid mobilisation of GLUT4 from a 
highly insulin-responsive GSV compartment (Bogan, et al., 2001) (4.4). These 
insulin-regulated exocytic events occur independently of TBC1D1 in C2C12 
myotubes. Furthermore, TBC1D1 does not appear to regulate the rate of 
release of these vesicles towards the plasma membrane. It is plausible that 
endogenous TBC1D1 may restrict insulin-stimulated responses through 
regulating the formation or size of this insulin-responsive vesicular compartment 
in C2C12 myotubes.  
The proposed mechanisms by which GLUT4 is trafficked within intracellular 
compartments to regulate GLUT4 sequestration in fat and muscle cells are 
controversial. In more recent years, two distinctly different but plausible models 
have been supported primarily based on experimental studies carried out in 
3T3-L1 adipocytes. The first model proposes ‘GLUT4 static retention’ which was 
pioneered by James and colleagues (Govers, et al., 2004) (Coster, et al., 2004) 
and which has been robustly supported (Muretta, et al., 2008) (Brewer, et al., 
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2011) (Fujita, et al., 2010) (1.3.2.6 Figure 1.4C). Conversely, model 2 proposed 
by McGraw and colleagues details that intracellular GLUT4 traffic is governed 
by a dynamic system where the entire insulin-responsive GLUT4 pool can 
eventually recycle with the plasma membrane in basal cells (Martin, et al., 
2006) (Karylowski, et al., 2004) (1.3.2.6 Figure 1.4D). These models have 
directly led to further controversies over the most important site for insulin 
action. For the static GLUT4 compartment model, insulin functions to release 
GLUT4 from an intracellular stored compartment ‘prefusion steps’. Conversely, 
a direct effect on vesicle docking/fusion at the plasma membrane in response to 
insulin stimulation fits with the dynamic recycling model (Dugani & Klip, 2005) 
(Leney & Tavare, 2009).  
In differentiated muscle cells, GLUT4 intracellular sequestration is regulated 
both by dynamic cycling and static retention mechanisms (Fazakerely, et al., 
2009) (4.3.2). In cultured skeletal muscles cells we and others have shown that 
they possess small statically retained GLUT4 pools (~10% of total GLUT4 pool) 
that are mobilised in to the actively cycling pool in response to insulin 
stimulation or AICAR-treatment. Furthermore, treatment with insulin and AICAR 
in combination result in a partially additive effect on the size of the actively 
recycling GLUT4 pool compared to basal cells (64% of the total GLUT4 pool, 
basal-state versus 85%, agonist-stimulated) (Figure 20, 4.3.2.2). Here we have 
shown that TBC1D1 knockdown increased the actively recycling GLUT4 pool in 
non-stimulated C2C12 myotubes (Figure 5.6). Although this observed trend did 
not reach statistical significance. Importantly, this mobilised GLUT4 pool 
appeared additive to the GLUT4 pool that is mobilised in response to insulin. 
These results are consistent with TBC1D1 functioning as a retention signal that 
is relieved upon phosphorylation by AMPK in response to AICAR treatment 
(Figure 5.7C, D). In a recent study the phosphorylation of ectopically expressed 
TBC1D1 at serine 237 has emerged as being vital to facilitate AICAR-
responsive GLUT4 liberation from a ‘statically retained’ compartment. This was 
established in a 3T3-L1-based GLUT4-retention ‘experimental reconstitution 
model’. (Hatakeyama & Kanzaki, 2013).  
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Through limitations of these experiments we were unable to investigate further 
the effect of TBC1D1 knockdown on GLUT4 exocytosis and endocytosis. It will 
be of importance to examine whether silencing TBC1D1 affects the rate for 
basal GLUT4 recycling (kex) at steady-state, in addition to regulating the release 
of GLUT4 from a storage compartment. Furthermore, it will be of interest to 
evaluate the effects of TBC1D1 knockdown on insulin-stimulated GLUT4 
exocytosis. Multiple insulin and AMPK-regulated phosphorylation sites have 
been identified in TBC1D1 (Peck, et al., 2009) (Chen, et al., 2008) (Taylor, et 
al., 2008) (Roach, et al., 2007). Furthermore, numerous studies have reported 
additive effects of both AMPK-activators and insulin on glucose uptake and/or 
GLUT4 translocation in to muscle (Bergeron, et al., 1999) (Yang & Holman, 
2005) (Yang & Holman, 2006) (Hayashi, et al., 1998) (Fazakerely, et al., 2009). 
In support of this, we have observed that the combined effect of insulin 
stimulation and AMPK-activation was synergistic to increase GLUT4 cell 
surface levels in C2C12 myotubes. Additionally, we have found that co-
stimulation with insulin and AICAR resulted in a greater increase in the steady-
state rate constant for HA-GLUT4 exocytosis (kex) compared to insulin 
stimulation alone (0.016 min-1 , basal state, 0.023 min-1, insulin-stimulated, 
0.031 min-1, insulin plus AICAR) (Figure 4.6, 4.3.2.3). Therefore, it may be that 
insulin and AICAR-mediated signalling pathways directly converge and 
phosphorylate TBC1D1 to regulate the release GLUT4 from a dynamic retention 
mechanism. Alternatively, AMPK-mediated phosphorylation of TBC1D1 (at 
serine 237) and subsequent binding to 14-3-3 proteins could liberate GLUT4 in 
to an insulin-responsive GSV compartment. Consistent with this, a unique 
‘regulatory mode shift’ mechanism of TBC1D1 has been recently described. 
TBC1D1 develops the capacity for insulin-responsive GLUT4 liberation and 
phosphorylation at threonine 596 only after pre-treatment with AICAR. 
Furthermore an intact PTB1 domain is essential for this (Hatakeyama & 
Kanzaki, 2013).  
In this present study we have found that siRNA-mediated knockdown of 
TBC1D4 did not affect basal cell surface levels of GLUT4 compared to control 
cells. These results indicated that in comparison to TBC1D1, endogenous 
TBC1D4 may not be required for basal retention in C2C12 myotubes. 
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Consistent with this, silencing TBC1D4 did not affect the size of the actively 
cycling GLUT4 pool in basal cells or in response to insulin. Thus, the 
mobilisation of a small statically retained GLUT4 pool in response to insulin 
stimulation occurs independently of TBC1D4. These results are in contrast to 
studies in basal L6 muscle cells where depletion of TBC1D4 elevated GLUT4 at 
the plasma membrane (Ishikura & Klip, 2008). However, notably, this increase 
was more marked in L6 myoblasts compared to differentiated myotubes.  
In cultured 3T3-L1 adipocytes TBC1D4 is essential for basal GLUT4 
intracellular retention and regulating the release of GLUT4 in to the plasma 
membrane (Larance, et al., 2005) (Eguez, et al., 2005) (Brewer, et al., 2011). 
shRNA-mediated knockdown of TBC1D4 increased GLUT4 at the cell surface in 
3T3-L1 adipocytes under basal conditions (Eguez, et al., 2005) (Brewer, et al., 
2011). Importantly, silencing TBC1D4 does not completely inhibit insulin-
induced gain of GLUT4 at the cell surface. Similarly, we have shown here that 
C2C12 myotubes are still insulin-responsive following the depletion of TBC1D4. 
Interestingly, shRNA mediated knockdown of TBC1D4 reduced the insulin 
response in 3T3-L1 adipocytes  (Eguez, et al., 2005) (Brewer, et al., 2011). 
Whilst, the depletion of TBC1D4 did not affect insulin-induced cell surface levels 
of GLUT4 in L6 cells (Ishikura & Klip, 2008). These dissimilar results may be 
explained simply by the fact that TBC1D4 knockdown efficiency is reduced in L6 
cells compared to 3T3-L1 adipocytes. Alternatively, TBC1D4 may have another 
role in insulin-stimulated responses in 3T3-L1 adipocytes.  
As two different models have been proposed to explain how GLUT4 is trafficked 
within intracellular compartments to regulate basal retention, this has have led 
to debate over how TBC1D4 regulates GLUT4 retention. More specifically, how 
insulin regulates the mobilisation of GLUT4 to directly increase cell surface 
levels. It is now well supported that this retention mechanism governed by 
TBC1D4 GAP activity is released upon phosphorylation by Akt following insulin 
stimulation. In support of this, the over expression of the mutant TBC1D4 4P 
(TBC1D4 mutated to alanine at four phosphorylation sites serine 318, serine 
588, threonine 642, serine, removing its capacity to undergo phosphorylation) in 
3T3-L1 adipocytes acts as a dominant-negative mutant and results in the partial 
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inhibition of insulin-stimulated cell surface GLUT4 levels (Zeigerer, et al., 2004) 
(Sano, et al., 2003). Similar effects have been observed in L6 cells (Stockli, et 
al., 2008) (Thong, et al., 2007). In addition, the over-expression of TBC1D4 4P 
inhibited insulin-stimulated glucose uptake in tibialis anterior muscle (Kramer, et 
al., 2006).The effect of the dominant interfering mutant was subsequently 
rescued by the concurrent disruption of Rab-GAP activity. It is likely that 
TBC1D4 is required for the pre-fusion events involving the recruitment/docking 
of GLUT4 containing vesicles to the plasma membrane. In support of this the 
over expression of TBC1D4 4P has been shown to inhibit the insulin-induced 
recruitment/docking of GLUT4 towards the plasma membrane in 3T3-L1 
adipocytes (Zeigerer, et al., 2004). This was determined using total internal 
reflection microscopy (TIRF) which detects HA-GLUT4-GFP fluorescence within 
an evanescent excitation field (250nm from the membrane). However, it is still 
not clear as yet to which specific pre-fusion step is regulated by TBC1D4. 
Additionally, Bai et al. have demonstrated that TBC1D4 is likely to be involved 
in regulating the docking of GSVs at the plasma membrane (Bai, et al., 2007). 
In support of this, Brewer et al. have shown that knockdown of TBC1D4 
mobilises GLUT4 from a static compartment to increase the size of a primed 
pre-fusion vesicular compartment (Brewer, et al., 2011). Interestingly, the 
transition from basal to insulin-stimulated steady-state was faster in TBC1D4 
knockdown cells compared with control cells. However, TBC1D4 depletion did 
not affect the rate constant for exocytosis (kex) for the actively cycling pool of 
GLUT4 under basal conditions or following insulin stimulation. It was therefore 
deduced that TBC1D4 is regulating a rate-limiting step (pre-fusion) in the 
transition from basal to an insulin-stimulated steady-state in control cells. 
Conversely, in the basal state the rate limiting step is situated downstream of 
TBC1D4 in the final stages of GLUT4 translocation. In contrast, in a dynamic 
recycling system it has been observed that the total ‘insulin-responsive’ GLUT4 
pool can access the plasma membrane in the absence of insulin. However, the 
actively cycling GLUT4 pool is governed by a very slow recycling rate under 
basal conditions. In these studies, shRNA-mediated silencing of Tbc1d4 
increases the basal exocytosis recycling rate constant (kex) for GLUT4 (0.005 
min-1 control to 0.02 min-1 TBC1D4 knockdown) and does not affect the kex for 
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GLUT4 following insulin stimulation (Eguez, et al., 2005). The reason for two 
very different GLUT4 recycling models is yet to be determined.  
Regardless of the exact mechanism, we have shown here that C2C12 
myotubes lack a robust ‘non-cycling/slow-cycling’ GSV compartment (Figure 
4.5, 4.3.2.2). Furthermore, on-going insulin stimulation has been found to 
induce only a minor increase in GLUT4 at the cell surface in C2C12 myotubes. 
C2C12 myotubes may lack critical components involved in the development and 
stability of a GLUT4 storage compartment. For instance, in a recent study, 
shRNA knockdown of TUG (a protein which is required for GSV intracellular 
retention) resulted in only a transient 2-fold pulse of GLUT4 exocytosis in 3T3-
L1 adipocytes in response to insulin stimulation (Xu, et al., 2011). These results 
are surprisingly similar to what we have observed here in C2C12 myotubes. It is 
therefore plausible that C2C12 cells may well be deficient in the protein TUG. 
Alternatively, the protein TUG could be part of a protein complex which is 
responsible for complete GLUT4 sequestration in basal cells. Therefore, we 
cannot rule out that other proteins are involved in maintaining an intact GLUT4 
retention compartment. This requires further investigation. Recently an 
‘experimental reconstitution model’ for insulin-responsive GLUT4 trafficking has 
been established by exogenously expressing TBC1D4 and sortilin in 3T3-L1 
fibroblasts. Through the direct analysis of GLUT4 dynamics using quantum dot 
technology it was observed that siRNA-mediated knockdown of sortilin in 
differentiated 3T3-L1 adipocytes ablated the GLUT4 static behaviour and 
increased GLUT4 movements (Hatakeyama & Kanzaki, 2011). Alternatively, the 
lack of an insulin-responsive compartment may be a consequence of reduced 
expression of endogenous TBC1D4. However, we observed similar protein 
expression levels of TBC1D4 (femto-moles of protein per microgram of lysate) 
in C2C12 myotubes to that in adipose tissue and soleus muscle. We may have 
underestimated intracellular levels of TBC1D4 in adipose and soleus muscle 
tissues (due to the abundance of extracellular cellular protein components in 
tissue samples). Furthermore, it has been reported that there are two protein 
coding splice variants of the Tbc1d4 gene (Baus, et al., 2008). The full-length 
transcript of Tbc1d4 has been found predominately expressed in skeletal 
muscle. Therefore, it is reasonable to suggest on this basis of our data that the 
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long variant is expressed in C2C12 muscle cells. Interestingly, the over-
expression of the short-variant TBC1D4 protein increased insulin-stimulated 
GLUT4 translocation and glucose uptake in L6 myotubes (Baus, et al., 2008). 
Conversely, the over expression of full-length TBC1D4 did not affect insulin-
induced cell surface levels of GLUT4 in L6 myotubes (Stockli, et al., 2008). 
Therefore, the differential expression of TBC1D4 splice variants could confer 
specific function. The inclusion/exclusion of a specific protein domain could 
impede protein-protein interactions and directly affect membrane targeting.  
Surprisingly, the double knockdown did not increase basal cell surface GLUT4 
levels compared to control myotubes. A possible explanation could be that the 
efficiency of TBC1D1 knockdown in TBC1D4/TBC1D1 double knockdown cells 
was reduced compared with the single targeting of TBC1D1 alone. A >70% 
knockdown ‘threshold’ is deemed by commercial companies as a cut-off for an 
efficient knockdown assay. In addition, it was apparent that the data obtained in 
control non-targeting siRNA cells were ambiguous which made the results from 
these experiments difficult to interpret. It is possible that the increased 
concentration of siRNA used for these experiments may have caused non-
specific silencing effects. It would therefore be important to further optimise 
these double knockdown experiments to ensure that the lowest effective 
concentration of siRNA is used.  
In conclusion, our results support a model whereby TBC1D1 inactivation by 
signalling-dependant phosphorylation is required for GLUT4 translocation. 
Knockdown of TBC1D1 increased cell surface levels of GLUT4 in basal and in 
insulin-stimulated C2C12 myotubes. Furthermore, TBC1D1 knockdown 
increased the release of GLUT4 in to the actively recycling pool. By contrast 
TBC1D1 knockdown did not change the levels of GLUT4 at the plasma 
membrane that occur in the presence of the AMPK-activator (AICAR). We have 
also revealed that TBC1D4 does not appear to regulate basal intracellular 
GLUT4 retention in C2C12 myotubes. This is likely due to the fact that C2C12 
myotubes lack a robust ‘non-cycling/slow cycling’ insulin-responsive GSV 
compartment. For future investigations it would be of interest to establish 
whether the formation/stability of a GLUT4 static compartment can be 
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programmed in C2C12 myotubes. This may help to improve the C2C12 muscle 
cell line as a model for studying GLUT4 trafficking. 
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6 Overall Discussion 
6.1 General discussion and conclusions 
A substantial amount of research has been dedicated to investigate GLUT4 
trafficking in primary adipose cells and 3T3-L1 adipocytes and how insulin 
signalling regulates GLUT4 translocation. Whereas, fewer studies have focused 
on how this is regulated in skeletal muscle cells. There have been many 
technical challenges associated with this complex tissue. The abundance of 
structural proteins in skeletal muscle tissue has made sub-cellular membrane 
fractionation procedures problematic for the analysis of GLUT4 intracellular 
distribution. Furthermore, there are difficulties associated with the isolation of 
single skeletal muscle fibres. This has impeded detailed kinetic analysis of 
endogenous GLUT4 trafficking using biotinylated photolabelling techniques and 
morphological analyses of GLUT4 using immunofluorescence microscopy. 
Alternative methods have been developed utilising the ectopic expression of 
epitope-tagged GLUT4 (GLUT4-GFP) in primary skeletal muscle tissue. This 
experimental approach has enabled more detailed investigations of GLUT4 
translocation in response to insulin and contraction-mediated signalling in situ 
(Lauritzen, et al., 2008) (Lauritzen, et al., 2006). More recently, the transgenic 
expression of an exofacial-tagged GLUT4 (HA-GLUT4-GFP) in mice has 
enabled direct measurements of GLUT4 inserted into the cell membrane of 
intact single muscle fibres (Lizunov, et al., 2012) (Fazakerely, et al., 2009). 
Technical problems associated with the preparation of primary muscle have 
prevented these models from being used more extensively used within the field 
for the examination of GLUT4 trafficking kinetics. Therefore, immortal skeletal 
muscle cell lines (L6 cells and C2C12 myotubes) have provided alternative 
model systems. Clonal skeletal muscle cells can be easily maintained in culture 
and can be efficiently manipulated through transduction and transfection 
techniques.  
The investigations carried out for this thesis utilised the exofacial-tagged GLUT4 
construct (HA-GLUT4) to analyse GLUT4 trafficking following insulin and 
contraction-mediated signalling in C2C12 skeletal muscle cells. Using this cell 
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model we were able to use the HA-tag to directly monitor the kinetics of HA-
GLUT4 translocation The objective for these current investigations was to 
examine the role of the Rab-GTPase activating proteins (GAP) TBC1D1 and 
TBC1D4 with respect to GLUT4 trafficking. In order to investigate this, small 
interfering RNA (siRNA) constructs were utilised to specifically knockdown 
TBC1D1 and TBC1D4 in C2C12 myotubes. To date, there is limited and varied 
information available regarding an efficient transfection system in C2C12 
myotubes. Many studies have used electroporation in order to effectively 
transfect C2C12 myotubes (Chadt, et al., 2008) (Tao, et al., 2011) (Verrier, et 
al., 2011). However, the high rate of cell death following electroporation has 
meant that this method is difficult to apply to plate assays where high numbers 
of cells are required. We have therefore optimised a siRNA gene silencing 
approach using lipid-based transfection. Un-differentiated C2C12 myoblasts 
expressing HA-GLUT4 were transfected at an intermediate differentiation stage 
(Day 2) and experiments were conducted using fully differentiated C2C12 
myotubes.  
The use of C2C12 myotubes disclosed unique insights into the regulation of 
GLUT4 trafficking. Our data revealed the activation of insulin or AMPK 
signalling pathways resulted in distinct effects on GLUT4 trafficking parameters 
in C2C12 cells. We have determined that insulin initiates an increase of GLUT4 
exocytosis and that activation of AMPK inhibited GLUT4 internalisation. The 
combined effect of insulin stimulation and AMPK-activation was synergistic and 
led to increased GLUT4 cell surface levels. Insulin stimulation and AICAR-
treatment in combination result in the partial additive mobilisation of GLUT4 into 
the actively recycling pool in C2C12 myotubes. Therefore, these data support 
the concept that these stimuli promote GLUT4 accumulation at the cell surface 
via distinct signalling pathways. In addition, GLUT4 exocytosis was enhanced 
following the co-stimulation with insulin and AICAR. Thus, the activation of both 
AMPK and Akt signalling pathways may also converge on a single signalling 
intermediate to enhance GLUT4 exocytosis. Together our results indicate that 
multiple and complex mechanisms exist in muscle cells to regulate GLUT4 
redistribution to the cell surface.  
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TBC1D1 and TBC1D4 are proposed to function as negative regulators of 
GLUT4 trafficking which function through maintaining an un-specified rab 
protein in its in-active GDP-bound state. The phosphorylation of 
TBC1D1/TBC1D4 leads to the in-activation of its GAP activity and therefore 
allows the rab to switch to an activate GTP bound state. Current evidence 
supports the model that the Rab-GAP TBC1D4 is primarily required for basal 
intracellular retention of GLUT4. This is supported through knockdown studies 
in 3T3-L1 adipocytes (Eguez, et al., 2005) (Brewer, et al., 2011) and in L6 
muscle cells (Ishikura & Klip, 2008). Therefore it was somewhat surprising to 
find that siRNA-mediated depletion of TBC1D4 did not affect basal cell surface 
levels of GLUT4 in C2C12 myotubes. However, there are several possible 
explanations for this result. Firstly, there was a significant amount of residual 
TBC1D4 protein within cells transfected with Tbc1d4-specific siRNA. Therefore, 
this could be sufficient to carry out a normal function. Further optimisation of 
knockdown protocols to improve efficiency will be important to test this. 
Secondly, this result could indicate that there is a limited role for TBC1D4 in 
C2C12 myotubes. In support of this, we have shown that TBC1D4 protein levels 
were to some extent down-regulated during C2C12 cell differentiation. TBC1D4 
is expressed predominately in oxidative soleus skeletal muscle than in glycolytic 
muscles such as tibialis anterior and extensor digitorum longus. Therefore it is 
possible that C2C12 myotubes may represent a characteristic glycolytic muscle 
type cell and therefore express a reduced level of TBC1D4. Alternatively, 
TBC1D4 is not able to function correctly in C2C12 myotubes. In support of this, 
TBC1D4 has been found to restrict the movement of GLUT4 from a ‘non-
cycling/slow-cycling’ GSV compartment into an actively cycling GLUT4 pool in 
3T3-L1 adipocytes (Eguez, et al., 2005) (Brewer, et al., 2011). The insulin-
mediated phosphorylation of TBC1D4 is required to release this brake through 
the inactivation of its Rab-GAP activity. Therefore, TBC1D4 is central for 
regulating the large proportion of insulin-stimulated GLUT4 translocation in 
adipocytes. Our findings revealed that a robust ‘non-cycling/slow-cycling’ GSV 
compartment is deficient in C2C12 myotubes (Figure 6.1). Furthermore, this 
inadequate basal GLUT4 retention mechanism is likely to be responsible for the 
lack of a robust insulin-responsive GLUT4 translocation system in C2C12 cells. 
Additional support for this mechanism has come from studies in L6 myoblasts, 
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where a slow GLUT4 recycling rate governs basal intracellular retention. Insulin 
stimulation markedly increases the rate of recycling for GLUT4, thus, 
redistributing GLUT4 to the cell surface (Foster, et al., 2001).  
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Figure 6.1: Regulation of GLUT4 trafficking in C2C12 myotubes. These models are based on 
the three-pool for GLUT4 recycling. In the three-pool models, GLUT4 recycles through two 
intracellular compartments; the endosomal recycling compartment (ERC) and GLUT4 storage 
vesicles and the plasma membrane. The additional pool can account for the initial rapid 
stimulation of GLUT4 translocation to the plasma membrane following insulin stimulation and 
the slower steady-state t1/2 value for GLUT4 exocytosis in the continued presence of insulin. 
In the basal state, cell surface levels of GLUT4 are kept low (14%) from the slow movement 
of GLUT4 to the plasma membrane and the rapid retrieval back to ERC. A small pool of 
GLUT4 is sequestered in a static GLUT4 storage compartment (GSV). GLUT4 retention is 
regulated by active TBC1D1 (1D1 green). Insulin simulates the release of GLUT4 from a 
static GSV pool in to the ERC to increase cell surface levels to 30%. AICAR inhibits the 
internalisation of GLUT4 from the plasma membrane and simulates the release of GLUT4 
from a static GSV pool in to the recycling compartment to increase cell surface levels (40%). 
Insulin plus AICAR in combination have additive effects to increase cell surface levels of 
GLUT4 (70%). The percentage values are measured as a fraction of total cellular GLUT4. A 
small proportion of GLUT4 is not actively recycling (15%) and is thought to reside in the 
Trans Golgi Network (TGN). Arrows indicate the movement of GLUT4 between 
compartments. Heavy weighted arrows indicate increased movement.  
Importantly, other retention mechanisms exist in order to maintain low surface 
levels of GLUT4 in basal C2C12 myotubes. TBC1D1 Rab-GAP activity is 
proposed to be regulated through phosphorylation in much the same way as 
TBC1D4. TBC1D1 contains many insulin-regulated phosphorylation sites (Peck, 
et al., 2009) (Taylor, et al., 2008). Several studies have demonstrated that 
TBC1D1 is phosphorylated in response to insulin in skeletal muscle (Kramer, et 
al., 2006) (Bruss, et al., 2005) (Funai & Cartee, 2008) (Funai & Cartee, 2009). 
However, in contrast to TBC1D4 multiple AMPK phosphorylation sites have 
been identified in TBC1D1 (Peck, et al., 2009) (Taylor, et al., 2008) (Chen, et 
al., 2008) (Roach, et al., 2007). The identification of TBC1D1 as an AMPK 
substrate supports a role for TBC1D1 as a downstream signalling intermediate 
of contraction. Furthermore, it has been proposed that TBC1D1 could be 
primarily responsible for regulating contraction-mediated glucose uptake in 
muscle (Funai & Cartee, 2009) (An, et al., 2010) (Vichaiwong, et al., 2010) 
(Pehmoller, et al., 2009). Importantly, we have shown here that the amount of 
TBC1D1 protein expressed (femto-moles of protein per microgram of tissue 
lysate) is significantly greater than the level of TBC1D4 in all types of skeletal 
muscle. This finding contradicts our current understanding that the expression 
of TBC1D1 and TBC1D4 is muscle-type specific (Taylor, et al., 2008) 
(Szekeres, et al., 2012). However, these assumptions were based on relative 
quantification experiments. This original hypothesis has led to speculation over 
the function of TBC1D1 in glycolytic fibre-type muscles (TA, EDL) than in 
oxidative soleus muscles. Instead, our observations enable us to address 
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TBC1D1 function as common feature of both oxidative and glycolytic skeletal 
muscles in general. However, the predominant expression of TBC1D4 in 
oxidative soleus muscle may indirectly affect the function of TBC1D1 in these 
muscles. 
It is important to note that mouse soleus muscle consists of ~80% type I (slow-
twitch) and type IIA (fast-twitch) oxidative muscle fibres. In contrast, rat soleus 
muscle has been shown to contain predominately type I slow twitch fibres 
(Bloemberg & Quadrilatero, 2012). This is comparable to human soleus muscle 
(Gollnick, et al., 1974). It is plausible therefore that the high level of TBC1D1 
expression in mouse soleus muscle that we have observed in this present study 
could be related to its content of type II fibres. Consequently, the relative Rab-
GAP expression levels may relate to the metabolic requirements for the 
individual muscle-fibres. Considering that most skeletal muscles are composed 
of a mixture of muscle fibres, it will be of great importance for future studies to 
investigate GLUT4 trafficking with respect to muscle fibre-type.  
Through siRNA-mediated silencing of TBC1D1 we show that TBC1D1 is 
required for basal GLUT4 intracellular retention in C2C12 myotubes. TBC1D1 is 
required for the sequestration of a ‘statically retained’ pool of GLUT4. We find 
that the depletion of TBC1D1 was only partially AICAR-mimetic and does not 
impair the maximum cell surface levels of GLUT4 attained following AICAR-
treatment. This supports the concept that TBC1D1 is at least partly required for 
regulating contraction-mediated GLUT4 translocation. The retention mechanism 
governed by the activity of Rab-GAP TBC1D1 is likely to be released upon 
phosphorylation by AMPK which follow AICAR-treatment (Figure 6.1). In 
support of this, we have shown here that TBC1D1 is phosphorylated on serine 
237 in response to AMPK-activation. This is in support of data presented in 
other studies (Peck, et al., 2009) (Pehmoller, et al., 2009) (Chen, et al., 2008) 
(Taylor, et al., 2008) (Roach, et al., 2007).  
In a recent study a GLUT4-retention ‘experimental reconstitution model’ has 
been established in 3T3-L1 fibroblasts over-expressing sortilin. The stationary 
behaviour of GLUT4 was determined through the direct analysis of GLUT4 
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dynamics using Quantum-dot nanometry. It has been revealed that sortilin is 
critical for the recruitment of internalised GLUT4 to the specialised sub-domain 
of the TGN via an endosome to TGN retrieval mechanism. This interaction is 
crucial for the development of a ‘static GLUT4 retention’ compartment in 3T3-L1 
adipocytes. Furthermore, the TGN-golgin Golgin 97 plays an important role in 
the recruitment of GLUT4 to the TGN for the development of a stationary 
GLUT4 compartment. Golgins are required for tethering events in membrane 
fusion. Additionally, the expression of TBC1D4 within this artificial cell model is 
essential for insulin-responsive liberation of GLUT4 from this static GLUT4 
compartment (Hatakeyama & Kanzaki, 2011). Following on from this study the 
‘experimental reconstitution model’ has been used to examine the functional 
role for TBC1D1. Interestingly, the phosphorylation of TBC1D1 at Serine 237 
has emerged as being critical to facilitate AICAR-responsive GLUT4 liberation 
from ‘static retention’ (Hatakeyama & Kanzaki, 2013).  
In 3T3-L1 adipocytes an insulin-dependent association between 14-3-3 and 
TBC1D4 plays an important role in the inactivation of TBC1D4 Rab-GAP activity 
and the regulation of GLUT4 trafficking (Ramm, et al., 2006) (Koumanov, et al., 
2011). In contrast, the binding of TBC1D1 to 14-3-3 is regulated through the 
phosphorylation of TBC1D1 at serine 237 in L6 myotubes (Chen, et al., 2008). 
Therefore, the association between TBC1D1 phosphorylated at AMPK sites and 
14-3-3 may play an important role in the mobilisation of GLUT4 in C2C12 
myotubes. 
Interestingly, we have found that TBC1D1 knockdown in C2C12 myotubes did 
not affect the cell response to insulin. Consistent with this, insulin alone does 
not liberate GLUT4 from ‘static retention’ within a cell-based GLUT4-retention 
‘experimental reconstitution model’ despite augmenting the phosphorylation of 
ectopically expressed TBC1D1 at threonine 596 (Hatakeyama & Kanzaki, 
2013). Furthermore, TBC1D1 phosphorylated at threonine 596 in response to 
insulin appears to be insufficient to induce 14-3-3 binding (Chen, et al., 2008) 
(Pehmoller, et al., 2009). Instead, we have found that TBC1D1 knockdown 
potentiated the transient cell surface levels of GLUT4 reached following insulin 
stimulation in C2C12 myotubes. Therefore, endogenous TBC1D1 appears to be 
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required to restrict insulin-induced GLUT4 redistribution to the cell surface. The 
rapid and transient accumulation of GLUT4 at the cell surface is likely to 
correspond with the early fusion of GLUT4 containing vesicles at the cell 
surface in response to insulin. It is possible that TBC1D1 could directly regulate 
the formation of this insulin-responsive GSV compartment. One plausible 
mechanism is that following TBC1D1 knockdown GLUT4 is liberated from ‘static 
retention’ and released directly into the insulin-responsive GSV compartment. 
Alternatively, TBC1D1 may regulate more than one discrete pathway in muscle 
cells. TBC1D1 could be differentially localised within the cell and may well be 
regulated through multiple signalling pathways. For instance, Insulin and 
AICAR-mediated signalling pathways could converge to phosphorylate TBC1D1 
and release GLUT4 from a dynamic retention mechanism. The phosphorylation 
of TBC1D1 on both putative AMPK and Akt sites could enable TBC1D1 to be 
differentially regulated. Consistent with the latter, TBC1D1 develops the 
capacity for insulin-responsive GLUT4 liberation from ‘static state’ only after 
pre-treatment with AICAR (Hatakeyama & Kanzaki, 2013). Furthermore, this 
function of TBC1D1 is dependent on an intact first phosphotyrosine-binding 
domain (PTB) domain (PTB1) (Hatakeyama & Kanzaki, 2013). A model such as 
this may explain the enhanced GLUT4 exocytosis following the co-stimulation 
with insulin and AICAR in C2C12 myotubes. Unfortunately, we were unable to 
determine whether silencing TBC1D1 affected GLUT4 exocytosis under either 
basal conditions or following insulin stimulation or AICAR-treatment. Further 
studies will be required to investigate this.  
This current study supports TBC1D1 as a regulator of insulin and AMPK-
mediated GLUT4 translocation. However, we find that TBC1D1 is not required 
for insulin-stimulated GLUT4 redistribution to the plasma membrane in C2C12 
myotubes. In support of this the over expression of TBC1D1 4P in TA muscle 
did not affect insulin-stimulated glucose transport (An, et al., 2010). However, 
the over expression of TBC1D1 carrying the missense mutation R125W 
(originally identified as a candidate causing severe familial obesity 
predisposition in humans (Stone, et al., 2006) (Meyre, et al., 2008) has been 
found to impair insulin-induced glucose transport in TA muscle. The precise 
mechanism for how this mutation affects TBC1D1 and its regulation is still 
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unknown. However, the mutation is found within the PTB1 domain. PTB 
domains are important for protein-protein interactions. Therefore, it is plausible 
that the R125W mutation could affect the interaction of TBC1D1 with 14-3-3 or 
other proteins involved in regulating Rab-GAP activity. Recently, a truncation 
mutant of TBC1D4 (AS160 R363X) has been described which is involved in 
acanthosis nigricans and postprandial hyperglycemia in humans. It was found 
that the mutant TBC1D4 protein interacts with wild-type TBC1D4 and inhibits 
insulin-stimulated GLUT4 translocation (Dash, et al., 2009). Furthermore, the 
overexpression of a TBC1D4 PTB tandem construct inhibits 14-3-3 binding to 
endogenous TBC1D4 and an in vitro vesicle fusion reaction which inhibits 
insulin-stimulated gain of GLUT4 at the cell surface in adipocytes (Koumanov, 
et al., 2011).   
Interestingly, the putative AMPK-phosphorylation motif at serine 237 is located 
between the two PTB domains of TBC1D1. Surprisingly, the over expression of 
TBC1D1 R125W in TA muscle did not affect contraction-stimulated glucose 
transport (An, et al., 2010). Further investigations are required to determine how 
the R125W mutation in TBC1D1 aberrantly impairs glucose uptake. It will be 
crucial to determine more specifically how this mutation in TBC1D1 affects 
GLUT4 trafficking.  
It seems plausible that a GLUT4 sorting defect through the absence of sortilin or 
an underdeveloped TGN could be responsible for the lack of a substantial ‘static 
GLUT4 compartment’ in C2C12 myotubes. Alternatively, the GSVs may form 
from the TGN but mechanisms which regulate retention and stability are 
compromised. For instance, through the lack of protein TUG. This static 
behaviour of GLUT4 is required for maximal insulin-stimulated cell surface 
GLUT4 levels. Therefore, for future investigations it would be of interest to 
establish whether the formation of a GLUT4 static compartment can be 
artificially programmed in C2C12 myotubes. To improve the C2C12 cell line as 
a model for studying GLUT4 trafficking in muscle.  
Further investigations will be needed to fully characterise the importance and 
function of TBC1D1 and TBC1D4 splice variants. It is clear that the long 
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variants of both proteins are primarily expressed in skeletal muscle (Baus, et al., 
2008). Furthermore, the long splice-variant of TBC1D1 is up-regulated during 
the differentiation of C2C12 myotubes. In contrast, the short splice variant of 
TBC1D4 is up-regulated during differentiation in 3T3-L1 adipocytes (Chavez, et 
al., 2008). This suggests that these variants may have a particular important 
role within these tissues.  
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6.2 Future Directions  
Both the transition experiments and anti-HA antibody uptake assays described 
in this thesis are based on those developed by Govers et al, for the studies of 
GLUT4 trafficking in 3T3-L1 adipocytes (Govers, et al., 2004) (Coster, et al., 
2004). Additionally, these assays have been optimised in our laboratory to study 
GLUT4 trafficking in L6 myotubes (Fazakerely, et al., 2009). These assays have 
been developed and optimised in a 96-well plate format which has enabled 
multiple variables and replicates to be tested and analysed in a single plate 
experiment. These assays can then be evaluated using a fluorescence-based 
micro titre plate reader which allows rapid quantitative analysis. Furthermore, 
plate-readers provide information for a cell-population which avoids any 
experimental bias through single-cell imaging techniques. However, we have 
made the assumption that the population average will reflect the most 
prominent effect within individual cells. During these experimental investigations 
some issues have emerged potentially regarding the application of 
investigations using population-based averages in C2C12 myotubes. Firstly, 
these studies do not provide sufficient information to ascertain whether multiple 
cell populations respond differently to insulin or contraction-mediated stimuli. 
Differentiated C2C12 cells form a heterogeneous population of multi-nucleated 
tubes, even under standardised culture conditions for both growth and 
differentiation of the cells (Yoshida, et al., 1998). In particular giant rounded 
multinucleated structures are a common feature in cultures of differentiated 
C2C12 cells. Furthermore, some cells remain as a myoblastic population. It is 
possible, therefore, that the error within the experimental results detailed in this 
thesis may have been affected because of this. Cell population-based analysis 
has been useful for the studies of GLUT4 trafficking in L6 myotubes 
(Fazakerely, et al., 2009) (Govers, et al., 2004) (Somwar, et al., 2001) (Foster, 
et al., 2001). However, this could be explained by the fact that L6 myotubes 
may form a less heterogeneous population at least morphologically.  
Secondly, we did not determine whether the transfection efficiency of siRNA 
constructs differed across sub-populations of differentiating C2C12 cells. This 
could heighten the variability in the functional read out of our assays (HA-
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GLUT4 at the cell surface) based on an average population of cells. In future 
investigations it may be more appropriate to develop short hairpin RNA 
(shRNA) constructs to target and knockdown Tbc1d1 and Tbc1d4 in C2C12 
myotubes. This approach has been routinely used to silence Tbc1d1 (Chavez, 
et al., 2008) and Tbc1d4 (Eguez, et al., 2005) (Brewer, et al., 2011) (Larance, et 
al., 2005) in 3T3-L1 adipocytes. These shRNA constructs are introduced using 
retroviral vectors. Use of this approach would overcome difficulties with 
transfection techniques and would allow for the selection of stable knockdown 
cells. Additionally, C2C12 myoblasts cells could be simultaneously co-infected 
with retroviruses for HA-GLUT4 and shRNA constructs which would prevent the 
manipulation of cells during the early stages of differentiation. However, even 
with shRNA-mediated gene silencing there will still be cell-to-cell variation of 
protein expression levels.  
Cell heterogeneity is an important factor and its impact on population based 
analyses has been recently reviewed (Altschuler & Wu, 2010). In future 
investigations using C2C12 myotubes it will be of great importance to address 
this issue. Detailed studies to establish whether the responses of sub 
populations of cells are different from each other and the population average 
would be required in order test this. Furthermore, a consistent theme addressed 
in this thesis is the importance of information obtained from time-course 
analysis and not just end point results. This is vital in order to understand the 
dynamic behaviour of a system.  
The application of confocal microscopy imaging techniques have been routinely 
used to study the kinetics of GLUT4 trafficking within populations of single-
nucleated 3T3-L1 cells (Karylowski, et al., 2004) (Martin, et al., 2006). However, 
traditional imaging techniques cannot be as easily applied to study large multi-
nucleated C2C12 cells. Furthermore, fluorescence imaging has the 
disadvantage of being less high-throughput especially when there are multiple 
sub-populations of cells. More recently, high content analysis (HCA) in cell-
based systems has been developed which effectively combines high-throughput 
automated fluorescence microscopy with quantitative imaging analysis. This 
technology enables detailed temporal and spatial information to be acquired 
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along with the capacity to identify and selectively analyse sub populations of 
cells. In future investigations the development of a high-content cell-based 
assay will be an extremely valuable tool to measure HA-GLUT4 trafficking in 
C2C12 myotubes.  
Although not presented in the thesis work, a validation experiment has been 
recently performed to investigate the usefulness of a HCA approach to study 
HA-GLUT4 translocation in C2C12 myotubes. We conducted a study to 
measure the time dependant accumulation of GLUT4 (HA-GLUT4) at the cell 
surface in response to insulin and AICAR using the confocal imaging plate 
reader, the IN Cell Analyzer system 2000 (GE Healthcare). The nuclei were 
identified based on DAPI staining. The results represent the fluorescence 
intensity measured around each nucleus.  Representative fluorescence images 
are presented in an appendix. Further work is required to develop and test 
custom built protocols to analyse multiple cell populations using the IN Cell 
Investigator Software. Furthermore, it will be a great advantage to correlate the 
knockdown of a target with the phenotypic changes and relate this to the 
different sub populations of cells. HCA systems will be an important and 
valuable tool for future investigations.  
In summary, we have attempted to comprehensively investigate GLUT4 
trafficking in the C2C12 skeletal muscle cells as they respond to insulin 
signalling and AMPK activation. We found that the combined activation of 
insulin and AMPK-signalling pathways were synergistic to increase GLUT4 at 
the cell surface. We present evidence that basal GLUT4 retention is regulated 
through mechanisms involving TBC1D1 in C2C12 myotubes. The results also 
support a model whereby TBC1D1 inactivation is required for AICAR-induced 
GLUT4 translocation. This may occur partly through the mobilisation of GLUT4 
into the actively recycling pool. Additionally, TBC1D1 may also be important for 
negatively-regulating insulin-stimulated GLUT4 at the cell surface in muscle 
cells. The activation of both AMPK and Akt signalling pathways may converge 
on TBC1D1 to enhance GLUT4 exocytosis. Furthermore, our findings support 
the concept that insulin can directly stimulate the accumulation of GLUT4 at the 
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plasma membrane through TBC1D4-independent mechanisms. This is likely to 
occur through the fusion of highly insulin-responsive GSVs at the cell surface.  
Finally, the work presented in this thesis provides evidence to support the 
involvement of AMP-activated protein kinase and subsequent downstream 
signalling pathways that lead to GLUT4 translocation. We thereby have added 
support to the idea that this activation route is an attractive therapeutic target for 
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Figure A1: Representative fluorescence microscopy images of basal, insulin-stimulated and 
AICAR-treated C2C12 myotubes expressing HA-GLUT4. C2C12 myoblasts were infected 
with 0.025ml HA-GLUT4 retro-virus or empty vector (EV) virus as a control. C2C12 
myotubes on day 7 post differentiation were maintained under basal conditions, stimulated 
with insulin at 200 nM for 5 min or treated with AICAR at 2 mM for 45 min. The cell surface 
levels of GLUT4 was determined by incubating fixed cells with anti-HA primary antibodies 
and anti-mouse Alexa 488 secondary antibodies. Total cellular GLUT4 was determined in 
premeabilised cells pre-treated with saponin prior to primary antibody staining. All cells were 
co-stained with the nuclear stain 4,6-diamidino-2- phenylindole (DAPI). Images were 
captured using the IN Cell Analyzer system 2000 high content analysis (HCA) confocal 
imaging plate reader (GE Healthcare). Images were aquired at 2x as a single image field on 
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Figure A2: Florescence microscopy images of basal, insulin-stimulated and AICAR-treated 
C2C12 myotubes expressing HA-GLUT4. C2C12 myoblasts were infected with 0.025ml HA-
GLUT4 retro-virus or empty vector (EV) virus as a control. C2C12 myotubes on day 7 post 
differentiation were maintained under basal conditions, stimulated with insulin at 200 nM for 
5 min or treated with AICAR at 2 mM for 45 min. The cell surface levels of GLUT4 was 
determined by incubating fixed cells with anti-HA primary antibodies and anti-mouse Alexa 
488 secondary antibodies. Total cellular GLUT4 was determined in premeabilised cells pre-
treated with saponin prior to primary antibody staining. All cells were co-stained with the 
nuclear stain 4,6-diamidino-2- phenylindole (DAPI). Images were captured using the IN Cell 
Analyzer system 2000 high content analysis (HCA) confocal imaging plate reader (GE 
Healthcare). One field was captured per well of a 96-Well plate. One field was captured per 
well of a 96-Well plate. Images were aquired using a 20x 0.75 NA objective lens.  
Appendix 
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Figure A3: Representative florescence microscopy images of basal, insulin-stimulated and 
AICAR-treated C2C12 myotubes expressing HA-GLUT4. C2C12 myoblasts were infected 
with 0.025ml HA-GLUT4 retro-virus or empty vector (EV) virus as a control. C2C12 
myotubes on day 7 post differentiation were maintained under basal conditions, stimulated 
with insulin at 200 nM for 5 min or treated with AICAR at 2 mM for 45 min. The cell surface 
levels of GLUT4 was determined by incubating fixed cells with anti-HA primary antibodies 
and anti-mouse Alexa 488 secondary antibodies. Total cellular GLUT4 was determined in 
premeabilised cells pre-treated with saponin prior to primary antibody staining. All cells were 
co-stained with the nuclear stain 4,6-diamidino-2- phenylindole (DAPI). Images were 
captured using the IN Cell Analyzer system 2000 high content analysis (HCA) confocal 
imaging plate reader (GE Healthcare). One field was captured per well of a 96-Well plate. 
Images were aquired using a 20x 0.75 NA objective lens. Images are representative of three 
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Figure A4: Representative fluorescence microscopy images of basal, insulin-stimulated and 
AICAR-treated C2C12 myotubes expressing HA-GLUT4. C2C12 myoblasts were infected 
with increasing volumes of HA-GLUT4 retro-virus (0.025 - 0.1 ml) or empty vector (EV) virus 
as a control. C2C12 myotubes on day 7 post differentiation were maintained under basal 
conditions, stimulated with insulin at 200 nM for 5 min or treated with AICAR at 2 mM for 45 
min. The cell surface levels of GLUT4 was determined by incubating fixed cells with anti-HA 
primary antibodies and anti-mouse Alexa 488 secondary antibodies. Total cellular GLUT4 
was determined in premeabilised cells pre-treated with saponin prior to primary antibody 
staining. All cells were costained with the nuclear stain 4,6-diamidino-2- phenylindole 
(DAPI). Images were captured using the high content analysis (HCA) confocal imaging plate 
reader, the IN Cell Analyzer system 2000 (GE Healthcare). the IN Cell Analyzer system 
2000 (GE Healthcare). One field was captured per well of a 96-Well plate. Images were 



































Figure A5: Splice variants of Tbc1d1 and Tbc1d4. (A) Schematic representation of Tbc1d1 
conserved splice variants in mouse (Mus musculus), rat (Rattus norvegicus) and human 
(Homo sapiens) which have been compiled from Ensembl. There appear to be two splice 
variants of Tbc1d1 conserved in rodent (Mu: long isoform: 6465 bp, translation: 1255 aa, 
molecular weight: 143 kDa and short isoform: 5410 bp, translation: 1162 aa, molecular 
weight: 132 kDa), (Rn: long isoform: 3867bp translation: 1257 aa 142 kDa and short 
isoform: 3582 translation: 1162 aa molecular weight: 132 kDa) and only one TBC1D1 
transcript: 5700 bp translation: 1159 aa molecular weight: 131 kDa in human. (B) Schematic 
representation Tbc1d4 splice variants in mouse and human compiled from Ensembl. Mouse: 
long transcript: 4762 bp, translation: 1306 aa, molecular weight: 147 kDa and short 
transcript: 6483 bp, translation: 1243 aa, molecular weight: 140 kDa. Human: long 
transcript: 6364 bp, translation: 1298 aa, molecular weight: 146 kDa and short transcript: 
6174 bp, translation: 1235 aa, molecular weight: 139 kDa. Appendix 1: Amino acid 
sequence alignment of TBC1D1 splice isoforms in Mouse, Rat and Human compiled from 
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